

|                      |  |
|----------------------|--|
| Title                | Bioengineering of nisin to enhance functionality against dairy pathogens   |
| Authors              | Healy, Brian   |
| Publication date     | 2014   |
| Original Citation    | Healy, B. C. 2014. Bioengineering of nisin to enhance functionality against dairy pathogens. PhD Thesis, University College Cork.          |
| Type of publication  | Doctoral thesis  |
| Rights               | © 2014, Brian C. Healy - <a href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</a> |
| Download date        | 2025-04-22 01:26:15  |
| Item downloaded from | <a href="https://hdl.handle.net/10468/2696">https://hdl.handle.net/10468/2696</a>  |



# UCC

**University College Cork, Ireland**  
 Coláiste na hOllscoile Corcaigh



# **Bioengineering of Nisin to Enhance Functionality against Dairy Pathogens**



**A Thesis Presented to the National University of Ireland  
for the Degree of  
Doctor of Philosophy  
By**

**Brian Cornelius Healy, B.Sc.**

**Student ID No. 109220278  
December 2014**

School of Microbiology  
University College Cork

Supervisors: Prof. Colin Hill, Dr. Paul Cotter and Prof. Paul Ross

Head of School: Professor Gerald Fitzgerald

For Mark, Helen and Grandad

# Table of Contents

|                    |    |
|--------------------|----|
| DECLARATION.....   | IV |
| PUBLICATIONS ..... | V  |

|                |   |
|----------------|---|
| ABSTRACT ..... | 1 |
|----------------|---|

## CHAPTER I

|  |   |
|--|---|
| LANTIBIOTIC-RELATED RESEARCH AND THE APPLICATION THEREOF ..... | 3 |
|--|---|

|   |    |
|---|----|
| 1.1 ABSTRACT .....  | 4  |
| 1.2 INTRODUCTION TO BACTERIOCINS.....                                   | 5  |
| 1.3 BIOSYNTHESIS AND POST-TRANSLATIONAL MODIFICATIONS.....              | 6  |
| 1.4 CLASSIFICATION .....  | 9  |
| 1.5 LANTIBIOTIC SUBGROUPS – BIOLOGY, STRUCTURE AND MODE OF ACTION ..... | 10 |
| 1.5.1 <i>Nisin-like lantibiotics</i> .....                              | 10 |
| 1.5.2 <i>Epidermin-like lantibiotics</i> .....                          | 11 |
| 1.5.3 <i>Planosporicin- and Streptin-like lantibiotics</i> .....        | 12 |
| 1.5.4 <i>Pep5-like peptides</i> .....                                   | 12 |
| 1.5.5 <i>Lacticin 481-like lantibiotics</i> .....                       | 13 |
| 1.5.6 <i>Mersacidin-like lantibiotics</i> .....                         | 14 |
| 1.5.7 <i>LtnA2-like peptides</i> .....                                  | 15 |
| 1.5.8 <i>Other Type II Lantibiotics</i> .....                           | 15 |
| 1.6 CURRENT AND FUTURE USE OF LANTIBIOTICS FOR FOOD APPLICATIONS .....  | 16 |
| 1.7 LANTIBIOTICS AND THEIR MEDICAL APPLICATIONS .....                   | 18 |
| 1.8 ENGINEERING OF LANTIBIOTICS.....                                    | 20 |
| 1.9 SCREENING FOR NEW LANTIBIOTICS .....                                | 22 |
| 1.10 OUTLOOK.....   | 24 |
| 1.11 ACKNOWLEDGEMENTS .....   | 26 |
| 1.12 BIBLIOGRAPHY .....   | 27 |
| 1.13 FIGURES.....   | 37 |

## CHAPTER II

|   |    |
|---|----|
| FATE OF <i>MYCOBACTERIUM AVIUM</i> SUBSPECIES <i>PARATUBERCULOSIS</i> ATCC19698 DURING MANUFACTURE AND RIPENING OF A NON-PASTEURISED SMEAR TYPE CHEESE MADE WITH AND WITHOUT LACTICIN 3147..... | 39 |
|---|----|

|   |    |
|---|----|
| 2.1 ABSTRACT .....  | 40 |
| 2.2 INTRODUCTION .....  | 42 |
| 2.3 MATERIALS AND METHODS.....  | 46 |
| 2.3.1 <i>Bacterial strains and growth conditions</i> .....              | 46 |
| 2.3.2 <i>Production of smeared cheese from unpasteurised milk</i> ..... | 46 |
| 2.3.3 <i>Sampling routine</i> .....                                     | 47 |
| 2.3.4 <i>Detection of lacticin 3147</i> .....                           | 48 |
| 2.3.5 <i>Confirmation of MAP colonies through PCR</i> .....             | 48 |
| 2.3.6 <i>Molecular Quantification using RT-PCR</i> .....                | 49 |
| 2.4 RESULTS .....   | 51 |
| 2.5 DISCUSSION .....  | 55 |
| 2.6 ACKNOWLEDGEMENTS .....  | 59 |
| 2.7 BIBLIOGRAPHY .....  | 60 |
| 2.8 TABLES AND FIGURES.....   | 63 |

## CHAPTER III

### INTENSIVE MUTAGENESIS OF THE NISIN HINGE LEADS TO THE RATIONAL DESIGN OF ENHANCED DERIVATIVES..... 71

|       |   |    |
|-------|---|----|
| 3.1   | ABSTRACT .....  | 72 |
| 3.2   | INTRODUCTION .....  | 73 |
| 3.3   | MATERIALS AND METHODS .....   | 76 |
| 3.3.1 | <i>Bacterial strains and growth conditions</i> .....                                | 76 |
| 3.3.2 | <i>Site-saturation mutagenesis of the nisin A 'hinge' region</i> .....              | 76 |
| 3.3.3 | <i>Site-directed mutagenesis of the nisin A 'hinge' region</i> .....                | 77 |
| 3.3.4 | <i>Deferred antagonism assays</i> .....   | 77 |
| 3.3.5 | <i>Agar well diffusion assays</i> .....   | 78 |
| 3.3.6 | <i>Identification of nisin A derivatives</i> .....                                  | 78 |
| 3.3.7 | <i>Purification of nisin A and derivatives thereof</i> .....                        | 78 |
| 3.3.8 | <i>Minimum Inhibitory Concentration (MIC) Assays</i> .....                          | 79 |
| 3.4   | RESULTS .....   | 80 |
| 3.4.1 | <i>Creation of a bank of producers of randomised hinge derivative</i> .....         | 80 |
| 3.4.2 | <i>Identification of nisin derivative producers with enhanced bioactivity</i> ..... | 80 |
| 3.4.3 | <i>Rational design of nisin derivatives with enhanced bioactivity</i> .....         | 82 |
| 3.5   | DISCUSSION .....  | 85 |
| 3.6   | ACKNOWLEDGEMENTS .....  | 89 |
| 3.7   | BIBLIOGRAPHY .....  | 90 |
| 3.8   | TABLES AND FIGURES.....   | 93 |

## CHAPTER IV

### BIOENGINEERING TO CREATE A TRYPSIN RESISTANT NISIN A DERIVATIVE ..... 101

|       |   |     |
|-------|---|-----|
| 4.1   | ABSTRACT .....  | 102 |
| 4.2   | INTRODUCTION .....  | 103 |
| 4.3   | MATERIALS AND METHODS .....   | 106 |
| 4.3.1 | <i>Bacterial strains and growth conditions</i> .....                        | 106 |
| 4.3.2 | <i>Site-saturation mutagenesis of the K12A</i> .....                        | 106 |
| 4.3.3 | <i>Site-saturation mutagenesis of K12,H31 and combination of both</i> ..... | 107 |
| 4.3.4 | <i>Derivative Identification</i> .....                                      | 107 |
| 4.3.5 | <i>Peptide Purification</i> .....   | 108 |
| 4.3.6 | <i>Bioactivity and specific activity assays</i> .....                       | 108 |
| 4.3.7 | <i>Trypsin Digestions</i> .....   | 109 |
| 4.4   | RESULTS .....   | 111 |
| 4.5   | DISCUSSION .....  | 115 |
| 4.6   | ACKNOWLEDGEMENTS .....  | 119 |
| 4.7   | BIBLIOGRAPHY .....  | 120 |
| 4.8   | TABLES AND FIGURES.....   | 123 |

## CHAPTER V

### COMPARISON OF THE EFFICACY OF A VARIETY OF NISIN DERIVATIVES AGAINST *STREPTOCOCCUS AGALACTIAE* ..... 131

|       |   |     |
|-------|---|-----|
| 5.1   | ABSTRACT .....  | 132 |
| 5.2   | INTRODUCTION .....  | 133 |
| 5.3   | MATERIALS AND METHODS .....                                       | 137 |
| 5.3.1 | <i>Bacterial strains and growth conditions</i> .....              | 137 |
| 5.3.2 | <i>Rifampicin tagging of <i>S. agalactiae</i> ATCC13813</i> ..... | 137 |
| 5.3.3 | <i>Bioactivity Assays</i> .....                                   | 138 |
| 5.3.4 | <i>Determination of Antimicrobial Activity in Milk</i> .....      | 138 |
| 5.3.5 | <i>Creation of <i>L. lactis</i> NZ9800 pLP712</i> .....           | 139 |
| 5.4   | RESULTS .....   | 140 |
| 5.5   | DISCUSSION .....  | 143 |
| 5.6   | ACKNOWLEDGEMENTS .....  | 147 |
| 5.7   | BIBLIOGRAPHY .....  | 148 |
| 5.8   | TABLES AND FIGURES.....   | 151 |

|                              |            |
|------------------------------|------------|
| <b>SUMMARY .....</b>         | <b>156</b> |
| BIBLIOGRAPHY.....            | 161        |
| <b>ACKNOWLEDGMENTS .....</b> | <b>162</b> |

## **Declaration**

I hereby declare that this thesis is my own work and has not been submitted for another degree, either at University College Cork or elsewhere.

Signed \_\_\_\_\_

**Brian Healy**



## **Publications**

Healy B, O'Mahony J, Hill C, Cotter PD & Ross RP (2010) 2 Lantibiotic-related Research and the Application Thereof. *Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies* **18**: 22.

Healy B, Field D, O'Connor PM, Hill C, Cotter PD & Ross RP (2013) Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives. *PLoS One* **8**: e79563

## Abstract

It is a cause for significant concern that, as the threat of multi-drug resistant strains of bacteria has increased, the discovery of effective and novel antibiotics has stalled. The bacteriocin class of antimicrobial peptides have, in recent times, emerged as a viable alternative to at least partially fill the void created by the end of golden age of antibiotic discovery. Along with this potential use in a clinical setting, a number of bacteriocins also play an important role as bio-preservatives in the food industry.

This thesis focuses on a specific group of the bacteriocins, the Class 1 lantibiotics (**Lanthionine-containing antibiotics**). The mature peptide structure contains a number of unique amino acids which result from enzymatically mediated post-translational modifications, including dehydration and cyclisation, leading to the formation of the eponymous (methyl)lanthionine bridges. Two characteristics associated with lantibiotics are exploited in this work. Firstly, the many ways in which they can be applied in a food setting, and secondly, how their gene-encoded nature can be modified to improve on overall bioactivity and functionality.

The research focuses on two lantibiotics, lacticin 3147 and nisin A, both of which are produced by strains of *Lactococcus lactis*. The use of a lacticin 3147 producing starter culture with a view to the control of the Crohn's disease-linked pathogen *Mycobacterium avium* subspecies *paratuberculosis* was assessed in a smear ripened raw milk cheese. The fact that bacteriocin production did not effectively control the pathogen was one of a number of factors that provided an impetus to explore a variety of PCR-based mutagenesis techniques with a view to the

creation of enhanced lantibiotic derivatives. Initially there was a specific focus on the three amino acid central ‘hinge’ region of nisin A, chosen because previous bioengineering of this region led to variants with enhanced properties.

Through the use of both site specific and site directed mutagenesis techniques, a number of enhanced derivatives were generated. A derivative in which the three hinge amino acids (asparagine, methionine and lysine) were replaced with three alanines represents the first enhanced derivative of nisin to have been designed through a rational process. This derivative, named nisin AAA, also formed the backbone for the creation of an active, trypsin resistant, nisin variant. This stemmed from the observation that the lysine at position 12 provided the only trypsin sensitive peptide bond in nisin AAA. Introduction of a methionine residue at this position led to the creation of nisin K12M-AAA, which maintained antimicrobial activity while demonstrating resistance to the protease. This functional change could see nisin used as an oral anti-bacterial in the future as this derivative is more likely to be capable of withstanding gastric transit. A number of lead nisin derivatives were investigated to assess their anti- *Streptococcus agalactiae* ability. The ability of the AAA producer to control this target, which can contribute to the commercially important disease, bovine mastitis, was evident from these studies. Finally, a system was also developed to facilitate the large scale production of these candidates, or other nisin derivatives, from dairy substrates with a view to anti-mastitis or other therapeutic preparations.

# **Chapter I**

## **Literature Review**

### **Lantibiotic-related research and the application thereof**

Brian Healy, Jim O'Mahony, Colin Hill, Paul D. Cotter and R. Paul Ross.

This chapter was published in *Antimicrobial peptides: discovery, design and novel therapeutic strategies* 18 (2010): 22-39.

## **1.1 Abstract**

Since the discovery, in 1925, that strains of *E. coli* can retard the growth of neighbouring bacteria, the study of bacteriocins has evolved continuously. During the intervening period a large and heterogeneous, collection of these antimicrobial peptides has been isolated from a myriad of sources and numerous investigations have been carried with a view to harnessing this potency. The most thoroughly investigated class of bacteriocins, the lantibiotics, will be the main focus of this review. These antimicrobial peptides inhibit many human and animal pathogens and have been the focus of considerable efforts to maximise the potential of existing lantibiotics, identify new and better lantibiotics from nature and to utilise bioengineering-based approaches to further improve upon existing well characterised compounds.

## 1.2 Introduction to Bacteriocins

In order for an organism to survive, thrive and proliferate in a particular niche, it is essential that it competes successfully. In the microbial world many bacteria gain an upper hand by producing antimicrobial compounds which inhibit their competitors. Bacteriocins, which are bacterially-produced ribosomally-synthesized peptides with antimicrobial spectra which can range from very narrow to extremely broad, can be among the most potent examples of bacterially produced antimicrobials (Tagg *et al.*, 1976, Jack *et al.*, 1995, Riley & Wertz, 2002, Cotter *et al.*, 2005). Indeed, bacteriocins frequently exhibit antimicrobial activity at nanomolar levels which contrasts with, for example, the cationic antimicrobial peptides (CAMPs) produced by eukaryotic cells which only exhibit similar levels of activity at micromolar concentrations (Nissen-Meyer *et al.*, 2009).

The identification of the first bacteriocin, a colicin (i.e. an *Escherichia coli*-associated bacteriocin (Gratia, 1925)), occurred in 1925. This was followed soon after by the first report of a bacteriocin produced by a Gram-positive bacterium when inhibition of a *Lactobacillus bulgaricus* by a *Streptococcus lactis* (since renamed *Lactococcus lactis*) was noted (Rogers, 1928). Since then, bacteriocins produced by lactococci and other lactic acid bacteria (LAB), i.e. microorganisms which have a long history of safe use in food and are of considerable industrial importance, have continued to be the focus of much attention (Nissen-Meyer *et al.*, 2009). There are a number of different classification systems for LAB bacteriocins but the simplest, and that used for this review, was proposed by Cotter *et al.*, (Cotter *et al.*, 2005) and comprises two classes i.e. Class I bacteriocins: the post-translationally modified lantibiotics (Chatterjee *et al.*, 2005, Cotter *et al.*, 2005), and Class II bacteriocins, which are a heterogeneous group of non lanthionine-containing peptides. As a

consequence of their unusual structure, unique mechanisms of action and their potential as antimicrobials for food, veterinary and clinical application, the lantibiotics have been the target of much attention in recent years and are the focus of this chapter.

### **1.3 Biosynthesis and Post-Translational Modifications**

The name lantibiotics is derived from *lan*thionine-containing *anti*biotics and reflects the feature which is shared by all of these peptides i.e. intra-molecular rings formed by the thioether amino acids lanthionine (Lan) and methyllanthionine (meLan) (Sahl *et al.*, 1995). Lantibiotic-associated gene clusters can be located on chromosomes (including transposable elements) or plasmids and in addition to the genes encoding a structural peptide(s) and the post-translational modification machinery that acts thereon, other genes responsible for regulation, transport and immunity are usually also present (Cotter *et al.*, 2005). Here the steps involved in lantibiotic biosynthesis are summarized.

The lantibiotic prepropeptide contains a leader region which is eventually cleaved generating propeptide which is modified to become the active antimicrobial. The corresponding gene is generically designated *lanA*. Lantibiotics can be further subdivided according to the enzymes which catalyse (me)Lan formation. Type I prepropeptides such as the prototypic lantibiotic, nisin A, undergoes dehydration as a result of the catalytic activity of the NisB protein (generically referred to as LanB enzymes) (Karakas Sen *et al.*, 1999). As a result specific serine and threonine residues are dehydrated to become the unique amino acids 2,3-dehydroalanine (Dha) and 2,3-dehydrobutyrine (Dhb), respectively. Some or all of these new residues are

then the subject of a LanC catalysed reaction which results in their interaction with the thiol groups of cysteines within the peptide to form Lan and meLan, from Dha and Dhb, respectively. Insight into the role of LanC was first provided by Meyer and co-workers (Meyer *et al.*, 1995) who, while working on the lantibiotic Pep5, showed that with the removal of the *pepC* gene, the peptide produced contained dehydrated residues but not lanthionine or methylanthionine bridges. In addition to being essential for converting the peptide to an active form, the (me)Lan structures are also believed to contribute to protease resistance (Kluskens *et al.*, 2005). Unlike the Type I peptides which are modified by two separate modification enzymes, Type II peptides, such as lactacin 481 and mersacidin, are modified by a single protein referred to as LanM (Willey and van der Donk, 2007). Another variation on this theme arises as a consequence of the existence of two peptide lantibiotics, such as lactacin 3147, which require the combined activity of two (me)Lan-containing peptides for optimal activity. In the majority of cases the production of lantibiotics of this kind relies on the presence of two LanM proteins, each of which are responsible for the dehydration and cyclisation of their respective subunit (McAuliffe *et al.*, 2000, Lawton *et al.*, 2007). A third category of peptides, Type III, is not described in this review as those identified to date, while possessing (me)Lan structures, lack antimicrobial activity (Willey & van der Donk, 2007) while yet another category, modified by a novel group of lantibiotic synthetases designated LanL, has recently been discovered (Goto *et al.*, 2010). It remains to be established if LanL modified peptides possess antimicrobial activity and thus it has been suggested that the term lantipeptides be used to describe lanthionine-containing peptides that lack antimicrobial activity (Goto *et al.*, 2010). With respect to the lantibiotics, in addition to the LanB, C and M enzymes, a number of other modification enzymes have been



associated with the modification of specific peptides (Kupke & Gotz, 1997, Peschel *et al.*, 1997, Majer *et al.*, 2002, Cotter *et al.*, 2005).

After modification, the peptide is transported *via* an ABC transport system to the cell surface (Fath & Kolter, 1993) and the leader sequence is proteolytically removed, although not necessarily in that order, leading to the production of the active lantibiotic (Havarstein *et al.*, 1995). For Type I lantibiotics these individual steps are carried out independently by a transporter (designated LanT) (Qiao and Saris, 1996) and a protease (LanP)(Ye *et al.*, 1995, Siezen, 1996), whereas in the case of Type II lantibiotics both activities are carried out by one enzyme (also designated LanT) (Rince *et al.*, 1994, Chen *et al.*, 1999, Altena *et al.*, 2000). To ensure that the active antimicrobial does not target the producing cells, immunity proteins are produced. Two immunity mechanisms have been described. One relies on a single immunity protein, LanI, while a second involves a multi-component ABC-transporter system referred to as LanEFG. Indeed some lantibiotic producers utilize two such mechanisms (Draper *et al.*, 2008). The remaining group of lantibiotic-associated proteins to which we have yet to refer are the regulators. Initial studies in this area focused on the regulation of nisin, and its related peptide, subtilin by two component signal transduction systems which consist of a histidine kinase (LanK) and a response regulator (LanR) (Klein *et al.*, 1993, Engelke *et al.*, 1994, Stock *et al.*, 2000, Kleerebezem, 2004). Examination of the genetic determinants of a subtilin producer revealed the presence of the *spaK* and *spaR* genes. Using a strategy of gene deletion, it was shown that mutants lacking these genes were no longer capable of lantibiotic production (Klein *et al.*, 1993). A similar approach also revealed the importance of the corresponding nisin genes (Engelke *et al.*, 1994). In both cases, it has been established that the associated antimicrobial peptides also

function as pheromones as part of a LanRK-mediated quorum sensing system which facilitates autoregulation (Kleerebezem, 2004). While two component systems play a major role in the production of a number of other lantibiotics, such as mersacidin (Guder *et al.*, 2002), other quite different regulators have also been noted (McAuliffe *et al.*, 2001).

## 1.4 Classification

A scheme to classify lantibiotics was first proposed by Jung in 1991 (Jung, 1991). This scheme grouped the peptides into two distinct categories. The first class, Type-A, contained the elongated flexible, amphipathic, peptides. These peptides also had an overall positive net charge and were thought to function through the permeabilization of the cell membrane. The second class, Type-B, were grouped on the basis of being globular proteins, with a net negative or neutral charge and were thought to function by inhibiting sensitive cells by forming complexes with specific membrane components. While some of this information continues to be pertinent, investigations which have established that some lantibiotics act in multiple different ways, coupled with the identification of new and more diverse lantibiotics, makes the use of this system more difficult. This issue has been addressed by approaches that reflect the genes and proteins involved in lantibiotic production. Most recently this has involved the fusion of two compatible approaches (Piper *et al.*, 2009a) in which peptides were classified on the basis of the sequence of the lantibiotic propeptide (Cotter *et al.*, 2005) or the composition of the associated modification/ transport systems (Pag & Sahl, 2002, Willey & van der Donk, 2007). Using this combined approach the lantibiotics can be subdivided into the three types, i.e. I, II and III,

referred to above, and 12 subgroups. The subclassification of the type I and II lantibiotics into 12 subgroups is based on the alignment of the unmodified amino acid sequence of the structural peptide. In each case homology results in the classification of the lantibiotic in question together with the eponymous member of the group i.e. planosporicin, nisin, epidermin, streptin, Pep5, lacticin 481, mersacidin, ltnA2, cytolysin, lactosin S, cinnamycin and sublancin (Fig. 1.1). Thus, for example, the mersacidin subgroup includes RumB, plantaricin C, mersacidin, michiganin, actagardine, C55a, LtnA1, SmbB, bhtA-alpha, Plwa, PmnA1 and BhaA1, all of which are modified by LanM enzymes (i.e. are of Type II) and contain a number of residues that are conserved across the group. It should be noted that problems can arise when trying to add newly purified lantibiotics for which a structure, but not gene sequences, are available to this system. Thus, while it is apparent from its unusual structure and modifications that microbisporicin represents a 13<sup>th</sup> lantibiotic subclass (Castiglione *et al.*, 2008), it will not be possible to satisfactorily incorporate it into the system until the associated biosynthetic genes are identified and the *lanA* gene sequenced.

## **1.5 Lantibiotic subgroups – Biology, Structure and Mode of Action**

### **1.5.1 Nisin-like lantibiotics**

Nisin A is the most thoroughly characterized lantibiotic. This 34 amino acid peptide contains three dehydrated amino acids and five thioether rings (Fig 1.2) (Gross & Morell, 1971, Buchman *et al.*, 1988) and is the eponymous member of the nisin-like lantibiotics, which also include nisin Z (Mulders *et al.*, 1991), nisin F (de

Kwaadsteniet, *et al.*, 2008), nisin U and U2 (Wirawan *et al.*, 2006), nisin Q (Zendo *et al.*, 2003), subtilin (Klein *et al.*, 1993), ericin S and ericin A (Stein *et al.*, 2002). The mechanism of action of nisin A (and nisin Z, which differs from nisin A by one amino acid) has been investigated in depth and it is likely that all related peptides function in a broadly similar manner. In addition to a long standing appreciation of its ability to form pores, it was revealed in the mid-90s that nisin binds to lipid II, an essential precursor of peptidoglycan and thus also inhibits cell wall synthesis (Brotz *et al.*, 1998, Breukink *et al.*, 1999). Structural analysis of the lipid II-nisin complex has revealed that the N-terminal region of the nisin peptide is responsible for lipid II binding (Hsu *et al.*, 2004). The C-terminal end of the peptide, which is linked to the N-terminus by a three amino acid 'hinge' region, is the pore-forming domain (Breukink *et al.*, 1997, Wiedemann *et al.*, 2001). The efficiency of pore formation is greatly enhanced by lipid II-binding (Breukink *et al.*, 1999). A third mode of action has also been revealed in that it is now apparent that nisin can induce the autolysis of susceptible staphylococcal strains as a consequence of the release of two cell wall hydrolyzing cationic enzymes during normal autolysis of dividing cells (Hasper *et al.*, 2004).

### **1.5.2 Epidermin-like lantibiotics**

Epidermin is produced by *Staphylococcus epidermidis* and is encoded by a structural gene, *epiA*, which is located on a 54 kb plasmid (Schnell *et al.*, 1992). The active lantibiotic is a 21 amino acid peptide which contains four rings including three (me)Lans and a 2-aminovinyl-D-cysteine (Allgaier *et al.*, 1986). After epidermin, gallidermin is the most extensively studied epidermin-like lantibiotic. The two peptides are structural analogues which differ by only one residue (at position

6)(Kellner *et al.*, 1988). NMR studies into the structure of gallidermin has revealed that the rigid N-terminally located rings A and B are connected to the C and D rings at the C-terminal end of the peptide by a somewhat flexible region spanning residues A12 to G15 (Ottenwalder *et al.*, 1995). A comparison of the structures of epidermin and nisin show a high homology in the N-terminal, lipid II-binding, ends of the peptides (Hsu *et al.*, 2004) whereas their C-terminal ends differ considerably, thereby explaining the inability of epidermin to form pores in certain targets (Bonelli *et al.*, 2006).

### **1.5.3 Planosporicin- and Streptin-like lantibiotics**

In addition, to the nisin- and epidermin-like peptides, there exist two other peptides, planosporicin and streptin, which resemble the former with respect to their N-terminal domains but differ quite considerably from these, and from one another, otherwise. As a result both are the eponymous (and sole) members of two lantibiotic sub-classes. Planosporicin, produced by *Planomonospora* sp., contains both Lan and meLan residues which generate five intramolecular thioether bridges (Fig 1.2) (Castiglione *et al.*, 2007, Maffioli *et al.*, 2009). Planosporocin functions primarily through the inhibition of peptidoglycan synthesis but unlike nisin and epidermin does not bind to the D-ala-D-ala motif of lipid II (Castiglione *et al.*, 2007). Streptin is a *Streptococcus pyogenes*-associated lantibiotic, two major forms of which have been purified. Streptin 1 is the fully mature 23 amino acid peptide while a second form, streptin 2 has three additional residues at the N-terminal end (TPY)(Karaya *et al.*, 2001, Wescombe & Tagg, 2003).

### **1.5.4 Pep5-like peptides**

Pep5 is a tricyclic lantibiotic consisting of 34 amino acids (including 3 lanthionine bridges; one meLan and two Lan)(Bierbaum *et al.*, 1994, Bierbaum *et al.*, 1996) and is both screw shaped and highly cationic, the latter being due to the presence of six lysine and two arginine residues in the mature peptide (Pag *et al.*, 1999). It is produced by *Staphylococcus epidermidis* strain 5 (Kaletta *et al.*, 1989) with the associated genes being located on the 20 kb plasmid pED503 (Ersfeld-Dressen *et al.*, 1984, Meyer *et al.*, 1995). Pep5 also has another less common feature i.e. an N-terminal 2-oxobutyryl group which is thought to be formed through the non-enzymatic hydrolysis of N-terminal Dhb residues (Xie & van der Donk, 2004). Pep 5 exerts its mode of action by forming voltage dependant pores in the cytoplasmic membrane of sensitive cells (Sahl *et al.*, 1987, Kordel *et al.*, 1989). These pores then cause the leakage of essential metabolites and ATP out of the cell resulting in the cessation of cellular metabolic processes and ultimately causing cell death. Pep5 can also induce the autolysis of staphylococci through the activation of cell wall hydrolysing enzymes (Bierbaum & Sahl, 1985, Bierbaum & Sahl, 1987).

### **1.5.5 Lacticin 481-like lantibiotics**

The Type II lacticin 481-like subgroup is the largest lantibiotic subgroup and the associated peptides are also notable by virtue of lacking post-translational modifications other than the common Dha, Dhb, Lan and meLan residues (Dufour *et al.*, 2007). The *Lactococcus lactis* ssp. *lactis* CNRZ481-produced eponymous member of this group, lacticin 481, is 27 amino acids in length and contains two Lans, one meLan and one Dhb residue (Fig 1.2)(Piard *et al.*, 1993, van den Hooven *et al.*, 1996). Interestingly, although lacticin 481 is quite similar to the related variacin (five amino acid differences), variacin appears to have a much broader

target-cell spectrum of activity (Pridmore *et al.*, 1996). Studies with another member of this group, nukacin ISK-1, indicate it to be bacteriostatic and incapable of pore formation (Asaduzzaman *et al.*, 2009) whereas the related streptococcin SA-FF2 peptide causes the formation of short-lived pores in target cells (Jack *et al.*, 1994).

### **1.5.6 Mersacidin-like lantibiotics**

Mersacidin is a small lantibiotic produced by *Bacillus* spp. (Chatterjee *et al.*, 1992). The biosynthetic gene cluster (12.3 kb in size) consists of 10 genes and is located on the bacterial chromosome. This hydrophobic and neutral peptide contains three meLans and a single 2-aminovinyl-2-methylcysteine corresponding to four intramolecular rings (Fig 1.2)(Chatterjee *et al.*, 1992). Mersacidin does not form pores in the cell membrane of sensitive cells but does inhibit cell wall synthesis through binding with lipid II (Brotz *et al.*, 1995). An NMR study carried out by Hsu and co-workers showed that mersacidin can change its conformation depending whether or not it is in the presence of lipid II (Hsu *et al.*, 2003). In addition to one peptide lantibiotics such as mersacidin, the mersacidin-like peptides also contain the A1 peptide of a number of two peptide lantibiotics i.e. lactacin 3147 (Fig 1.2)(Ryan *et al.*, 1999), staphylococcin C55 (Navaratna *et al.*, 1998), plantaricin W (Holo *et al.*, 2001), BHT (Hyink *et al.*, 2005), Smb (Yonezawa & Kuramitsu, 2005), licheniciden (Begley *et al.*, 2009, Dischinger *et al.*, 2009) and haloduricin (Fig 1.2)(Mc Clerren *et al.*, 2006, Lawton *et al.*, 2007). These two peptide lantibiotics only exhibit optimal activity when the A1 component is combined with its A2 counterpart. These conserved A2 peptides are referred to as the LtnA2-like peptides and are described below.

### 1.5.7 LtnA2-like peptides

Lactacin 3147 is the most extensively studied two peptide lantibiotic and is produced by *Lactococcus lactis* subsp. *lactis* DPC3147 (Ryan *et al.*, 1996). The genes responsible for the production of the lantibiotic, and of the associated immunity proteins, are encoded on a 60.2 kb conjugative plasmid, pMRC01, which contains 10 ORFs (Dougherty *et al.*, 1998). The mechanism of action of lactacin 3147, which is also lipid II mediated, depends on the presence of both components i.e. Ltn $\alpha$  and  $\beta$  (derived from the LtnA1 and LtnA2 propeptides, respectively). More specifically, Ltn $\alpha$  first binds to lipid II in sensitive cells. This binding is thought to lead to a conformational change which produces a high affinity binding site for the Ltn $\beta$  peptide. Cell death occurs through the permeabilization of the cell membrane (Wiedemann *et al.*, 2006) leading to the efflux of K<sup>+</sup> ions and phosphate resulting in hydrolysis of cellular ATP. The related haloduracin peptide has recently been shown to function in a similar way (Oman and van der Donk, 2009)

### 1.5.8 Other Type II Lantibiotics

Other type II subgroups include the cinnamycin-like, sublancin-like, lactocin S-like and cytolysin-like subgroups. While there are a number of cinnamycin-like peptides, sublancin, lactocin S and cytolysin are the sole members of their respective subgroups. Cinnamycin is a tetracyclic lantibiotic produced by *Streptoverticillium grisoverticillutum*. It is a 19 amino acid peptide and contains the unusual residues lysinoalanine and 3-hydroxyaspartic acid (Fig 1.2). In addition to its antimicrobial activity, cinnamycin and related peptides have other potentially useful



pharmaceutical properties, including the inhibition of phospholipase A2 and angiotensin converting enzyme (Fredenhagen *et al.*, 1990, Kaletta *et al.*, 1991, Hosoda *et al.*, 1996). Sublancin, produced from *B. subtilis* 168, is a 37 amino acid peptide which contains one meLan and two disulphide bridges. The presence of the stabilizing lanthionine bridges along with relatively weak disulphide bridges suggests a conformational uniqueness which could confer a selective advantage (Paik *et al.*, 1998). Lactocin S, produced from *L. sake* L45, is a 37 amino acid lantibiotic (Mortvedt *et al.*, 1991, Skaugen *et al.*, 1997). This lantibiotic is noteworthy as a consequence of containing D-alanine residues (Skaugen *et al.*, 1994). Among lantibiotics only lactacin 3147 shares this trait. At a neutral pH, this lantibiotic exhibits a net neutral charge (Rawlinson *et al.*, 2002). Finally, cytolysin is a two peptide lantibiotic (Cyl<sub>L</sub> and Cyl<sub>S</sub>) produced by enterococci which is unique by virtue of its ability to target both eukaryotic and prokaryotic cells (Booth *et al.*, 1996).

## **1.6 Current and Future Use of Lantibiotics for Food Applications**

The most prominent event in the majority of food fermentations is the conversion of sugars to lactic acid by the LAB. In addition to lactic acid, LAB can produce other metabolites with antimicrobial activity such as hydrogen peroxide, diacetyl, acetoin and bacteriocins, including a number of lantibiotics such as nisin A. Highlights in the industrial application of nisin A as a food preservative include its initial use by the food industry in 1953 and its approval by the World Health Organization, European Union and US FDA in 1969, 1983 and 1988, respectively.

Currently, nisin A has been approved for use in over 48 countries worldwide (Delves-Broughton *et al.*, 1996, Cotter *et al.*, 2005, Deegan *et al.*, 2006). There are a number of ways via which nisin can be added to a food. This includes the direct application of the peptide, in a highly purified form if necessary, as an ‘additive’ (being one of only two authorised, natural food antimicrobials; the other being the anti-mould additive natamycin), the introduction of a nisin-producing bacteria, as a starter or an adjunct culture, to a fermented food (and the subsequent production of nisin *in situ*) or the producer can be used to make a food-grade fermentate, which can be dried to make a powdered ‘ingredient’. This powder can then be incorporated into either fermented or non-fermented foods. In the case of nisin, all three alternatives are employed e.g. ‘Additive’ Nisaplin (from Danisco; <http://www.daniscocare4u.com/nisaplin.html>), Nisin-producing cultures (from culture providers such as Christian Hansen and CSK) or ‘Ingredient’ DURAfresh® (from Kerry).

Other than nisin, lacticin 3147 and lacticin 481 are the two most extensively studied LAB lantibiotics. Both exhibit traits that suggest they have commercial value and a few selected examples of potential applications are presented here. In the case of lacticin 3147 it has been established that lactococcal producers thereof can be employed as starter cultures for the manufacture of cheddar cheese (Ryan *et al.*, 1996). Here lacticin 3147 producers successfully reduce the pH of the milk to 5.2 while also generating sufficient quantities of the lantibiotic to control the adventitious non-starter lactic acid bacteria (NSLAB) over a six-month ripening period (Ryan *et al.*, 1996). This is significant as NSLAB can be the cause of flavour defects and calcium lactate formation (Thomas & Crow, 1983). The use of lacticin 481-producing strains as adjunct cultures in cheese production has also been mooted

(O'Sullivan *et al.*, 2003). This lantibiotic, which is produced by *Lactococcus lactis* strains (Piard *et al.*, 1992), demonstrates a higher ability to lyse sensitive lactococci than lacticin 3147 when used in combination with the starter culture *L. lactis* HP. The associated benefits are the release of intracellular enzymes, thereby speeding up the ripening process, and a reduction in the numbers of NSLAB (O'Sullivan *et al.*, 2003). Studies investigating the use of a lacticin 3147-based powder as a bio-preservative have also yielded interesting results (Morgan *et al.*, 2001). Like nisin, a fermentate containing lacticin 3147 provides an alternative means of introducing the lantibiotic into food. Incorporation of a whey powder (10%), which was fermented with a lacticin 3147 producer, has been found to bring about a 99.9% reduction in *Listeria monocytogenes* in natural yoghurt and an 85% reduction in pathogen numbers in a cottage cheese sample within a two hour time frame. It has also been established that an 80% reduction in *Bacillus cereus* numbers occurs within three hours when this powder is added (1% powder) to soup. For a comprehensive review on the use of bacteriocins as biological agents for food safety see Deegan *et al.* (2006).

## **1.7 Lantibiotics and their medical applications**

The possibility of using lantibiotics to control or treat multi-drug resistant forms of pathogens such as *Staphylococcus aureus*, *Enterococcus* species and *Clostridium difficile* has gained increased attention in recent years due to a number of positive results obtained by researchers in the field (for a comprehensive review please refer to Piper *et al.* (2009a). *In vitro*, many lantibiotics, including lacticin 3147, mutacin B-Ny266, nisin, mutacin 1140, show activity against clinical targets

such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus faecalis* (VRE), *Propionibacterium acne*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Clostridium difficile*, *Listeria* and *Bacillus* species (Severina *et al.*, 1998, Galvin *et al.*, 1999, Mota-Meira *et al.*, 2000, Brumfitt *et al.*, 2002, Rea *et al.*, 2007, Ghobrial *et al.*, 2009, Piper *et al.*, 2009b). It is also interesting to note that both Pep 5 and epidermin successfully inhibit the adhesion of staphylococcal cells to the surfaces of catheters (Fontana *et al.*, 2006). It is important to note, however, that these represent just a selection of the studies which have highlighted the efficacy of lantibiotics against Gram-positive clinical pathogens. It is anticipated that the number of studies in this area will continue to increase as a consequence of the further investigation of existing lantibiotic peptides and the continued identification of new forms of these antimicrobials. Some recent examples of note include the two peptide lantibiotic, lichenicidin, which exhibits antimicrobial activity against MRSA and VRE strains (Begley *et al.*, 2009) and microbisporicin, active against MRSA, VRE and clinical streptococci (Castiglione *et al.*, 2008).

While the *in vitro* success of a chemotherapeutic agent does not always correspond to its *in vivo* efficacy, there have been a number of studies which indicate that this may not be a major failing of lantibiotics. It has been revealed that mutacin B-Ny266 can be as active as vancomycin against MRSA *in vivo* (Mota-Meira *et al.*, 2005), mersacidin can be employed to eradicate a nasal MRSA infection (Kruszewska *et al.*, 2004) and that nisin F, both alone and when used in combination with lysozyme and lactoferrin, can successfully treat respiratory tract MRSA infections in mice (De Kwaadsteniet *et al.*, 2009). Trials investigating the use of lantibiotics to control the microorganisms responsible for dental plaque, halitosis,

‘strep’ throat (Hillman, 2002, Burton *et al.*, 2006, Dierksen *et al.*, 2007) and even bovine mastitis (Ryan *et al.*, 1999, Twomey *et al.*, 2000) have also all been successful.

## 1.8 Engineering of lantibiotics

Lantibiotics are gene encoded and thus one can take advantage of this trait in order to engineer novel variants of the parent peptide. Such variants have been used to study structure/ function relationships and, in some cases, engineering strategies have led to the generation of peptides with enhanced antimicrobial activity. Lantibiotic engineering can take place *in vivo*, i.e. by manipulating the original producing strain or expressing the genes heterologously in an alternative host, or *in vitro*, i.e. harnessing the activity of purified forms of the individual components of biosynthetic machinery outside of a host. The application of engineering in lantibiotic research commenced in 1992. Although initial nisin-focused investigations did not lead to the production of variants with enhanced activity (Kuipers *et al.*, 1992), they clearly demonstrated the power of this technology. During the same year the extreme consequences of making single deliberate amino acid changes was demonstrated when it was established that a single residue change in subtilin resulted in a 57-fold increase in its biological and chemical stability (Liu & Hansen, 1992). This technology has continued to be applied and in 2006 the first alanine-scanning mutagenesis of a lantibiotic, lactacin 3147, was completed (Cotter *et al.*, 2006). In this study, alanine (or glycine in cases where an alanine was already present) was introduced in place of the 59 amino acids, in turn, and the impact on the antimicrobial activity of the associated producing strain was quantified. The data generated highlighted specific areas of the peptides in which subsequent site specific

mutagenesis approaches might be beneficial. This strategy was taken a step further when site-saturation mutagenesis was employed to engineer both nukacin ISK-1 (Islam *et al.*, 2009) and mersacidin (Appleyard *et al.*, 2009). Both studies provided an in-depth insight into the structure-function relationships within the respective peptides and, in the case of nukacin ISK-1, two variants which displayed a two-fold increase in specific activity were identified (Islam *et al.*, 2009). The use of engineering to study/improve nisin has also continued at pace and since the 1990s this lantibiotic has been the subject of a number of engineering-based strategies which have employed site-directed, site-saturation and/ or random mutagenesis. While various different regions of the peptide have been engineered, the N-terminal and 'hinge' regions have been the focus of greatest attention. The benefits of manipulating the hinge (consisting of Asn20-Met21-Lys22) have been particularly notable (Yuan *et al.*, 2004, Field *et al.*, 2008). Yuan and co-workers employed a site-directed approach whereby either positively or negatively charged amino acids were introduced into the hinge. These studies demonstrated that specific changes (i.e. N20K and M21K) increased the activity of the peptide against Gram-negative bacteria such as *Shigella* species., *Pseudomonas* species. and *Salmonella* species. In the case of Field *et al.*, screening of a bank of random mutagenised nisin variants revealed that a K22T variant displayed enhanced activity against the mastitic pathogen *Streptococcus agalactiae*. This prompted the use of site-saturation mutagenesis (Field *et al.*, 2008) for each of the individual hinge residues which, when coupled with a larger selection of target strains, lead to the identification of a number of peptides with enhanced activity against *Streptococcus agalactiae*, *Staphylococcus aureus* and *Listeria monocytogenes*. Yet another study, focusing on rings A and B at the N-terminal end of nisin A, showed that the various activities of

nisin can be altered by changing the amino acid arrangement in this region of the peptide (Rink *et al.*, 2007). Two mutants, designated KFI and KSI (letters indicate the amino acids present at positions 4, 5 and 6), displayed increased antimicrobial activity against a number of bacteria such as *Leuconostoc mesenteroides*, *Lactobacillus johnsonii* and *Lactococcus lactis*. KFI, and another variant VFG, also inhibited the outgrowth of *Bacillus subtilis* 168 spores more effectively than the wild-type.

It should be noted that these and other (bio)engineering-related strategies have also been used for a variety of other purposes such as increasing lantibiotic production (Cotter *et al.*, 2006, Heinzmann *et al.*, 2006), introducing lanthionines into class II bacteriocins (Majchrzykiewicz *et al.*, 2010) and even the post-translational modification of other bioactive peptides (Kuipers *et al.*, 2004, Kluskens *et al.*, 2009, Rink *et al.*, In Press). In addition to these approaches, the ever-improving ability of chemists to generate lantibiotic-like peptides through synthetic chemistry (Cobb & Vederas, 2007, Arnusch *et al.*, 2008, Ross *et al.*, 2010) is particularly exciting and has already facilitated the creation of potent nisin-vancomycin hybrids (Arnusch *et al.*, 2008).

## **1.9 Screening for new lantibiotics**

While scientists are continuing with their efforts to further improve known lantibiotics, there is still considerable merit attached to identifying new peptides. It has also become apparent in recent years that the use of bioinformatics can be a very useful means of screening for such novel lantibiotics. The availability of databases, including both general (NCBI) and dedicated (BAGEL and BACTIBASE (de Jong *et*

*al.*, 2006, Hammami *et al.*, 2007, Hammami *et al.*, 2010)), has facilitated the use of *in silico* approaches to lantibiotic screening. The two-peptide lantibiotic lichenicidin (Begley *et al.*, 2009) was identified using such an approach. Here, the highly conserved nature of the *lanM* gene was exploited to screen the ever increasing number of bacterial genome sequences that are publicly available. Initial screening revealed 89 *lanM* genes of which 61 had not previously been associated with lantibiotic production. One of the potential novel lantibiotic producers identified, *B. licheniformis* ATCC 14580, was selected and from it lichenicidin was isolated (Begley *et al.*, 2009). A similar approach was previously employed to identify another two-peptide lantibiotic, haloduracin, which is produced by *Bacillus halodurans* C-125 (McClerren *et al.*, 2006, Lawton *et al.*, 2007). Bioinformatics has also been of considerable use when designing engineered lantibiotics and novel lanthionine-containing peptides. A study by Rink and co-workers (Rink *et al.*, 2005) used bioinformatics to predict the impact of flanking amino acids on the dehydration of serine and threonine residues, and subsequent (me)Lan formation, in lantibiotic peptides. An *in silico* comparison of known lantibiotics found that the majority of modified serines and threonines were flanked by hydrophobic residues. *In silico* models predicted the likely impact of specific residues on modification when located adjacent to hydroxyl-amino acid residues. The subsequent creation, and investigation, of these peptides validated this theory.

The discovery of the lantibiotics microbisporisin and planosporicin was achieved using a more traditional screening method (Castiglione *et al.*, 2007, Castiglione *et al.*, 2008) involving 120,000 broth extracts obtained by fermenting 40,000 actinomycetes. Firstly the microbial products were screened to assess their activity against *S. aureus* before then selecting those which retained activity



following exposure to a  $\beta$ -lactamase cocktail or D-alanyl-D-alanine affinity resin i.e. were neither  $\beta$ -lactams nor vancomycin-like glycopeptides. Those which retained antimicrobial activity after these steps were selected for further investigation. This strategy yielded thirty-five lantibiotics, of which five showed little or no similarity to any known lantibiotics.

## 1.10 Outlook

The lantibiotic class of bacteriocins has the potential to be employed in a wide variety of different ways. As outlined above they have shown great promise as chemotherapeutics that can target the multi-drug resistant Gram-positive clinical pathogens, including the particularly problematic pathogens MRSA, VRE and *Clostridium difficile*. A number of these peptides are particularly attractive as a consequence of research that has established that they have mechanisms of action and target binding sites that are distinct from those of non-lantibiotics. This coupled with high potency and their generally non-cytotoxic nature could lead to these compounds having clinical applications in the future. The possibility of engineering new and improved lantibiotics, producing novel chemotherapeutics through the fusion of lantibiotics with antibiotics, the introduction of the lantibiotic-associated modifications into non-lantibiotics and the chemical synthesis of new lantibiotic-like peptides, as well as the ongoing use of traditional and *in silico* strategies to find novel compounds, all bring this potential to a new level. In addition to these new markets, it should not be forgotten that a lantibiotic, nisin, has been successfully employed by the food industry for over a half century. Other lantibiotics have the potential to be similarly employed and, as a consequence of the limited activity of nisin against certain target strains and species, together with its poor activity at

neutral pH, there are obvious niche-markets that these can fill. The commercial potential of lantibiotics and lantibiotic-related technology and the cutting edge fundamental science that underpins lantibiotic research will ensure that these peptides will continue to attract great attention in the coming years.

## **1.11 Acknowledgements**

This work was financed by a grant from the Irish Department of Agriculture, Food and the Marine through the Food Institutional Research Measure (08/RD/C/691) and with Science Foundation Ireland Investigator award (10/IN.1/B3027). The authors would like to thank Des Field for contributing to figure preparation.

## 1.12 Bibliography

Allgaier H, Jung G, Werner RG, Schneider U & Zahner H (1986) Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. *Eur J Biochem* **160**: 9-22.

Altena K, Guder A, Cramer C & Bierbaum G (2000) Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. *Appl Environ Microbiol* **66**: 2565-2571.

Appleyard AN, Choi S, Read DM, *et al.* (2009) Dissecting structural and functional diversity of the lantibiotic mersacidin. *Chem Biol* **16**: 490-498.

Arnusch CJ, Bonvin AM, Verel AM, Jansen WT, Liskamp RM, de Kruijff B, Pieters RJ & Breukink E (2008) The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci. *Biochemistry* **47**: 12661-12663.

Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J & Sonomoto K (2009) Nukacin ISK-1, a bacteriostatic lantibiotic. *Antimicrob Agents Chemother* **53**: 3595-3598.

Begley M, Cotter PD, Hill C & Ross RP (2009) Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. *Appl Environ Microbiol* **75**: 5451-5460.

Bierbaum G & Sahl HG (1985) Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. *Arch Microbiol* **141**: 249-254.

Bierbaum G & Sahl HG (1987) Autolytic system of *Staphylococcus simulans* 22: influence of cationic peptides on activity of N-acetylmuramoyl-L-alanine amidase. *J Bacteriol* **169**: 5452-5458.

Bierbaum G, Reis M, Szekat C & Sahl HG (1994) Construction of an expression system for engineering of the lantibiotic Pep5. *Appl Environ Microbiol* **60**: 4332-4338.

Bierbaum G, Szekat C, Josten M, Heidrich C, Kempter C, Jung G & Sahl HG (1996) Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. *Appl Environ Microbiol* **62**: 385-392.

Bonelli RR, Schneider T, Sahl HG & Wiedemann I (2006) Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action studies. *Antimicrob Agents Chemother* **50**: 1449-1457.

Booth MC, Bogie CP, Sahl HG, Siezen RJ, Hatter KL & Gilmore MS (1996) Structural analysis and proteolytic activation of *Enterococcus faecalis* cytolysin, a novel lantibiotic. *Mol Microbiol* **21**: 1175-1184.

Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP & de Kruijff B (1997) The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. *Biochemistry* **36**: 6968-6976.

Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H & de Kruijff B (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. *Science* **286**: 2361-2364.

- Brotz H, Bierbaum G, Markus A, Molitor E & Sahl HG (1995) Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis *via* a novel mechanism? *Antimicrob Agents Chemother* **39**: 714-719.
- Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G & Sahl HG (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. *Mol Microbiol* **30**: 317-327.
- Brumfitt W, Salton MR & Hamilton-Miller JM (2002) Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. *J Antimicrob Chemother* **50**: 731-734.
- Buchman GW, Banerjee S & Hansen JN (1988) Structure, expression, and evolution of a gene encoding the precursor of nisin, a small protein antibiotic. *J Biol Chem* **263**: 16260-16266.
- Burton JP, Chilcott CN, Moore CJ, Speiser G & Tagg JR (2006) A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters. *J Appl Microbiol* **100**: 754-764.
- Castiglione F, Cavaletti L, Losi D, *et al.* (2007) A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete *Planomonospora sp.* *Biochemistry* **46**: 5884-5895.
- Castiglione F, Lazzarini A, Carrano L, *et al.* (2008) Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. *Chem Biol* **15**: 22-31.
- Chatterjee C, Paul M, Xie L & van der Donk WA (2005) Biosynthesis and mode of action of lantibiotics. *Chem Rev* **105**: 633-684.
- Chatterjee S, Lad SJ, Phansalkar MS, Rupp RH, Ganguli BN, Fehlhaber HW & Kogler H (1992) Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. *J Antibiot (Tokyo)* **45**: 832-838.
- Chen P, Qi F, Novak J & Caufield PW (1999) The specific genes for lantibiotic mutacin II biosynthesis in *Streptococcus mutans* T8 are clustered and can be transferred en bloc. *Appl Environ Microbiol* **65**: 1356-1360.
- Cobb SL & Vederas JC (2007) A concise stereoselective synthesis of orthogonally protected lanthionine and beta-methylanthionine. *Org Biomol Chem* **5**: 1031-1038.
- Cotter PD, Hill C & Ross RP (2005) Bacterial lantibiotics: strategies to improve therapeutic potential. *Curr Protein Pept Sci* **6**: 61-75.
- Cotter PD, Hill C & Ross RP (2005) Bacteriocins: developing innate immunity for food. *Nat Rev Microbiol* **3**: 777-788.
- Cotter PD, Draper LA, Lawton EM, McAuliffe O, Hill C & Ross RP (2006) Overproduction of wild-type and bioengineered derivatives of the lantibiotic lactacin 3147. *Appl Environ Microbiol* **72**: 4492-4496.
- Cotter PD, O'Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C & Ross RP (2005) Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lactacin 3147. *Proc Natl Acad Sci U S A* **102**: 18584-18589.

- Cotter PD, Deegan LH, Lawton EM, Draper LA, O'Connor PM, Hill C & Ross RP (2006) Complete alanine scanning of the two-component lantibiotic lactacin 3147: generating a blueprint for rational drug design. *Mol Microbiol* **62**: 735-747.
- de Jong A, van Hijum SA, Bijlsma JJ, Kok J & Kuipers OP (2006) BAGEL: a web-based bacteriocin genome mining tool. *Nucleic Acids Res* **34**: W273-279.
- de Kwaadsteniet M, Ten Doeschate K & Dicks LM (2008) Characterization of the structural gene encoding nisin F, a new lantibiotic produced by a *Lactococcus lactis* subsp. *lactis* isolate from freshwater catfish (*Clarias gariepinus*). *Appl Environ Microbiol* **74**: 547-549.
- de Kwaadsteniet M, Doeschate KT & Dicks LM (2009) Nisin F in the treatment of respiratory tract infections caused by *Staphylococcus aureus*. *Lett Appl Microbiol* **48**: 65-70.
- Deegan LH, Cotter PD, Hill C & Ross P (2006) Bacteriocins: Biological tools for bio-preservation and shelf-life extension. *International Dairy Journal* **16**: 1058-1071.
- Delves-Broughton J, Blackburn P, Evans RJ & Hugenholtz J (1996) Applications of the bacteriocin, nisin. *Antonie Van Leeuwenhoek* **69**: 193-202.
- Dierksen KP, Moore CJ, Inglis M, Wescombe PA & Tagg JR (2007) The effect of ingestion of milk supplemented with salivaricin A-producing *Streptococcus salivarius* on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. *FEMS Microbiol Ecol* **59**: 584-591.
- Dischinger J, Josten M, Szekat C, Sahl HG & Bierbaum G (2009) Production of the novel two-peptide lantibiotic lichenicidin by *Bacillus licheniformis* DSM 13. *PLoS One* **4**: e6788.
- Dougherty BA, Hill C, Weidman JF, Richardson DR, Venter JC & Ross RP (1998) Sequence and analysis of the 60 kb conjugative, bacteriocin-producing plasmid pMRC01 from *Lactococcus lactis* DPC3147. *Mol Microbiol* **29**: 1029-1038.
- Draper LA, Ross RP, Hill C & Cotter PD (2008) Lantibiotic immunity. *Curr Protein Pept Sci* **9**: 39-49.
- Dufour A, Hindre T, Haras D & Le Pennec JP (2007) The biology of lantibiotics from the lactacin 481 group is coming of age. *FEMS Microbiol Rev* **31**: 134-167.
- Engelke G, Gutowski-Eckel Z, Kiesau P, Siegers K, Hammelmann M & Entian KD (1994) Regulation of nisin biosynthesis and immunity in *Lactococcus lactis* 6F3. *Appl Environ Microbiol* **60**: 814-825.
- Ersfeld-Dressen H, Sahl HG & Brandis H (1984) Plasmid involvement in production of and immunity to the staphylococcin-like peptide Pep 5. *J Gen Microbiol* **130**: 3029-3035.
- Fath MJ & Kolter R (1993) ABC transporters: bacterial exporters. *Microbiol Rev* **57**: 995-1017.
- Field D, Connor PMO, Cotter PD, Hill C & Ross RP (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. *Mol Microbiol* **69**: 218-230.

- Fontana MB, de Bastos Mdo C & Brandelli A (2006) Bacteriocins Pep5 and epidermin inhibit *Staphylococcus epidermidis* adhesion to catheters. *Curr Microbiol* **52**: 350-353.
- Fredenhagen A, Fendrich G, Marki F, Marki W, Gruner J, Raschdorf F & Peter HH (1990) Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin. *J Antibiot (Tokyo)* **43**: 1403-1412.
- Galvin M, Hill C & Ross RP (1999) Lacticin 3147 displays activity in buffer against Gram-positive bacterial pathogens which appear insensitive in standard plate assays. *Lett Appl Microbiol* **28**: 355-358.
- Ghobrial OG, Derendorf H & Hillman JD (2009) Pharmacodynamic activity of the lantibiotic MU1140. *Int J Antimicrob Agents* **33**: 70-74.
- Goto Y, Li B, Claesen J, Shi Y, Bibb MJ & van der Donk WA (2010) Discovery of unique lanthionine synthetases reveals new mechanistic and evolutionary insights. *PLoS Biol* **8**: e1000339.
- Gratia A (1925) Sur un remarquable exemple d'antagonisme entre deux souches de Colibacille. *C R Soc Biol* **93**: 1040-1041.
- Gross E & Morell JL (1971) Structure of nisin. *Journal of the American Chemical Society* **93**: 4634-4635.
- Guder A, Schmitter T, Wiedemann I, Sahl HG & Bierbaum G (2002) Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity. *Appl Environ Microbiol* **68**: 106-113.
- Hammami R, Zouhir A, Ben Hamida J & Fliss I (2007) BACTIBASE: a new web-accessible database for bacteriocin characterization. *BMC Microbiol* **7**: 89.
- Hammami R, Zouhir A, Le Lay C, Ben Hamida J & Fliss I (2010) BACTIBASE second release: a database and tool platform for bacteriocin characterization. *BMC Microbiol* **10**: 22.
- Hasper HE, de Kruijff B & Breukink E (2004) Assembly and stability of nisin-lipid II pores. *Biochemistry* **43**: 11567-11575.
- Havarstein LS, Diep DB & Nes IF (1995) A family of bacteriocin ABC transporters carry out proteolytic processing of their substrates concomitant with export. *Mol Microbiol* **16**: 229-240.
- Heinzmann S, Entian KD & Stein T (2006) Engineering *Bacillus subtilis* ATCC 6633 for improved production of the lantibiotic subtilin. *Appl Microbiol Biotechnol* **69**: 532-536.
- Hillman JD (2002) Genetically modified *Streptococcus mutans* for the prevention of dental caries. *Antonie Van Leeuwenhoek* **82**: 361-366.
- Holo H, Jeknic Z, Daeschel M, Stevanovic S & Nes IF (2001) Plantaricin W from *Lactobacillus plantarum* belongs to a new family of two-peptide lantibiotics. *Microbiology* **147**: 643-651.
- Hosoda K, Ohya M, Kohno T, Maeda T, Endo S & Wakamatsu K (1996) Structure determination of an immunopotentiator peptide, cinnamycin, complexed with lysophosphatidylethanolamine by 1H-NMR. *J Biochem* **119**: 226-230.

- Hsu ST, Breukink E, Bierbaum G, Sahl HG, de Kruijff B, Kaptein R, van Nuland NA & Bonvin AM (2003) NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. *J Biol Chem* **278**: 13110-13117.
- Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM & van Nuland NA (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. *Nat Struct Mol Biol* **11**: 963-967.
- Hyink O, Balakrishnan M & Tagg JR (2005) *Streptococcus rattus* strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. *FEMS Microbiol Lett* **252**: 235-241.
- Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, Nakayama J & Sonomoto K (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. *Mol Microbiol* **72**: 1438-1447.
- Jack R, Benz R, Tagg J & Sahl HG (1994) The mode of action of SA-FF22, a lantibiotic isolated from *Streptococcus pyogenes* strain FF22. *European Journal of Biochemistry* **219**: 699-705.
- Jack RW, Tagg JR & Ray B (1995) Bacteriocins of Gram-positive bacteria. *Microbiological Reviews* **59**: 171-200.
- Jung G (1991) Lantibiotics - ribosomally synthesized biologically active polypeptides containing sulfide bridges and  $\alpha,\beta$ -didehydroamino acids. *Angew Chem Int Ed Engl* **30**: 1051-1192.
- Kaletta C, Entian KD & Jung G (1991) Prepeptide sequence of cinnamycin (Ro 09-0198): the first structural gene of a duramycin-type lantibiotic. *Eur J Biochem* **199**: 411-415.
- Kaletta C, Entian KD, Kellner R, Jung G, Reis M & Sahl HG (1989) Pep5, a new lantibiotic: structural gene isolation and prepeptide sequence. *Arch Microbiol* **152**: 16-19.
- Karakas Sen A, Narbad A, Horn N, Dodd HM, Parr AJ, Colquhoun I & Gasson MJ (1999) Post-translational modification of nisin. The involvement of NisB in the dehydration process. *Eur J Biochem* **261**: 524-532.
- Karaya K, Shimizu T & Taketo A (2001) New gene cluster for lantibiotic streptin possibly involved in streptolysin S formation. *J Biochem* **129**: 769-775.
- Kellner R, Jung G, Horner T, Zahner H, Schnell N, Entian KD & Gotz F (1988) Gallidermin: a new lanthionine-containing polypeptide antibiotic. *Eur J Biochem* **177**: 53-59.
- Kleerebezem M (2004) Quorum sensing control of lantibiotic production; nisin and subtilin autoregulate their own biosynthesis. *Peptides* **25**: 1405-1414.
- Klein C, Kaletta C & Entian KD (1993) Biosynthesis of the lantibiotic subtilin is regulated by a histidine kinase/response regulator system. *Appl Environ Microbiol* **59**: 296-303.
- Kluskens LD, Kuipers A, Rink R, de Boef E, Fekken S, Driessen AJ, Kuipers OP & Moll GN (2005) Post-translational modification of therapeutic peptides by NisB, the dehydratase of the lantibiotic nisin. *Biochemistry* **44**: 12827-12834.



- Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN & Haas M (2009) Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. *J Pharmacol Exp Ther* **328**: 849-854.
- Kordel M, Schuller F & Sahl HG (1989) Interaction of the pore forming-peptide antibiotics Pep 5, nisin and subtilin with non-energized liposomes. *FEBS Lett* **244**: 99-102.
- Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO & Ljungh A (2004) Mersacidin eradicates methicillin-resistant *Staphylococcus aureus* (MRSA) in a mouse rhinitis model. *J Antimicrob Chemother* **54**: 648-653.
- Kuipers A, de Boef E, Rink R, Fekken S, Kluskens LD, Driessen AJ, Leenhouts K, Kuipers OP & Moll GN (2004) NisT, the transporter of the lantibiotic nisin, can transport fully modified, dehydrated, and unmodified prenisin and fusions of the leader peptide with non-lantibiotic peptides. *J Biol Chem* **279**: 22176-22182.
- Kuipers OP, Rollema HS, Yap WM, Boot HJ, Siezen RJ & de Vos WM (1992) Engineering dehydrated amino acid residues in the antimicrobial peptide nisin. *J Biol Chem* **267**: 24340-24346.
- Kupke T & Gotz F (1997) The enethiolate anion reaction products of EpiD. pKa value of the enethiol side chain is lower than that of the thiol side chain of peptides. *J Biol Chem* **272**: 4759-4762.
- Lawton EM, Cotter PD, Hill C & Ross RP (2007) Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile *Bacillus halodurans* C-125. *FEMS Microbiol Lett* **267**: 64-71.
- Lawton EM, Ross RP, Hill C & Cotter PD (2007) Two-peptide lantibiotics: a medical perspective. *Mini Rev Med Chem* **7**: 1236-1247.
- Liu W & Hansen JN (1992) Enhancement of the chemical and antimicrobial properties of subtilin by site-directed mutagenesis. *J Biol Chem* **267**: 25078-25085.
- Maffioli SI, Potenza D, Vasile F, De Matteo M, Sosio M, Marsiglia B, Rizzo V, Scolastico C & Donadio S (2009) Structure revision of the lantibiotic 97518. *J Nat Prod* **72**: 605-607.
- Majchrzykiewicz JA, Lubelski J, Moll GN, Kuipers A, Bijlsma JJ, Kuipers OP & Rink R (2010) Production of a class II two-component lantibiotic of *Streptococcus pneumoniae* using the class I nisin synthetic machinery and leader sequence. *Antimicrob Agents Chemother* **54**: 1498-1505.
- Majer F, Schmid DG, Altena K, Bierbaum G & Kupke T (2002) The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. *J Bacteriol* **184**: 1234-1243.
- Mc Clerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL & van der Donk WA (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. *Proc Natl Acad Sci U S A* **103**: 17243-17248.
- McAuliffe O, Hill C & Ross RP (2000) Each peptide of the two-component lantibiotic lactacin 3147 requires a separate modification enzyme for activity. *Microbiology* **146** ( Pt 9): 2147-2154.

- McAuliffe O, O'Keeffe T, Hill C & Ross RP (2001) Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR. *Mol Microbiol* **39**: 982-993.
- McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL & van der Donk WA (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. *Proc Natl Acad Sci U S A* **103**: 17243-17248.
- Meyer C, Bierbaum G, Heidrich C, Reis M, Suling J, Iglesias-Wind MI, Kempter C, Molitor E & Sahl HG (1995) Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC. Evidence for a role of PepC in thioether formation. *Eur J Biochem* **232**: 478-489.
- Morgan SM, Galvin M, Ross RP & Hill C (2001) Evaluation of a spray-dried lacticin 3147 powder for the control of *Listeria monocytogenes* and *Bacillus cereus* in a range of food systems. *Lett Appl Microbiol* **33**: 387-391.
- Mortvedt CI, Nissen-Meyer J, Sletten K & Nes IF (1991) Purification and amino acid sequence of lactocin S, a bacteriocin produced by *Lactobacillus sake* L45. *Appl Environ Microbiol* **57**: 1829-1834.
- Mota-Meira M, Morency H & Lavoie MC (2005) In vivo activity of mutacin B-Ny266. *J Antimicrob Chemother* **56**: 869-871.
- Mota-Meira M, LaPointe G, Lacroix C & Lavoie MC (2000) MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. *Antimicrob Agents Chemother* **44**: 24-29.
- Mulders JW, Boerrigter IJ, Rollema HS, Siezen RJ & de Vos WM (1991) Identification and characterization of the lantibiotic nisin Z, a natural nisin variant. *Eur J Biochem* **201**: 581-584.
- Navaratna MA, Sahl HG & Tagg JR (1998) Two-component anti-*Staphylococcus aureus* lantibiotic activity produced by *Staphylococcus aureus* C55. *Appl Environ Microbiol* **64**: 4803-4808.
- Nissen-Meyer J, Rogne P, Oppegard C, Haugen HS & Kristiansen PE (2009) Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by Gram-positive bacteria. *Curr Pharm Biotechnol* **10**: 19-37.
- O'Sullivan L, Ross RP & Hill C (2003) A lacticin 481-producing adjunct culture increases starter lysis while inhibiting nonstarter lactic acid bacteria proliferation during Cheddar cheese ripening. *J Appl Microbiol* **95**: 1235-1241.
- Oman TJ & van der Donk WA (2009) Insights into the mode of action of the two-peptide lantibiotic haloduracin. *ACS Chem Biol* **4**: 865-874.
- Ottenwalder B, Kupke T, Brecht S, Gnau V, Metzger J, Jung G & Gotz F (1995) Isolation and characterization of genetically engineered gallidermin and epidermin analogs. *Appl Environ Microbiol* **61**: 3894-3903.
- Pag U & Sahl HG (2002) Multiple activities in lantibiotics-models for the design of novel antibiotics? *Curr Pharm Des* **8**: 815-833.
- Pag U, Heidrich C, Bierbaum G & Sahl HG (1999) Molecular analysis of expression of the lantibiotic pep5 immunity phenotype. *Appl Environ Microbiol* **65**: 591-598.
- Paik SH, Chakicherla A & Hansen JN (1998) Identification and characterization of the structural and transporter genes for, and the chemical and biological properties

of, sublancin 168, a novel lantibiotic produced by *Bacillus subtilis* 168. *J Biol Chem* **273**: 23134-23142.

Peschel A, Schnell N, Hille M, Entian KD & Gotz F (1997) Secretion of the lantibiotics epidermin and gallidermin: sequence analysis of the genes *gdmT* and *gdmH*, their influence on epidermin production and their regulation by EpiQ. *Mol Gen Genet* **254**: 312-318.

Piard JC, Muriana PM, Desmazeaud MJ & Klaenhammer TR (1992) Purification and partial characterization of lacticin 481, a lanthionine-containing bacteriocin produced by *Lactococcus lactis* subsp. *lactis* CNRZ 481. *Appl Environ Microbiol* **58**: 279-284.

Piard JC, Kuipers OP, Rollema HS, Desmazeaud MJ & de Vos WM (1993) Structure, organization, and expression of the *lct* gene for lacticin 481, a novel lantibiotic produced by *Lactococcus lactis*. *J Biol Chem* **268**: 16361-16368.

Piper C, Cotter PD, Ross RP & Hill C (2009) Discovery of medically significant lantibiotics. *Curr Drug Discov Technol* **6**: 1-18.

Piper C, Draper LA, Cotter PD, Ross RP & Hill C (2009) A comparison of the activities of lacticin 3147 and nisin against drug-resistant *Staphylococcus aureus* and *Enterococcus* species. *J Antimicrob Chemother* **64**: 546-551.

Pridmore D, Rekhif N, Pittet AC, Suri B & Mollet B (1996) Variacin, a new lanthionine-containing bacteriocin produced by *Micrococcus varians*: Comparison to lacticin 481 of *Lactococcus lactis*. *Appl Environ Microbiol* **62**: 1799-1802.

Qiao M & Saris PE (1996) Evidence for a role of NisT in transport of the lantibiotic nisin produced by *Lactococcus lactis* N8. *FEMS Microbiol Lett* **144**: 89-93.

Rawlinson EL, Nes IF & Skaugen M (2002) LasX, a transcriptional regulator of the lactocin S biosynthetic genes in *Lactobacillus sakei* L45, acts both as an activator and a repressor. *Biochimie* **84**: 559-567.

Rea MC, Clayton E, O'Connor PM, Shanahan F, Kiely B, Ross RP & Hill C (2007) Antimicrobial activity of lacticin 3,147 against clinical *Clostridium difficile* strains. *J Med Microbiol* **56**: 940-946.

Riley MA & Wertz JE (2002) Bacteriocin diversity: ecological and evolutionary perspectives. *Biochimie* **84**: 357-364.

Rince A, Dufour A, Le Pogam S, Thuault D, Bourgeois CM & Le Pennec JP (1994) Cloning, expression, and nucleotide sequence of genes involved in production of lactococcin DR, a bacteriocin from *Lactococcus lactis* subsp. *lactis*. *Appl Environ Microbiol* **60**: 1652-1657.

Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJ, Moll GN & Kuipers OP (2005) Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. *Biochemistry* **44**: 8873-8882.

Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJ, Kuipers OP & Moll GN (2007) Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C-terminal truncation. *Appl Environ Microbiol* **73**: 5809-5816.

- Rink R, Arkema-Meter A, Baudoin I, Post E, Kuipers A, Nelemans SA, Akanbi MHJ & Moll GN (2010) To protect peptide pharmaceuticals against peptidases. *Journal of Pharmacological and Toxicological Methods* **61**(2), 210-218.
- Rogers LA (1928) The Inhibiting Effect of *Streptococcus lactis* on *Lactobacillus bulgaricus*. *J Bacteriol* **16**: 321-325.
- Ross AC, Liu H, Pattabiraman VR & Vederas JC (2010) Synthesis of the lantibiotic lactocin S using peptide cyclizations on solid phase. *J Am Chem Soc* **132**: 462-463.
- Ryan MP, Rea MC, Hill C & Ross RP (1996) An application in cheddar cheese manufacture for a strain of *Lactococcus lactis* producing a novel broad-spectrum bacteriocin, lacticin 3147. *Appl Environ Microbiol* **62**: 612-619.
- Ryan MP, Flynn J, Hill C, Ross RP & Meaney WJ (1999) The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental challenge with *Streptococcus dysgalactiae* in nonlactating dairy cows. *J Dairy Sci* **82**: 2625-2631.
- Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP & Hill C (1999) Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. *J Biol Chem* **274**: 37544-37550.
- Sahl HG, Jack RW & Bierbaum G (1995) Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. *Eur J Biochem* **230**: 827-853.
- Sahl HG, Ersfeld-Dressen H, Bierbaum G, Josten M, Kordel M, Reis M & Schuller F (1987) Different mechanisms of insensitivity to the staphylococcin-like peptide Pep 5. *Zentralbl Bakteriol Mikrobiol Hyg A* **267**: 173-185.
- Schnell N, Engelke G, Augustin J, Rosenstein R, Ungermann V, Gotz F & Entian KD (1992) Analysis of genes involved in the biosynthesis of lantibiotic epidermin. *Eur J Biochem* **204**: 57-68.
- Severina E, Severin A & Tomasz A (1998) Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. *J Antimicrob Chemother* **41**: 341-347.
- Siezen RJ (1996) Subtilases: subtilisin-like serine proteases. *Adv Exp Med Biol* **379**: 75-93.
- Skaugen M, Abildgaard CI & Nes IF (1997) Organization and expression of a gene cluster involved in the biosynthesis of the lantibiotic lactocin S. *Mol Gen Genet* **253**: 674-686.
- Skaugen M, Nissen-Meyer J, Jung G, Stevanovic S, Sletten K, Inger C, Abildgaard M & Nes IF (1994) In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. *J Biol Chem* **269**: 27183-27185.
- Stein, T., Borchert, S., Conrad, B., Feesche, J., Hofemeister, B., Hofemeister, J., & Entian, K. D. (2002) Two different lantibiotic-like peptides originate from the ericin gene cluster of *Bacillus subtilis* A1/3. *Journal of Bacteriology*, **184**(6), 1703-1711.
- Stock AM, Robinson VL & Goudreau PN (2000) Two-component signal transduction. *Annu Rev Biochem* **69**: 183-215.
- Tagg JR, Dajani AS & Wannamaker LW (1976) Bacteriocins of Gram-positive bacteria. *Bacteriol Rev* **40**: 722-756.

- Thomas TD & Crow VL (1983) Mechanism of D(-)-lactic acid formation in cheddar cheese. *New Zealand Journal of Dairy Science and Technology* **18**: 131-141.
- Twomey DP, Wheelock AI, Flynn J, Meaney WJ, Hill C & Ross RP (2000) Protection against *Staphylococcus aureus* mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147. *J Dairy Sci* **83**: 1981-1988.
- van den Hooven HW, Lagerwerf FM, Heerma W, Haverkamp J, Piard JC, Hilbers CW, Siezen RJ, Kuipers OP & Rollema HS (1996) The structure of the lantibiotic lacticin 481 produced by *Lactococcus lactis*: location of the thioether bridges. *FEBS Lett* **391**: 317-322.
- Wescombe PA & Tagg JR (2003) Purification and characterization of streptin, a type A1 lantibiotic produced by *Streptococcus pyogenes*. *Appl Environ Microbiol* **69**: 2737-2747.
- Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B & Sahl HG (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J Biol Chem* **276**: 1772-1779.
- Wiedemann I, Bottiger T, Bonelli RR, *et al.* (2006) The mode of action of the lantibiotic lacticin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. *Mol Microbiol* **61**: 285-296.
- Willey JM & van der Donk WA (2007) Lantibiotics: peptides of diverse structure and function. *Annu Rev Microbiol* **61**: 477-501.
- Wirawan RE, Klesse NA, Jack RW & Tagg JR (2006) Molecular and genetic characterization of a novel nisin variant produced by *Streptococcus uberis*. *Appl Environ Microbiol* **72**: 1148-1156.
- Xie L & van der Donk WA (2004) Post-translational modifications during lantibiotic biosynthesis. *Curr Opin Chem Biol* **8**: 498-507.
- Ye SY, Koponen O, Qiao M, Immonen T & Saris PE (1995) NisP is related to nisin precursor processing and possibly to immunity in *Lactococcus lactis*. *J Tongji Med Univ* **15**: 193-197.
- Yonezawa H & Kuramitsu HK (2005) Genetic analysis of a unique bacteriocin, Smb, produced by *Streptococcus mutans* GS5. *Antimicrob Agents Chemother* **49**: 541-548.
- Yuan J, Zhang ZZ, Chen XZ, Yang W & Huan LD (2004) Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. *Appl Microbiol Biotechnol* **64**: 806-815.
- Zendo T, Fukao M, Ueda K, Higuchi T, Nakayama J & Sonomoto K (2003) Identification of the lantibiotic nisin Q, a new natural nisin variant produced by *Lactococcus lactis* 61-14 isolated from a river in Japan. *Biosci Biotechnol Biochem* **67**: 1616-1619.


## 1.13 Figures

Figure 1.1 Lantibiotic classification

|                           |                   |                   |               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|---------------------------|-------------------|-------------------|---------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|--|--|--|--|--|--|--|--|--|--|--|
| <b>Class I</b><br>(LanBC) | Planosporicin     | <b>Mersacidin</b> | RumB          | G | E | P | R | V | S | D | G | S | Q | F | C | T | S | T | K | E | N | W | G | T | I | M | F | V | C | C |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Nisin             |                   | Plantaricin C |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | C | T | L | T | S | E | D | H | L | A | T | W | V | C | X |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Epidermin         |                   | Mersacidin    | C | T | F | T | L | P | G | G | G | G | V | C | T | L | T | S | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Streptin          |                   | Michiganin    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | S | G | W | L | C | T | L | T | I | Q | G | I | I | A | R |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Pep5              |                   | Actagardine   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | C |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
| <b>Class II</b><br>(LanM) | Lactacin 481      |                   | C55a          | C | S | T | N | T | F | S | L | S | D | Y | W | G | N | K | G | N | W | C | T | A | T | H | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | <b>Mersacidin</b> |                   | LtnA1         | C | S | T | N | T | F | S | L | S | D | Y | W | G | N | N | G | A | W | C | T | L | T | H | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | LtnA1             |                   | SmbB          | I | G | T | T | V | V | N | S | T | F | S | I | V | L | G | N | K | G | V | I | C | T | V | T | V | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Cytolysin         |                   | bhtA-alpha    | I | G | T | T | V | V | N | S | T | F | S | I | V | L | G | N | K | G | V | I | C | T | V | T | V | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Lactocin S        |                   | Phwa          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   | K | C | K | W | W | N | I | S | C | D | L | G | N | N | G | H | V | C | T | L | S | H | E |  |  |  |  |  |  |  |  |  |  |  |
| <b>Class III</b>          | Cinnamycin        |                   | BlhA1         | T | I | T | L | S | T | C | A | I | L | S | K | P | L | G | N | N | G | A | V | C | T | V | T | K | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |
|                           | Sublancin         |                   | BhaA1         | C | A | W | Y | N | I | S | C | R | L | G | N | K | G | A | Y | C | T | L | T | V | E |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |  |  |  |  |  |  |  |  |  |  |

Lantibiotics can be divided into Type I, II and III peptides. The Type I and II peptides can be further divided into 12 groups on the basis of the sequence of the lantibiotic propeptide. In one representative case, the mersacidin-like peptides, each of the corresponding propeptides are listed and aligned. Amino acids that are 100% conserved are highlighted in black.

**Figure 1.2** Representative lantibiotic structures



Modified residues are coloured (dehydrobutyrine – Dhb, green; dehydroalanine – Dha, orange; lanthionineAla-S-Ala, yellow;  $\beta$ -methylanthionine – Abu-S-Ala, light blue; D-alanine – Ala, grey; lysinoalanine – Lys-NH-Ala; other modified residues - pink).

## **Chapter II**

### **Fate of *Mycobacterium avium* subspecies *paratuberculosis* ATCC19698 during Manufacture and Ripening of a Non-Pasteurised Smear Type Cheese made with and without Lacticin 3147.**

Brian Healy, Mary C. Rea, R. Paul Ross, Colin Hill and Paul D. Cotter



## 2.1 Abstract

*Mycobacterium avium* subspecies *paratuberculosis* (*MAP*) is an obligate pathogenic bacterium which is the causative agent for Johne's disease, a localized chronic infection of the lower intestine (ileum) of animals. *MAP* has also been implicated in Crohn's disease in humans, although this association remains highly controversial. There has also been considerable debate as to whether or not the microorganism can withstand HTST (High Temperature Short Time) pasteurization. Therefore, until it can be definitively established that the consumption of *MAP* infected food does not lead to human infections, the elimination of this pathogen from the food chain would be prudent.

In this study, an additional hurdle was introduced into a dairy product in order to determine if it provided additional protection against *MAP*. More specifically, a lacticin 3147 producing starter culture was employed for the production of smear ripened raw milk cheese. Lacticin 3147 is a two peptide bacteriocin (Bac) produced by a number of *Lactococcus lactis* strains, has been comprehensively characterised and has been shown to inhibit many clinically relevant Gram-positive pathogens, including *MAP*. Two separate cheeses were produced using either Bac<sup>+</sup> or Bac<sup>-</sup> versions of the same starter culture. Both were allowed to ripen for 4 weeks after the addition of the smear and along with the 'gold standard' plate enumeration method, the viability of the pathogen was also determined using a molecular approach.

Although some decrease in *MAP* numbers was observed over ripening, this decrease was independent of lacticin 3147 production. Thus, other strategies will

need to be tested with a view to harnessing the anti-*MAP* activity of this bacteriocin in dairy products.

## 2.2 Introduction

*Mycobacterium avium* subspecies *paratuberculosis* (*MAP*) is an obligate pathogenic bacterium and is the causative agent of Johne's disease (Cocito *et al.*, 1994), a localized infection of the lower intestine (ileum) which mainly affects ruminants. The resulting lesions from this chronic enteritis are similar to those present in the intestines of patients with Crohn's disease (Davis & Madsen-Bouterse, 2012), consistent with suggestions that this bacterium also contributes to this disease. However, a definite link between *MAP* and Crohn's disease has yet to be established and conflicting research outcomes (Hermon-Taylor, 2002, Momotani *et al.*, 2012) on this subject continues to evoke much debate.

In Ireland it is apparent that the levels of Johne's disease are on the rise. The opening up of the Single European market in 1992 is thought to have contributed to this increase. In 1955, Johne's disease became notifiable (S.I. No. 86 of 1955) although only 92 cases were reported between 1932 and 1992, despite the payment of compensation for confirmed cases. In stark contrast, 232 cases were reported between 1995 and 2002 (Good *et al.*, 2009). As well as the associated economic implications (culling, lower milk and beef yields, veterinary costs), the potential for significant increases in the frequency of *MAP*-containing milk is of concern. Indeed, infected animals excrete the bacterium in large numbers, which contributes greatly to the subsequent infection of calves and the contamination of milk (Fecteau & Whitlock, 2010). This, coupled with *MAP*'s ability to survive outside its host for extended periods of time (Rowe & Grant, 2006) and the possibility of the bacterium surviving pasteurisation, another disputed issue (Lynch *et al.*, 1997, Grant *et al.*, 2002), highlights a route *via* which the pathogen could enter the human food chain.

It is thus a concern that the pathogen has been identified in off-the-shelf dairy products. Out of 357 commercially pasteurized milk samples from Ireland tested, 9.8% were found to be PCR positive for *MAP* (O'Reilly *et al.*, 2004) while, in the US, 2.8% of 702 pasteurised milk samples were found to be culture positive (Ellingson *et al.*, 2005). In the latter case, given the fastidious nature of the strain, this is likely to be a significant under-representation. Given that Irish exports of milk and milk products make a very significant contribution to Irish national GDP, the elimination of any potential zoonotic pathogens from the Irish milk can only be seen as prudent both from a public health and economic perspective.

One potential method to increase the safety of dairy products is through the introduction of additional barriers to aid in the eradication of pathogenic bacteria. One such barrier is the use of bacteriocins (Deegan *et al.*, 2006, Gálvez *et al.*, 2007). Defined as ribosomally synthesised antimicrobial peptides (Cotter *et al.*, 2005), many bacteriocins are produced by lactic acid bacteria. One such strain is *Lactococcus lactis* DPC 3147, which produces the Class 1 bacteriocin, lacticin 3147 (Ryan *et al.*, 1996). *L. lactis* are also the most important industrial starter cultures, both from a biotechnological and economic viewpoint (Bolotin *et al.*, 2001, Fox *et al.*, 2004). The selection of technologically superior strains is based on a number of traits such as rapid lactose metabolism, proteolytic activity, citrate metabolism, bacteriophage resistance, antibiotic resistance, exopolysaccharide (EPS) production and bacteriocin production (Dal Bello *et al.*, 2012). Importantly, many of these traits are plasmid encoded and their self-transmissible nature has been exploited to improve the genotypes of industrial starters in a food grade manner (Mills *et al.*, 2006).

*L. lactis* DPC 3147 harbours the 60.2 kb plasmid pMRC01. This plasmid carries genes involved in conjugative transfer, phage resistance through abortive infection and the production of and immunity to the lantibiotic, lacticin 3147 (Coakley *et al.*, 1997). Lantibiotics are distinguished by the presence of rare amino acids found within their mature structures, resulting from a number of post-translational modifications (Healy *et al.*, 2010). Two of these, dehydroalanine and dehydrobutyrine, are involved in the formation of the lanthionine bridges, the structures that give these antimicrobials their name. The mode of action of lacticin 3147 is two-fold and involves the synergistic interaction of its two component peptides, Ltn $\alpha$  and Ltn $\beta$ , leading to the sequestration of essential peptidoglycan precursors and pore formation (McAuliffe *et al.*, 1998, Wiedemann *et al.*, 2006). Like many lantibiotics, lacticin 3147 displays activity in the micro to nano-molar range against many clinically significant pathogens (Piper *et al.*, 2009a, Piper *et al.*, 2009b, Iancu *et al.*, 2012).

There are numerous ways in which lantibiotics can be used in order to enhance the safety of a food (see Deegan *et al.* (2006) for an extensive review on this topic). In this study, an *in situ* method of production by a starter culture in the manufacture of a smear ripened cheese from unpasteurized milk was assessed as a means of controlling the growth of *MAP*. Smear ripened cheeses are characterised by the development of microbial growth on their surfaces during ripening (Brennan *et al.*, 2004). A previous study, by O'Sullivan *et al.* (2006), showed that the introduction of a lacticin 3147 producing *L. lactis* culture to the surface of a smear-ripened cheese led to a 100-fold decrease in *Listeria monocytogenes* numbers. Here, two smear ripened cheeses were manufactured to assess the survival of *MAP* over a 28 day ripening period. The first cheese was made with a lacticin 3147 producing

starter culture while the second was made with a non-bacteriocin producing equivalent and served as a control. It was found that although an approximate 1 log reduction in *MAP* numbers occurred over the ripening period, this reduction occurred regardless of which starter strain was used and, thus, was independent of bacteriocin production.

## **2.3 Materials and Methods**

### **2.3.1 Bacterial strains and growth conditions**

The strains used in this study are listed in Table 2.1. All *L. lactis* strains were grown on/ in M17 agar and broth (Oxoid) supplemented with 0.5% lactose and incubated at 30°C overnight. *MAP* ATCC19698 was grown on Middlebrook 7H9 broth (Becton Dickinson) containing 10% oleic acid-albumin-dextrose-catalase (OADC) supplement (Becton Dickinson) and 0.05% Tween 80. Mycobactine J was added at 2 µg/ ml (Synbiotics Europe) while vancomycin, nalidixic acid and amphotericin B were added at concentrations of 17.5 µg /ml, 17.5 µg/ ml and 12.5 µg/ ml, respectively. Incubation was for 37°C for up to 6 weeks with constant gentle agitation. For enumeration, *MAP* was also grown on Middlebrook 7H10 agar (Becton Dickinson) and Herrold's Egg Yolk agar (HEYA) (Becton Dickinson), with the same supplements and antibiotics as for 7H9 agar. Due to the long incubation times required, all enumerations were carried out in 25 cm<sup>3</sup> culture flasks so as to prevent dehydration of the agar (Sarstedt).

### **2.3.2 Production of smeared cheese from unpasteurised milk**

Twenty litres of unpasteurized milk were collected from bulk milk tanks on the Moorepark Farm and refrigerated at 4°C. Samples were analysed to determine total bacterial counts (TBCs) on Milk Plate Count Agar (MPCA), somatic cell counts (SCCs), %fat, %lactose, %protein (all using a MilkoScan 600) and to test for the absence of antibiotics (Delvo test). 10 l of milk were added to two separate vats and heated. At 20°C, 1.5% (v/v) of *L. lactis* DPC3147 (lacticin 3147 producing starter culture) and 1.5% (v/v) of *L. lactis* DPC5399 (non lacticin 3147 producing starter culture) were inoculated into separate vats. At 30°C, 15 ml of the *MAP* strain (~1.0 x

$10^9$  cfu/ml) was added to each vat to give a final concentration of  $\sim 10^5$  cfu/ml and mixed well. Once a pH of 6.55 was reached, 1.6 ml/l of rennet was added to each vat and the milk was left to coagulate for 75 minutes. The curd was cut and allowed to rest for 5 minutes. With constant stirring, both samples were cooked to 36°C over 30 min increasing the temperature by 1°C every 5 min. After cooking, the curd was stirred gently until a pH of 6.0 was reached. At this stage the curd from each vat was added tightly to 6 moulds. These moulds were turned every 30min for the first 3hrs and twice more bringing the total time post-moulding to 5hrs when the moulds were kept at 8°C overnight. The moulds were next brined in 23% sterile NaCl containing 200  $\mu\text{g/l}$   $\text{Ca}^{2+}$  for 75 min followed by drainage for 10 min. The cheese was then smeared with Lyrofast SRC1 (Sacco; 1.25 g/250 ml sterile water) and incubated at 13-15°C with 95% relative humidity. The cheeses were turned daily and washed in brine solution every two days. The smear was applied again after day 5. After 2 weeks, the cheeses were moved to an 8°C incubator and allowed to ripen for a further 2 weeks.

### **2.3.3 Sampling routine**

#### 2.3.3.1 MAP enumeration

The raw milk from the bulk tanks was tested to ensure the absence of *MAP*. The cheese was sampled immediately post smearing (T0) and weekly for 4 weeks during ripening. At each sampling time 5 g of a representative sample (wedge) was homogenised in 2% tri sodium citrate. 100  $\mu\text{l}$  of dilution was added to HEYA and 7H10 agar in 25cm<sup>3</sup> culture flask with the relevant selection agents and supplements added. Cetylpyridinium chloride (CPC) (Sigma Chemicals, MO, USA) was added at a concentration of 0.001% to a duplicate of each sample to decrease background contamination. These flasks were incubated at 37°C for 8 weeks.



#### 2.3.3.2 Salt, moisture and pH

All three parameters were determined for both the surface and interior of the cheese using standard methods as described by Lynch *et al.* (1997). Salt concentrations were determined after two weeks of ripening (T2). Measurements were taken to determine moisture and pH immediately post smearing and weekly during ripening.

#### **2.3.4 Detection of lacticin 3147**

Well diffusion assays were carried out in LM17 agar seeded (0.5% v/v) with either *L. lactis* HP (lacticin 3147 sensitive) or *L. lactis* HP pMRC01 (lacticin 3147 resistant). 2 g of cheese at T0 (addition of smear) and at week 1, 2, 3 and 4 of ripening was added to 2 ml of 2% tri-sodium citrate, homogenised and centrifuged for 5 min at 13000 rpm. The fat layer was removed with sterile pipette and 50 µl of the supernatant was added to wells in the seeded plates followed by incubation overnight at 30°C. The production of lacticin 3147 was evident through the production of zones against the HP indicator that were not apparent when the HP pMRC01 indicator was used.

#### **2.3.5 Confirmation of *MAP* colonies through PCR**

Two separate primer sets (L1 and L2, and AV1 and AV2) (Table 2.2), which target the same *MAP*-specific gene (*IS900*), were employed to confirm the identification of colonies on 7H10 plates. Template DNA was acquired from colonies through IGEPAL denaturation (5 µl incubated 94°C for 10 min). PCR mix (other than primers used, 50 µl total volume) and cycling conditions were the same for both reactions. The PCR mix consisted of 5 µl 10X Buffer for KOD Hot Start DNA Polymerase, 3 µl 25mM MgSO<sub>4</sub>, 5 µl of 2 mM dNTPs, 2.5 µl 0.2 µM forward and reverse primer, 5 µl of template from previous reaction, 1 µl of KOD Hot Start DNA

Polymerase (1U  $\mu$ l) (Novagen) and 26  $\mu$ l of H<sub>2</sub>O. Initial denaturation at 95°C for 2 min followed by 30 cycles of 95°C for 20 sec, 58°C for 10 sec and 72°C for 15 sec with a final extension of 72°C for 5 min.

### **2.3.6 Molecular Quantification using RT-PCR**

#### 2.3.6.1 Sample preparation prior to DNA extraction

Duplicate 5g samples of cheese from each sample period were diluted 1:10 in cheese diluent composed of 0.5% (wt/vol) sodium chloride, 1% (wt/vol) Casitone (Difco), and 2% (wt/vol) sodium citrate. This mixture was next stomached at 260 rpm for 4 min. The samples were incubated for hr at 37°C shaking at 90°C followed by stomaching at the same conditions as above. This mix was then centrifuged for 15 min at 4000 rpm. The supernatant was removed and the remaining pelleted resuspended in 10 ml of phosphate buffered saline.

#### 2.3.6.2 DNA Extraction

DNA extraction was achieved using an Adiapure paraTB Milk kit (Adiagene). The procedure was carried out as stated in manufacturer's instructions. In brief, *MAP* DNA was separated through the specific capture of *MAP* cells on magnetic beads with subsequent grinding to destroy the cell wall.

#### 2.3.6.3 Real-Time-PCR

This method used was based on that developed by Rodriguez-Lazaro *et al.* (2005). The target area for the RT-PCR was the IS900 insertion sequence in the *MAP* genome. Applied Biosystems® 7500 Fast Real-Time PCR System was used for the analysis. Taqman® Universal PCR MasterMix (Applied Biosystems®) was used as per manufacturer's specifications. To ensure fluorescence was not being inhibited, a

Taqman IPC (Applied Cat. No.43083223) was included. The primers and probe used are listed on Table 2.2.

## 2.4 Results

For this study, two separate cheese trials were carried with the aim of determining if *MAP* could survive the process involved in the production of a smear ripened cheese from raw milk. The second goal was to determine if the presence of a lactacin 3147-producing starter culture could provide an additional means of eradicating this pathogen from the human food chain. Finally, a comparison was made between the ‘gold standard’ plate based enumeration method with a molecular quantification technique to quantify *MAP* levels.

As the cheese was made from raw unpasteurised milk, a high microbial load was to be expected both after manufacture and during ripening. Added to this was the large consortium of bacteria arising from the smear that was applied post production. These features and the extremely fastidious nature of the pathogen meant that isolation of *MAP* at low levels was impractical. Thus, it was decided that the starting inoculum for the *MAP* strain in the raw milk was to be approximately  $10^5$  cfu/ml.

The raw milk for this trial was obtained from the bulk milk tank from the Teagasc Moorepark farm. Table 2.3 displays the percentage fat, the percentage lactose and the percentage protein - all of which were at acceptable limits. The total bacterial count and the somatic cell count were also below stated limits (Regulation (EC) No. 853/2004) and no antibiotic residues were detected. The smear ripened cheese make procedure was carried out as outlined in the materials and methods section. Along with the enumeration of *MAP* during the ripening procedure, the percentage moisture and pH was recorded at Day 0 (addition of the smear), and weekly for a period of four weeks.

Figure 2.1, panels A-E shows the development of the smear over the ripening period. For this study a fast-growing commercial blend was used, Lyrofast SRC1 (Sacco), a blend which consists of specifically selected strains of *Debaryomyces hansenii*, *Staphylococcus xylosus*, *Arthrobacter globiformis*, *Brevibacterium linens* and *Geotrichum candidum*. The low starting pH favours the growth of *D. hansenii* and *G. candidum* which in turn increases the pH leading to conditions that favour the growth of the remaining members of the consortium. During this process the smear develops on the surface resulting in a softening of the cheese through the proteolytic and lipolytic action of the smear bacteria. As the smear develops a yellow colour appears on the surface.

The percentage moisture, for both the surface and the interior of the cheese, was monitored (Figure 2.2). Unlike cheeses such as cheddar or Gouda, which are either vacuum-packed in plastic or have a wax coat applied during ripening, a smear type cheese is ripened without any physical protection. In order to protect the cheese from moisture loss, ripening took place within a humidity controlled chamber. While some variation was noted for the % moisture on the surface of both cheeses at day 28, moisture levels which ranged from 44% up to 60% were within the accepted guidelines for a smear type cheese.

As is normal for a smear type cheese, the pH (Figure 2.3) on the surface increased from pH 5.1 on Day 0 to over pH 7.0 at the end of ripening for both the control and lacticin 3147 containing cheese. This increase corresponds to the development of the smear. A more subtle rise in pH was seen for the interior of both cheeses with a difference of 0.2 pH units observed. Both the percentage moisture and pH results shown here are averages of both trials.

Unlike Cheddar, which is dry salted before pressing, smear cheeses are brine salted after molding. As time is needed for the migration of the salt from exterior to interior, and to eventually reach an equilibrium, the percentage salt was measured after 2 weeks ripening. Samples were taken from the surface, the interior and midway. The mean of these three values was averaged from both trials and the standard deviation determined. The percentage salt for the control cheese was 1.4 with a SD of 0.106 while the lacticin 3147 containing cheese was 1.5 with a SD of 0.213. Both figures fall within acceptable norms for this type of cheese.

Well diffusion assays were employed to ensure that lacticin 3147 was produced at all stages during ripening. *L. lactis* HP was used as a lacticin 3147 sensitive indicator while a derivative of HP that contains a plasmid, pMRC01, encoding for immunity to the lantibiotic was also used to ensure that any inhibition was due to the lacticin 3147 specifically and not another inhibitor in the cheese matrix. In all cases, no lacticin 3147 production was detected in the control cheese while a zone of inhibition was observed in the test cheese throughout ripening (data not shown). It was thus apparent that the *MAP* cells were exposed to lacticin 3147 from manufacturing to ripening.

Survival of *MAP* was monitored over the 28 day ripening period by plating on HEYE and 7H10 (Figure 2.4). The initial 1:10 dilution was made in 2% tri-sodium citrate with subsequent dilutions made in maximum recovery diluent (MRD). Each sample was weighed twice. In order to reduce background flora, 0.001% CPC was added to one while the second was plated without addition of the antiseptic. At T<sub>0</sub>, *MAP* cells were detected at  $\sim 10^5$  cfu/g in both trials and in both the control and lacticin 3147 cheeses. An approximate 1 log reduction was observed for both the control and the test cheese over the first two weeks of ripening with this figure

remaining constant at the end of week three. By the end of week 4, the levels of *MAP* showed a slight increase. Both the control and the test cheese when treated with CPC showed a more constant decrease in cell numbers with a log reduction of 2.4 observed for each. HEYM was found to be unsuitable for the recovery of *MAP* from raw milk due to the high levels of background contamination present on the plates. Therefore all counts were from the 7H10 plates. No difference was observed in *MAP* levels between cheeses containing the lacticin 3147 producing starter culture and the control, either with or without the addition of CPC. All presumptive *MAP* colonies were confirmed as *MAP* through PCR with the use of two IS900 primer sets, L1& L2 and AV1 & AV2 (Bull *et al.*, 2003).

Molecular quantification of the levels of *MAP* in the cheese samples was completed using real-time PCR so as to ascertain whether this was a valid method for future studies. The resulting Ct values (Table 2.4) indicate a good replication of the trend observed for the plate based enumeration in that a less than 1 log reduction was observed over the ripening period and no discernible difference in numbers was apparent between cheese containing the lacticin 3147 producing starter culture and that produced with the non-bacteriocin producing equivalent.

## 2.5 Discussion

Members of the family Mycobacteriaceae include many slow-growing pathogenic species such as *Mycobacterium tuberculosis* and *Mycobacterium leprae*, the etiological agents of human tuberculosis and leprosy, respectively. Two important animal pathogens also belong to this family; *Mycobacterium bovis*, the causative agent of bovine tuberculosis, and *Mycobacterium paratuberculosis*, the causative agent of Johne's disease. It is the latter bacterium which is the focal point of this study.

Johne's disease has been detected on every continent (Rowe & Grant, 2006) and, due to difficulties in its detection during a sub-clinical period of between 2 to 5 years (Stabel, 1998), treatment of the condition is challenging. The clinical period of infection manifests as a chronic and intermittent diarrhoea leading to contamination of the environment and colostrum, with increased herd infection (Cocito *et al.*, 1994). Infected cattle become increasingly emaciated and die of dehydration and severe cachexia. Coupling this with *MAP*'s innate resistance to chlorine (Whan *et al.*, 2001) and processes such as temperature treatments (Grant *et al.*, 2002) afforded to it by its waxy cell wall, contaminated milk provides a realistic route for the introduction of the bacterium into the human food chain.

Three questions were addressed in this study. Firstly, does *MAP* survive manufacture and ripening of a smear ripened cheese made from unpasteurized milk? Cheeses of this variety are high risk products with respect to contamination by pathogens due the risks associated with the use of unpasteurised milk and technological factors such as their high moisture content, low salt concentrations and short-ripening times. Secondly, does the bacteriocin producing strain *L. lactis* DPC



3147, when used as a starter culture in the same process, impact on the survival of the pathogen? Thirdly, we compared the gold standard method of *MAP* enumeration, i.e. culturing on solid media, with a real-time PCR technique targeting the IS900 insertion sequence (McFadden *et al.*, 1987, Green *et al.*, 1989), which is present at 14-18 copies per genome.

Lantibiotics such as nisin and lacticin 3147 have previously demonstrated effectiveness against a number of clinically significant mycobacteria (Carroll *et al.*, 2010). Indeed in that previous study, a purified form of lacticin 3147 displayed particularly potent activity against *Mycobacterium tuberculosis* H37Ra, *Mycobacterium kansasii* CIT11/06 and *MAP* ATCC19698. This activity provided the rationale for employing a lacticin 3147 producing starter for this cheese trial.

Plating on selective agar, without CPC treatment, (Figure 2.4) revealed that viable counts of *MAP* from both the control and lacticin 3147 producing starter-containing cheeses decreased less than 10-fold after four weeks of ripening. Although lacticin 3147 was produced throughout the ripening period, as demonstrated by well diffusion assays, it had no effect on *MAP* numbers. Current culture methods do not allow the enumeration of low numbers of *MAP* in the presence of high background microflora found in smear ripened raw milk cheese. In this study an artificially high inoculum was used for these reasons. It may be that bacteriocin producing cultures would provide significantly improved killing of *MAP* if the levels of the pathogen are within the normal range for naturally contaminated milk. As the % moisture, pH and appearance of both the control and the lacticin 3147 containing cheeses were all within the accepted norms, it could be concluded that the presence of lacticin 3147 in the cheese matrix, which was present right through ripening, did not impact on the bacterial constituent of the smear.

When samples were treated with CPC prior to plating, a more dramatic decrease in cell numbers was observed. For both the control and the test cheese, a greater than 2 log reduction was observed. This decrease is likely due to the inability of *MAP* cells that are sub-lethally injured as a result of the ripening process to survive CPC treatment. The similarity in *MAP* survival levels across the control and the test cheeses again highlighted that bacteriocin production did provide enhanced protection against the pathogen.

RT-PCR may be a valuable tool to confirm the viability of *MAP* in a complex matrix, such as smear ripened raw milk cheese, where the bacterial load is extremely high and the flora quite diverse. In this study, RT-PCR results confirmed the conclusions reached from plate enumeration, including the observation that lacticin 3147 producing cultures did not offer added protection through inhibition of the *MAP* cultures during cheese ripening in raw milk smear ripened cheese. As noted previously, due to sensitivity limits, the starting inoculum was high, which may have impacted on the effectiveness of the bacteriocin. As the sensitivity afforded by this molecular quantification is lower than that of plate counts, future studies could assess the effectiveness of bacteriocins at more realistic levels of *MAP* contamination.

Although not classed as a zoonotic agent, *MAP* has often been linked with Crohn's disease, an inflammatory bowel disorder of global importance. In this study, a possible route of infection was assessed, i.e. smear-ripened cheese from raw milk. Even with a bacteriocin producing starter culture, this study indicates that the bacterium would survive manufacture and ripening. Interestingly, lacticin 3147 did not impair the normal cheese flora and therefore could be employed in future trials, with RT-PCR-based detection, using a *MAP* inoculum more reflective of normal

contamination. However, it is clear from this study that raw milk from animals shedding high numbers of *MAP* cells should not be used for the manufacture of smear type cheese.

## **2.6 Acknowledgements**

This work was financed by a grant from the Irish Department of Agriculture, Food and the Marine through the Food Institutional Research Measure (08/RD/C/691) and with Science Foundation Ireland Investigator award (10/IN.1/B3027).

The DNA extraction and the RT-PCR were completed with the assistance of Dr. John Donaghy and his research team at the Agriculture, Food and Biosciences Institute (AFBI) Belfast. We would also like to acknowledge Dr. Sheila Morgan for the assistance during the cheese making process.

## 2.7 Bibliography

Bolotin A, Wincker P, Mauger S, *et al.* (2001) The complete genome sequence of the lactic acid bacterium *Lactococcus lactis* ssp. *lactis* IL1403. *Genome research* **11**: 731-753.

Brennan N, Cogan T, Loessner M & Scherer S (2004) Bacterial surface-ripened cheeses. *Cheese: chemistry, physics and microbiology* **2**: 199-225.

Bull TJ, McMinn EJ, Sidi-Boumedine K, *et al.* (2003) Detection and verification of *Mycobacterium avium* subsp. *paratuberculosis* in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. *Journal of Clinical Microbiology* **41**: 2915-2923.

Carroll J, Draper LA, O'Connor PM, *et al.* (2010) Comparison of the activities of the lantibiotics nisin and lactacin 3147 against clinically significant mycobacteria. *International Journal of Antimicrobial Agents* **36**: 132-136.

Coakley M, Fitzgerald G & Ros R (1997) Application and evaluation of the phage resistance-and bacteriocin-encoding plasmid pMRC01 for the improvement of dairy starter cultures. *Applied and Environmental Microbiology* **63**: 1434-1440.

Cocito C, Gilot P, Coene M, de Kesel M, Poupart P & Vannuffel P (1994) Paratuberculosis. *Clin Microbiol Rev* **7**: 328-345.

Cotter PD, Hill C & Ross RP (2005) Bacteriocins: developing innate immunity for food. *Nat Rev Microbiol* **3**: 777-788.

Dal Bello B, Cocolin L, Zeppa G, Field D, Cotter PD & Hill C (2012) Technological characterization of bacteriocin producing *Lactococcus lactis* strains employed to control *Listeria monocytogenes* in cottage cheese. *International Journal of Food Microbiology* **1**: 153.

Davis WC & Madsen-Bouterse SA (2012) Crohn's disease and *Mycobacterium avium* subsp. *paratuberculosis*: the need for a study is long overdue. *Vet Immunol Immunopathol* **145**: 1-6.

Deegan LH, Cotter PD, Hill C & Ross P (2006) Bacteriocins: biological tools for bio-preservation and shelf-life extension. *International Dairy Journal* **16**: 1058-1071.

Ellingson JL, Anderson JL, Koziczowski JJ, Radcliff RP, Sloan SJ, Allen SE & Sullivan NM (2005) Detection of viable *Mycobacterium avium* subsp. *paratuberculosis* in retail pasteurized whole milk by two culture methods and PCR. *Journal of Food Protection*® **68**: 966-972.

Fecteau M-E & Whitlock RH (2010) 14 Paratuberculosis in Cattle. *Paratuberculosis: Organism, Disease, Control* 144.

Fox PF, McSweeney PL, Cogan TM & Guinee TP (2004) *Cheese: Chemistry, Physics and Microbiology: General Aspects*. Academic Press.

Gálvez A, Abriouel H, López RL & Omar NB (2007) Bacteriocin-based strategies for food biopreservation. *International Journal of Food Microbiology* **120**: 51-70.

Good M, Clegg T, Sheridan H, Yearsely D, O'Brien T, Egan J & Mullaney P (2009) Prevalence and distribution of paratuberculosis (Johne's disease) in cattle herds in Ireland. *Irish Veterinary Journal* **62**: 597.

Grant IR, Hitchings EI, McCartney A, Ferguson F & Rowe MT (2002) Effect of commercial-scale high-temperature, short-time pasteurization on the viability of *Mycobacterium paratuberculosis* in naturally infected cows' milk. *Applied and Environmental Microbiology* **68**: 602-607.

Green, E. P., Tizard, M. L. V., Moss, M. T., Thompson, J., Winterbourne, D. J., McFadden, J. J., & Hermon-Taylor, J. (1989). Sequence and characteristics of IS900, an insertion element identified in a human Crohn's disease isolate of *Mycobacterium paratuberculosis*. *Nucleic Acids Research*, **17(22)**, 9063-9073.

D, McFadden J & Hermon-Taylor J (1989) Sequence and characteristics of IS900, an insertion element identified in a human Crohn's disease isolate of *Mycobacterium paratuberculosis*. *Nucleic Acids Research* **17**: 9063-9073.

Healy B, O'Mahony J, Hill C, Cotter PD & Ross RP (2010) 2 Lantibiotic-related Research and the Application Thereof. *Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies* **18**: 22.

Hermon-Taylor J (2002) Treatment with drugs active against *Mycobacterium avium* subspecies *paratuberculosis* can heal Crohn's disease: more evidence for a neglected public health tragedy. *Dig Liver Dis* **34**: 9-12.

Iancu C, Grainger A, Field D, Cotter PD, Hill C & Ross RP (2012) Comparison of the potency of the lipid II targeting antimicrobials nisin, lactacin 3147 and vancomycin against Gram-positive bacteria. *Probiotics and Antimicrobial Proteins* **4**: 108-115.

Lynch CM, McSweeney PLH, Fox PF, Cogan TM & Drinan FD (1997) Contribution of starter lactococci and non-starter lactobacilli to proteolysis in Cheddar cheese with a controlled microflora. *Lait* **77**: 441-459.

McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P & Abee T (1998) Lactacin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. *Applied and Environmental Microbiology* **64**: 439-445.

McFadden J, Butcher P, Chiodini R & Hermon-Taylor J (1987) Crohn's disease-isolated mycobacteria are identical to *Mycobacterium paratuberculosis*, as determined by DNA probes that distinguish between mycobacterial species. *Journal of Clinical Microbiology* **25**: 796-801.

Mills S, McAuliffe OE, Coffey A, Fitzgerald GF & Ross RP (2006) Plasmids of lactococci—genetic accessories or genetic necessities? *FEMS Microbiology Reviews* **30**: 243-273.

Momotani E, Romona NM, Yoshihara K, *et al.* (2012) Molecular pathogenesis of bovine paratuberculosis and human inflammatory bowel diseases. *Vet Immunol Immunopathol* **148**: 55-68.

O'Reilly C, O'Connor L, Anderson W, *et al.* (2004) Surveillance of bulk raw and commercially pasteurized cows' milk from approved Irish liquid-milk pasteurization plants to determine the incidence of *Mycobacterium paratuberculosis*. *Applied and Environmental Microbiology* **70**: 5138-5144.

O'Sullivan L, O'Connor E, Ross R & Hill C (2006) Evaluation of live-culture-producing lacticin 3147 as a treatment for the control of *Listeria monocytogenes* on the surface of smear-ripened cheese. *Journal of Applied Microbiology* **100**: 135-143.

Piper C, Cotter PD, Ross RP & Hill C (2009) Discovery of medically significant lantibiotics. *Current Drug Discovery Technologies* **6**: 1-18.

Piper C, Draper LA, Cotter PD, Ross RP & Hill C (2009) A comparison of the activities of lacticin 3147 and nisin against drug-resistant *Staphylococcus aureus* and *Enterococcus* species. *Journal of Antimicrobial Chemotherapy* **64**: 546-551.

Rodriguez-Lazaro D, D'Agostino M, Herrewegh A, Pla M, Cook N & Ikononopoulos J (2005) Real-time PCR-based methods for detection of *Mycobacterium avium* subsp. *paratuberculosis* in water and milk. *Int J Food Microbiol* **101**: 93-104.

Rowe M & Grant I (2006) *Mycobacterium avium* ssp. *paratuberculosis* and its potential survival tactics. *Letters in Applied Microbiology* **42**: 305-311.

Ryan MP, Rea MC, Hill C & Ross RP (1996) An application in cheddar cheese manufacture for a strain of *Lactococcus lactis* producing a novel broad-spectrum bacteriocin, lacticin 3147. *Appl Environ Microbiol* **62**: 612-619.

Stabel J (1998) Johne's disease: a hidden threat. *Journal of Dairy Science* **81**: 283-288.

Whan L, Grant I, Ball H, Scott R & Rowe M (2001) Bactericidal effect of chlorine on *Mycobacterium paratuberculosis* in drinking water. *Letters in Applied Microbiology* **33**: 227-231.

Wiedemann I, Böttiger T, Bonelli RR, *et al.* (2006) The mode of action of the lantibiotic lacticin 3147—a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. *Molecular Microbiology* **61**: 285-296.

## 2.8 Tables and Figures

**Table 2.1** Strains used in this study

| <b>Strains</b>            | <b>Characteristic</b>                                       | <b>Reference/Source</b>   |
|---------------------------|---|---------------------------|
| <i>L. lactis</i> DPC3147  | Natural lacticin 3147 producing starter culture             | <i>Ryan et al. (1996)</i> |
| <i>L. lactis</i> DPC5399  | Bac <sup>-</sup> Isogenic strain of DPC3147 starter culture | DPC Culture Collection    |
| <i>L.lactis</i> HP        | Lacticin 3147 sensitive indicator                           | DPC Culture Collection    |
| <i>L.lactis</i> HP pMRC01 | Lacticin 3147 resistant indicator                           | DPC Culture Collection    |
| <i>MAP</i> ATCC19698      | Target organism   | ATCC                      |

DPC: Dairy Products Research Centre, ATCC: American Type Culture Collection



**Table 2.2** Oligonucleotides used in this study

| Oligonucleotide | Target gene | Sequence                                   | Reference                               |
|-----------------|-------------|--|---|
| L1              | IS900       | 5'-CTTTCTTGAAGGGTGTTCGG-3'                 |   |
| L2              | IS900       | 5'-ACGTGACCTCGCCTCCAT-3'                   | (Bull <i>et al.</i> , 2003)             |
| AV1             | IS900       | 5'-ATGTGGTGGCTGTGTTGGATGG-3'               |   |
| AV2             | IS900       | 5'-CCGCCGCAATCAACTCCAG-3'                  |   |
| IS900QFForward  | IS900       | 5'-CCGGTAAGGCCGACCATTA-3'                  | (Rodriguez-Lazaro <i>et al.</i> , 2005) |
| IS900QR Reverse | IS900       | 5'-ACCCGCTGCGAGAGCA-3'                     |   |
| IS900QP Probe   | IS900       | 5'-FAM-CATGGTTATTAACGACGACGCGCAGC-TAMR -3' |   |


**Table 2.3** Raw Milk Analysis

| <b>Analysis</b>              | <b>Cheese Trail 1</b>         | <b>Cheese Trial 2</b>        |
|------------------------------|-------------------------------|------------------------------|
| <b>Total bacterial count</b> | 9.9 x 10 <sup>3</sup> cfu /ml | 4.4 x 10 <sup>3</sup> cfu/ml |
| <b>Somatic cell count</b>    | 3.4 x 10 <sup>5</sup> cfu/ml  | 2.8 x 10 <sup>5</sup> cfu/ml |
| <b>% Fat</b>                 | 4.53                          | 4.30                         |
| <b>% Lactose</b>             | 4.46                          | 4.71                         |
| <b>% Protein</b>             | 3.16                          | 3.24                         |
| <b>Antibiotic residues</b>   | Absent                        | Absent                       |

**Table 2.4 RT-PCR Results**


| <b>Sample Reference</b>               | <b>Ct Value</b> |
|---------------------------------------|-----------------|
| Trail 1 Day 0 Control                 | 18.0000         |
| Trail 1 Day 0 Lacticin 3147 Producer  | 17.4656         |
| Trail 1 Week 1 Control                | 17.2108         |
| Trail 1 Week 1 Lacticin 3147 Producer | 16.9647         |
| Trail 1 Week 2 Control                | 16.9362         |
| Trail 1 Week 2 Lacticin 3147 Producer | 16.6056         |
| Trail 1 Week 3 Control                | 17.1505         |
| Trail 1 Week 3 Lacticin 3147 Producer | 16.5786         |
| Trail 1 Week 4 Control                | 17.5554         |
| Trail 1 Week 4 Lacticin 3147 Producer | 17.3316         |
| Trail 2 Day 0 Control                 | 17.2042         |
| Trail 2 Day 0 Lacticin 3147 Producer  | 18.0386         |
| Trail 2 Week 1 Control                | 16.2401         |
| Trail 2 Week 1 Lacticin 3147 Producer | 16.4913         |
| Trail 2 Week 2 Control                | 16.1759         |
| Trail 2 Week 2 Lacticin 3147 Producer | 16.5469         |
| Trail 2 Week 3 Control                | 15.9728         |
| Trail 2 Week 3 Lacticin 3147 Producer | 16.1388         |
| Trail 2 Week 4 Control                | 19.6297         |
| Trail 2 Week 4 Lacticin 3147 Producer | 16.3408         |

**Figure 2.1** Production of the smear on the surface of the cheese




The growth of the smear from appliance (panel A.) and its growth over the ripening period of the cheese; panel B. after 1 week, panel C. after 2 weeks, panel D. after 3 weeks and panel E. after 4 weeks.


**Figure 2.2** % Moisture during ripening period



**Figure 2.3** pH change during ripening period



**Figure 2.4** *MAP* enumerations over 28 day ripening period



Survival of *MAP* ATCC19698 in a raw milk smear ripened cheeses in the presence and absence of a lacticin 3147-producing starter culture. CPC - Cetylpyridinium chloride

## **Chapter III**

### **Intensive mutagenesis of the Nisin hinge leads to the rational design of enhanced derivatives**

Brian Healy, Des Field, Paula M O'Connor, Colin Hill, Paul D. Cotter and R. Paul Ross

This chapter was published in *PLoS One* 8, 2013 (11): e79563



### 3.1 Abstract

Nisin A is the most extensively studied lantibiotic and has been used as a preservative by the food industry since 1953. This 34 amino acid peptide contains three dehydrated amino acids and five thioether rings. These rings, resulting from one lanthionine and four methyllanthionine bridges, confer the peptide with its unique structure. Nisin A has two mechanisms of action, with the N-terminal domain of the peptide inhibiting cell wall synthesis through lipid II binding and the C-terminal domain responsible for pore-formation. The focus of this study is the three amino acid ‘hinge’ region (N 20, M 21 and K 22) which separates these two domains and allows for conformational flexibility.

As all lantibiotics are gene encoded, novel variants can be generated through manipulation of the corresponding gene. A number of derivatives in which the hinge region was altered have previously been shown to possess enhanced antimicrobial activity. Here we take this approach further by employing simultaneous, indiscriminate site-saturation mutagenesis of all three hinge residues to create a novel bank of nisin derivative producers. Screening of this bank revealed that producers of peptides with hinge regions consisting of AAK, NAI and SLS displayed enhanced bioactivity against a variety of targets. These and other results suggested a preference for small, chiral amino acids within the hinge region, leading to the design and creation of producers of peptides with hinges consisting of AAA and SAA. These producers, and the corresponding peptides, exhibited enhanced bioactivity against *Lactococcus lactis* HP, *Streptococcus agalactiae* ATCC 13813, *Mycobacterium smegmatis* MC2155 and *Staphylococcus aureus* RF122 and thus represent the first example of nisin derivatives that possess enhanced activity as a consequence of rational design.

## 3.2 Introduction

Bacteriocins are small, bacterially produced, ribosomally synthesized peptides that are active against other bacteria and against which the producer has a specific immunity mechanism (Cotter *et al.*, 2005, Cotter *et al.*, 2013). The bacteriocins can be subdivided on the basis of their structure with Class 1 consisting of peptides that have undergone post-translational modification (Rea *et al.*, 2011). Of these, the lantibiotics have been the focus of particular attention (Chatterjee, 2005, Bierbaum & Sahl, 2009). The name of these bacteriocins reflects their structure; ‘**L**anthionine-containing **ant**ibiotics’, where lanthionines/  $\beta$ -methyllanthionines are unusual residues that are formed between cysteines and neighbouring dehydrated serines (dehydroalanines) or threonines (dehydrobutyrines), respectively (Bierbaum & Sahl, 2009).

The lantibiotic Nisin A (Fig. 3.1) has been used a commercial food additive since 1953 and has been approved for use in food by the FAO, WHO, EU and the USFDA (Delves-Broughton *et al.*, 1996, Cotter *et al.*, 2005). Unsurprisingly, Nisin A is by far the most extensively studied lantibiotic (Delves-Broughton *et al.*, 1996, Cotter *et al.*, 2005, Lubelski *et al.*, 2008). In addition, the gene encoded nature of nisin, and indeed other lantibiotics, can be exploited through engineering to even further enhance its activity and/ or investigate structure-function relationships. Such engineering can be carried out *in vivo* (manipulation of the producer or heterologous expression of the genes in another host) or *in vitro* (using purified components of the biosynthetic machinery) (Rink *et al.*, 2005, Field *et al.*, 2008, Healy *et al.*, 2010, Knerr & van der Donk, 2012).

The *in vivo* engineering of nisin through the replacement of specific amino acids commenced in 1992 (Kuipers *et al.*, 1992) and a number of derivatives were identified that have been of considerable value with respect to revealing the fundamentals of nisin biology (Cotter *et al.*, 2005, Field *et al.*, 2010). More recently, derivatives have been identified with academic and potential commercial value that display enhanced activity against pathogenic bacteria (Yuan *et al.*, 2004, Field *et al.*, 2008, Field *et al.*, 2012, Molloy *et al.*, 2012, Rouse *et al.*, 2012, Molloy *et al.*, 2013). The majority of these enhanced derivatives differ with respect to the amino acids found in the 3 amino acid 'hinge' region of the peptide. This region is thought to be key with respect to linking the two functional domains of the nisin peptide and providing conformational flexibility between these regions (Breukink *et al.*, 1997, Wiedemann *et al.*, 2001). Nisin inhibits cell wall synthesis through the formation of a complex with lipid II, an essential precursor of peptidoglycan synthesis (Brotz *et al.*, 1998, Breukink *et al.*, 1999), with the N-terminus region being responsible for this binding (Hsu *et al.*, 2004). The hinge links this domain with the C-terminal end of the peptide, which is responsible for a second mechanism of antimicrobial activity, which involves permeabilisation of the cell membrane. The first indication that mutagenesis of the hinge could bring about beneficial consequences was provided by Yuan and co-workers (2004) who established that two derivatives of nisin Z (N20K and M21K), exhibited enhanced activity against Gram-negative (*Shigella*, *Pseudomonas* and *Salmonella*), but not Gram-positive, pathogens. This was followed by the identification of hinge derivatives, such as N20P, M21V, K22S and K22T (Field *et al.*, 2008), with enhanced activity against Gram-positive pathogens (*Streptococcus agalactiae*, *Staphylococcus aureus* and *Listeria monocytogenes*). Further studies have emphasised the enhanced potency of one of

these variants, nisin V (M21V) (Field *et al.*, 2010), against a broad variety of drug-resistant pathogens and have identified other hinge derivatives, such as that containing the residues SVA, that exhibit enhanced activity in complex matrices (Rouse *et al.*, 2012).

The hinge derivatives that have been studied to date have resulted from strategies in which one or two of the hinge residues have been manipulated. Here we go a step further through the randomisation of all three hinge residues simultaneously. Screening of a bank of producers of such derivatives revealed a pattern whereby many producers of derivatives containing small chiral amino acids within the hinge displayed enhanced bioactivity. This prompted the rational design of additional derivatives not identified from the random bank, peptides containing AAA and SAA hinges, which were particularly notable with respect to the extent to which bioactivity was enhanced, relative to the wild-type producer.

### **3.3 Materials and Methods**

#### **3.3.1 Bacterial strains and growth conditions**

All strains and plasmids used in this study are listed in Table 3.1 *Lactococcus lactis* cultures were grown in M17 broth or agar (1.5%) (Oxoid) supplemented with 0.5% glucose at 30°C. *Escherichia coli* strains were grown in Luria-Bertani (LB) broth or agar with continuous shaking at 37°C. Where necessary, chloramphenicol was used at 10 µg/ml for *L. lactis* and *E. coli*. *Staphylococcus aureus* RF122 was grown in Brain Heart Infusion (BHI) broth or agar (Oxoid) at 37°C. *Streptococcus agalactiae* ATCC 13813 was grown in Tryptic Soy Broth (TSB) (Merck) or TS agar supplemented with Yeast Extract (YE) (Oxoid) at a concentration of 0.6% at 37°C. *Mycobacterium smegmatis* MC2155 was grown on Middlebrook 7H9 broth (BD) or Middlebrook 7H10 agar (BD) supplemented with 0.05% tween 80 and 2% glycerol at 37°C.

#### **3.3.2 Site-saturation mutagenesis of the nisin A ‘hinge’ region**

The complete randomisation of the ‘hinge’ amino acids was achieved by PCR using the template pDF05 (pCI372-*nisA*) and primers NisAXXXHingeFor and NisAXXXHingeRev (Table 3.2). The template DNA was extracted using a High Pure Plasmid Isolation Kit (Roche) from *dam*<sup>+</sup> *E. coli* Top10 (Invitrogen) to ensure its methylation. PCR amplification was performed in 50µl volumes with 1 ng per 50 µl of template, 2 units of Phusion High Fidelity DNA Polymerase (Finnzymes), approximately 0.5 ng of template, 1x HF buffer, 200 µM dNTPs and 0.5 µM of the relevant oligonucleotides. Cycling conditions were as follows: 98°C for 30 secs, 55°C for 15 secs, 72°C for 3.5 mins for 40 cycles followed by final extension for 10 mins. Samples were PCR cleaned using GeneJet PCR Purification Kit (Thermo

Scientific) followed by *DpnI* treatment (Stratagene) at 37°C for 3 hours. 2.5 µl of mutated pCI372-NisA was added to a vial of Top 10 Chemically Competent *Escherichia coli* (Invitrogen). These transformants were pooled, plasmids extracted using a High Pure Plasmid Isolation Kit (Roche) and transformed into electro-competent *L. lactis* ssp. *cremoris* NZ9800Δ*nisA* and selected for on GM17 Cm<sup>10</sup> agar within Q-Trays. Resultant colonies were picked and added to GM17 within Genetix 96-well plates (Genetix X6011), incubated overnight at 30°C before storage at -80°C in 44% glycerol (Sigma).

### **3.3.3 Site-directed mutagenesis of the nisin A ‘hinge’ region**

The creation of targeted changes was also facilitated using a PCR-based approach, using oligonucleotides (Table 3.2) and a suitable pDF05 based template (one which most closely resembles the desired change). Amplification was through a 50µl PCR reaction containing 0.02U/µl KOD Hot-Start Polymerase (Novagen), 1.5 mM MgSO<sub>4</sub>, 0.2 mM of each dNTP, 0.3 µM of both oligonucleotides and approximately 10 ng of template. Cycling conditions were as described above. Engineered plasmids were introduced into *L. lactis* NZ9800Δ*nisA* via *E. coli* Top10 as described above.

### **3.3.4 Deferred antagonism assays**

Deferred antagonism agar-based assays were employed to assess the bioactivity of nisin derivative-producing strains (Rouse *et al.*, 2012). Briefly, the *L. lactis* producers were ‘spotted’ (approximately 3 µl) onto GM17 agar and incubated for 16 hours at 30°C. In the case of *M. smegmatis*, the *L. lactis* producers were incubated for 40 hours. Growth media (0.75% agar) appropriate for growth of the individual target was seeded (0.5%) and poured over the *L. lactis* producers followed by further incubation at conditions suitable for the indicator. Enhancement in bioactivity was

indicated by increased zone of inhibition relative to that generated by the wild-type producer.

### **3.3.5 Agar well diffusion assays**

50 µl volumes of purified peptide were added to wells bored in the appropriate agar-containing media (1.5% agar, 0.75% for *M. smegmatis*) seeded with 0.5% of a 16 hour culture (40 hour culture for *M. smegmatis*) of the indicator of interest. Plates were incubated for 16 hours (40 hours for *M. smegmatis*) and bioactivity assessed on the basis of the size of the zone of inhibition.

### **3.3.6 Identification of nisin A derivatives**

Colony mass spectrometric analysis was carried out on colonies exhibiting enhanced bioactivity using an Axima CFR plus MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) and analyzed in positive-ion reflectron mode as previously described (Field *et al.*, 2008). The changes to the *nisA* genes within the corresponding pDF05 derivatives were established through DNA sequencing (MWG, Biotech, Germany). The sequences for AAA, AAK, NAI, SAA and SLS were deposited in GenBank under the accession numbers KF664587, KF664588, KF664589, KF664590 and KF664591, respectively.

### **3.3.7 Purification of nisin A and derivatives thereof**

2 litres of Tryptone Yeast (TY) broth were incubated for 20 hours with 20 ml of an overnight culture of producing strain. This culture was centrifuged for 20 minutes @ 8630g. The supernatant was decanted and passed through 60g of pre equilibrated Amberlite XAD16 beads (Sigma-Aldrich). The beads were washed with 500ml 30% ethanol and eluted with 500 ml 70% isopropanol (IPA) (Fisher) 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich). Concomitantly, the cell pellets were resuspended in

300 ml of 70% IPA 0.1% TFA and stirred at room temperature for 3 hours followed by centrifugation. This cell supernatant was combined with that referred to above and concentrated through rotary-evaporation (Buchi, Switzerland) to approximately 250ml. After the pH was adjusted to 4.5 further concentration was achieved through the use of a Phenomenex SPE C-18 column to a final volume of 60 ml. 7 ml of this sample was concentrated, through rotary evaporation, to 2 ml and purified through HPLC using a Phenomenex C12 Reverse-Phase (RP) HPLC column (Jupiter 4  $\mu$  proteo 90 Å, 250 X 10.0 mm, 4  $\mu$ m). To facilitate this, a gradient of 30-50% acetonitrile (Fisher) containing 0.1% TFA was developed. The relevant fractions were collected and pooled, subjected to rotary-evaporation to remove acetonitrile and freeze-dried (LABCONCO). The purified peptides were subjected to MALDI-ToF Mass Spectrometric analysis to confirm their purity before use.

### **3.3.8 Minimum Inhibitory Concentration (MIC) Assays**

Minimum inhibitory concentration assays were carried out in triplicate using 96-well plates (Sarstedt) pretreated with bovine serum albumin (BSA) as previously described (Wiedemann *et al.*, 2006). Wild-type nisin A and nisin derivatives were adjusted to a 500 nM (when using *L. lactis* as a target) or 7.5  $\mu$ M (all other indicators) starting concentration and 2-fold serial dilutions of each peptide were carried out. An overnight of the target strain was subcultured and incubated to an OD<sub>600nm</sub> of 0.5 before being diluted to give a final inoculum of  $10^5$  cfu/ml in 200  $\mu$ l. The plates were incubated at an appropriate temperature and inspected after 16 hours. The MIC was determined as the lowest concentration at which no growth was visible.



## **3.4 Results**

### **3.4.1 Creation of a bank of producers of randomised hinge derivative**

In order to fully exploit the potential of the nisin ‘hinge’ region (N20-M21-K22) to generate enhanced derivatives, it was decided to undertake a complete randomisation of this area. Using NNK scanning of the nisin A structural gene (*nisA*), a large bank of *L. lactis* NZ9800 pCI372*nisA* (pDF05) hinge variants were produced. In order to obtain full coverage with a 95% confidence limit using NNK scanning on three positions, a bank of 341,601 variants would have to be screened (Nov, 2012). Creating and screening a bank of this size against four indicators would not have been feasible and thus a more practical bank of 12,000 variants was produced in order to increase the likelihood of finding interesting candidates in a short/ medium time frame.

### **3.4.2 Identification of nisin derivative producers with enhanced bioactivity**

The bank of producers of randomised hinge derivatives was screened using deferred antagonism agar diffusion assays to identify producers that display enhanced bioactivity. The term bioactivity, as used here and elsewhere (Field *et al.*, 2008, Rouse *et al.*, 2012, Molloy *et al.*, 2013), reflects the overall activity of producer strains and does not discriminate between effects due to increased/ decreased specific activity, altered peptide production levels, or effects on other physico-chemical properties such as diffusion in agar. Enhanced bioactivity was characterised by zones of clearing greater than that generated by the corresponding nisin A producing control against *Lactococcus lactis* HP, *Streptococcus agalactiae* ATCC 13813, *Mycobacterium smegmatis* MC2155 or *Staphylococcus aureus*

RF122. From this screen 63 potentially enhanced producers were selected for further investigation and, after DNA sequencing, it was established that these corresponded to 23 unique mutants (Table 3.3). These 23 derivatives contained hinge regions consisting of combinations of 12 distinct amino acids (Table 3.4), none of which were aromatic or negatively charged in nature. Of these 12, alanine was most common (22%), followed by serine (16%) and glutamine (12%). To exclude that a bias or over-presentation of specific residues had occurred, and to insure the overall randomisation of the bank, 20 clones were chosen randomly and their hinge region was sequenced. The results are presented in Table 3.5 and establish that alanine and serine are not considerably over-represented within the bank. From the agar diffusion assays it was apparent that three producers consistently produced large zones of inhibition and these were selected for further investigation. DNA sequencing and mass spectrometric analysis revealed that the derivatives produced by these strains contained hinge regions consisting of AAK, SLS and NAI (Table 3.6). Assays with four target microorganisms established that the producer of the AAK-containing derivative exhibited enhanced bioactivity against *L. lactis* HP, *S. aureus* RF122 and *M. smegmatis* MC2155, the producer of the SLS-containing derivative exhibited enhanced bioactivity against *L. lactis* HP and *M. smegmatis* MC2155 and the producer of the NAI-containing derivative exhibited enhanced bioactivity against *L. lactis* HP, *S. agalactiae* ATCC 13813 and *M. smegmatis* MC2155. This enhancement could potentially be as a result of enhanced production, enhanced specific activity or some other enhancement with respect to the attributes of the peptide. To investigate these various possibilities, the three peptides produced by these strains (and wild-type nisin A) were purified through HPLC and broth-based specific activity and agar diffusion assays were performed (Table 3.7). Against *L.*

*lactis* HP, all three bioengineered peptides displayed enhanced activity, relative to equal concentrations of nisin A, when assessed through agar diffusion assays. However, this was not due to enhanced specific activity as broth-based MIC assays revealed that the activity of the NAI-containing peptide was equal, and those of the AAK- and SLS-containing peptides were reduced, relative to that of nisin A against this target (Table 3.7). All of the nisin derivatives displayed specific activity in broth which was reduced relative that of the wild-type peptide against *S. aureus* RF122, yet the AAK- and NAI-containing peptides exhibited enhanced activity when assessed through agar diffusion assays, with the enhanced activity of the AAK-containing peptide being most significant (Table 3.7). When tested against *S. agalactiae* ATCC 13813, the NAI-containing peptide displayed significantly enhanced activity against this target in agar diffusion assays and in broth based specific activity assays. Regardless of assay, neither the AAK- nor the SLS-containing peptides exhibited enhanced activity against *S. agalactiae* ATCC 13813 (Table 3.7). *M. smegmatis* MC2155 was also included as an indicator as *M. smegmatis* is frequently used as a model microorganism/ substitute for slow-growing, pathogenic mycobacteria. The AAK-containing peptide and the SLS-containing peptides both showed significant enhanced activity against this target in agar diffusion assays (Table 3.7), but the aggregative nature of MC2155 in broth precluded the generation of consistent MIC data from broth-based studies.

### **3.4.3 Rational design of nisin derivatives with enhanced bioactivity**

The amino acid composition of nisin hinges within strains exhibiting enhanced bioactivity revealed some trends. All ‘improved’ hinge regions had a mass less than that of the wild-type, alanines were frequently identified at each position and, on a

number of occasions, multiple alanines were present. Based on these observations, it was postulated that a nisin derivative with a hinge consisting of AAA could potentially display enhanced properties. The presence of a serine, particularly at position 20, in the nisin hinge of other strains displaying enhanced bioactivity has also been noted, including hinges consisting of SMT and SLS from this study and SVA from Rouse *et al.* (2012). On the basis of this observation, a nisin derivative containing a SAA hinge was also created. To further test the theory that nisin derivatives with a hinge consisting of small amino acids may exhibit enhanced features, site-directed mutagenesis was also used to create a hinge derivative consisting of glycine residues only. In this last case, the producer of the GGG-containing hinge did not exhibit antimicrobial activity. It would thus seem that a lack of chirality within the hinge is a negative feature.

In contrast, the respective producers of the AAA- and SAA-containing peptides displayed enhanced bioactivity against each of the four strains tested and again were purified for specific activity assays (Tables 3.6 and 3.7). Both the AAA- and SAA-containing peptides showed significantly enhanced specific activity relative to nisin A against all four indicators in agar diffusion assays. In each case, this enhancement was more significant in the case of the AAA-containing peptide. In contrast, in broth based specific activity assays the bioengineered peptides exhibited activity that was equal or reduced relative to that of the wild-type peptide, with the exception that the AAA-containing peptide showed a two-fold improvement relative to the natural peptide against *S. agalactiae* ATCC 13813. Thus, while in many cases it would appear that enhanced bioactivity is attributable to enhanced diffusion through complex media, a phenomenon previously reported by Rouse *et al.* (2012), this

result establishes that antimicrobial potency can also be a contributory factor with respect to some targets.

### 3.5 Discussion

In this study a large bank of derivatives of the lantibiotic nisin was generated in which all three hinge residues were simultaneously randomised. To facilitate the relatively rapid screening of such a large number of derivative-producing strains, the deferred antagonism assay was employed. This approach allows for the identification of variants with enhanced bioactivity and can be supported by further assays to determine if this enhanced bioactivity is attributable to enhanced specific activity (Field *et al.*, 2010, Field *et al.*, 2012) production and/ or solubility /diffusion (Rouse *et al.*, 2012). Regardless of the specific underlying basis for the enhanced bioactivity of a particular derivative, any enhanced feature has the potential to be exploited in food or medicine. This is especially true when one considers the number of applications which are available to lantibiotics, and nisin in particular (Cotter *et al.*, 2005).

Preliminary screening of this bank resulted in the identification of 23 derivative producers with enhanced bioactivity. Of these 23, producers of nisin derivatives containing SLS, AAK or NAI within the hinge region were brought forward for further characterisation. In the case of the SLS-containing example, the selection of a strain producing nisin with a serine (S) at positions 20 and 22 was consistent with observations made by Field *et al.* (2008) and Rouse *et al.* (2012), who previously established that the introduction of this hydrophilic amino acid at position 22 and 20 can result in enhanced bioactivity. Field and co-workers have also previously noted that the introduction of a leucine (L) at position 21, in several instances, lead to relatively high levels of activity. With respect to the NAI-containing derivative, nisin A naturally contains an asparagine (N) at position 20, the

benefits of incorporating alanines will be discussed in greater depth below and, although there is no precedent for an enhanced derivative containing an isoleucine (I) at position 22, its introduction at the other two hinge positions has had varying effects on bioactivity (Field *et al.*, 2008). The introduction of alanines in the AAK-containing peptide will be discussed below.

Although this is not the first study which has fully randomised the nisin 'hinge' region, it is the first to do so in the context of the full length nisin peptide. Previously, Plat and co-workers (2011) randomised all three positions in a truncated form of nisin, i.e. nisin-(1-22), and found when they analysed 16 of the active derivatives that the size of the zone was directly, for the most part, proportional to the amount of the prepeptide produced. However, in that instance the derivatives that exhibited the largest zones of activity both contained the aromatic amino acid tryptophan (W); AWR and WRA. In contrast, in this study none of the peptides produced by the 'hinge' mutants that displayed enhanced bioactivity contained aromatic amino acids. The differences between the composition of the hinges in enhanced peptides from these respective studies suggest that the hinge is performing a different role in the truncated, relative to the intact, peptide and that in the latter instance the impact on the hinge residues on the C-terminal domain is critical. Despite these differences, it is apparent that there is a consistent absence of negatively charged amino acids from within the hinge of all peptides and strains exhibiting enhanced bioactivity. This is also consistent with the previous studies of Field *et al.* (2008) and Yuan *et al.* (2004).

Well diffusion assays using purified forms of the SLS-, AAK- and NAI-containing peptides established that enhanced bioactivity was attributable to an enhanced diffusion in agar in a manner similar to that previously reported by Rouse

*et al.* (2012). This trait was previously noted as being a valuable one in that such a peptide performed better than wild-type nisin A with respect to controlling *Listeria monocytogenes* in a food system. The identity of these, and other, changes that occurred in the hinge region of peptides associated with enhanced bioactivity in the preliminary screening also provided a further insight into the flexibility of the hinge and revealed distinct patterns (Tables 3.3 and 3.4). The frequency with which alanine appears was particularly notable. Among the strains that exhibited enhanced bioactivity, alanine was the amino acid that was most frequently located at positions 20 (30%) and 21 (22%) and was also frequently identified at position 22 (13%). It was also noted that a pair of alanines was located in the hinge region of peptides from three strains exhibiting enhanced bioactivity. The AAK-containing peptide is a perfect example of this pattern. The third residue, lysine, is conserved across all natural variants of nisin; nisin A (Kaletta & Entian, 1989), nisin Z (Mulders *et al.*, 1991), nisin Q (Zendo *et al.*, 2003), nisin F (de Kwaadsteniet, *et al.*, 2008), nisin U and U2 (Wirawan *et al.*, 2006) and most recently nisin P (Zhang *et al.*, 2012). The enhanced bioactivity of the corresponding strain and the specific activity in agar of the corresponding peptide was particularly apparent against *S. aureus* RF122 (Tables 3.6 and 3.7). Despite the conserved nature of this lysine, this study and others (Field *et al.*, 2008, Rouse *et al.*, 2012) have demonstrated that this residue can be changed. On the basis of these observations it was decided to bioengineer a strain to produce a peptide in which the 'hinge' would consist wholly of alanines. The fact that these changes enhanced the bioactivity of the associated strain means that this is the first instance upon which a characteristic of nisin has been enhanced through rational design. The additional hinge derivative to result from rational design contained a hinge consisting of SAA. The creation of this peptide was targeted due to the



previous observation that enhanced bioactivity was evident in strains that produced peptides with a serine at position 20 of the nisin peptide, including SMT, SLS and SVA (Rouse *et al.*, 2012). The bioactivity of the resultant strain (Table 3.6) was also greater than that of nisin wild-type producer against all indicators tested. The fact that the newly introduced serine remained unmodified is in agreement with observations made previously by Lubelski (2009), where it was suggested that serines in positions immediately preceding lanthionine bridges remain unmodified. The fact that the addition of small chiral amino acids to the hinge resulted in an increase in bioactivity may be attributable to an increase in ‘hinge’ flexibility. In contrast, the production of the achiral glycine ‘hinge’ may confer a structurally weak hyper flexible ‘hinge’ lacking in any distinguishable conformity through misfolding. It should also be noted that, while we focused on the observation that alanine and serine were frequently identified across all hinge residues in strains with enhanced bioactivity, there may be merit in designing residues whereby the amino acid at each respective location is optimised. Indeed, the positively charged histidine was found very frequently at position 20 in these strains while, at position 21, the hydrophobic residues valine, leucine and isoleucine are very prominent. The identity of the residues located at position 22 was more variable.

Ultimately, the ‘hinge’ region of nisin has again been established to be a worthy target with respect to bioengineering to enhance bioactivity. The benefits of incorporating small chiral amino acids were particularly apparent leading to, for the first time, the rational design of nisin ‘hinge’ derivatives with enhanced properties.

### **3.6 Acknowledgements**

This work was financed by a grant from the Irish Department of Agriculture, Food and the Marine through the Food Institutional Research Measure (08/RD/C/691) and with Science Foundation Ireland Investigator award (10/IN.1/B3027). The authors are grateful to Paddy O'Reilly for technical assistance.

### 3.7 Bibliography

Bierbaum G & Sahl HG (2009) Lantibiotics: mode of action, biosynthesis and bioengineering. *Curr Pharm Biotechnol* **10**: 2-18.

Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP & de Kruijff B (1997) The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. *Biochemistry* **36**: 6968-6976.

Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H & de Kruijff B (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. *Science* **286**: 2361-2364.

Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G & Sahl HG (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. *Mol Microbiol* **30**: 317-327.

Chatterjee C (2005) Biosynthesis and mode of action of lantibiotics. *Chem. Rev.* **105**: 633-684.

Cotter PD, Hill C & Ross RP (2005) Bacteriocins: developing innate immunity for food. *Nat Rev Microbiol* **3**: 777-788.

Cotter PD, Hill C & Ross RP (2005) Bacterial lantibiotics: strategies to improve therapeutic potential. *Curr Protein Pept Sci* **6**: 61-75.

Cotter PD, Ross RP & Hill C (2013) Bacteriocins - a viable alternative to antibiotics? *Nature Reviews Microbiology* **11**: 95-105.

de Kwaadsteniet M, Ten Doeschate K & Dicks LM (2008) Characterization of the structural gene encoding nisin F, a new lantibiotic produced by a *Lactococcus lactis* subsp. *lactis* isolate from freshwater catfish (*Clarias gariepinus*). *Appl Environ Microbiol* **74**: 547-549.

Delves-Broughton J, Blackburn P, Evans RJ & Hugenholtz J (1996) Applications of the bacteriocin, nisin. *Antonie Van Leeuwenhoek* **69**: 193-202.

Field D, Hill C, Cotter PD & Ross RP (2010) The dawning of a 'Golden era' in lantibiotic bioengineering. *Mol Microbiol* **78**: 1077-1087.

Field D, Connor PM, Cotter PD, Hill C & Ross RP (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. *Mol Microbiol* **69**: 218-230.

Field D, Quigley L, O'Connor PM, *et al.* (2010) Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. *Microb Biotechnol* **3**: 473-486.

Field D, Begley M, O'Connor PM, *et al.* (2012) Bioengineered nisin A derivatives with enhanced activity against both Gram-positive and Gram-negative pathogens. *PLoS One* **7**: e46884.

Healy B, O'Mahony J, Hill C, Cotter P & Ross R (2010) Lantibiotic-related research and the application thereof. *Antimicrobial peptides: discovery, design and novel therapeutic strategies* **18**: 22-39.

- Herron-Olson L, Fitzgerald JR, Musser JM & Kapur V (2007) Molecular correlates of host specialization in *Staphylococcus aureus*. *PLoS One* **2**: e1120.
- Hsu ST, Breukink E, Tischenko E, *et al.* (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. *Nat Struct Mol Biol* **11**: 963-967.
- Kaletta C & Entian KD (1989) Nisin, a peptide antibiotic: cloning and sequencing of the *nisA* gene and posttranslational processing of its peptide product. *J Bacteriol* **171**: 1597-1601.
- Knerr PJ & van der Donk WA (2012) Discovery, biosynthesis, and engineering of lantipeptides. *Annu Rev Biochem* **81**: 479-505.
- Kuipers OP, Rollema HS, Yap WM, Boot HJ, Siezen RJ & de Vos WM (1992) Engineering dehydrated amino acid residues in the antimicrobial peptide nisin. *J Biol Chem* **267**: 24340-24346.
- Lubelski J, Khusainov R & Kuipers OP (2009) Directionality and coordination of dehydration and ring formation during biosynthesis of the lantibiotic nisin. *J Biol Chem* **284**: 25962-25972.
- Lubelski J, Rink R, Khusainov R, Moll GN & Kuipers OP (2008) Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. *Cell Mol Life Sci* **65**: 455-476.
- Molloy EM, Ross RP & Hill C (2012) 'Bac' to the future: bioengineering lantibiotics for designer purposes. *Biochem Soc Trans* **40**: 1492-1497.
- Molloy EM, Field D, PM OC, Cotter PD, Hill C & Ross RP (2013) Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity. *PLoS One* **8**: e58530.
- Mulders JW, Boerrigter IJ, Rollema HS, Siezen RJ & de Vos WM (1991) Identification and characterization of the lantibiotic nisin Z, a natural nisin variant. *Eur J Biochem* **201**: 581-584.
- Nov Y (2012) When second best is good enough: another probabilistic look at saturation mutagenesis. *Appl Environ Microbiol* **78**: 258-262.
- Plat A, Kuipers A, de Lange JG, Moll GN & Rink R (2011) Activity and Export of Engineered Nisin-(1-22) Analogs. *Polymers* **3**: 1282-1296.
- Rea MC, Ross RP, Cotter PD & Hill C (2011) Classification of bacteriocins from Gram-positive bacteria. *Prokaryotic antimicrobial peptides*, Drider, D. and Rebuffat, S., 29-53. Springer.
- Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJM, Moll GN & Kuipers OP (2005) Lantibiotic structures as guidelines for the design of peptides that can be modified by lantibiotic enzymes. *Biochemistry* **44**: 8873-8882.
- Rouse S, Field D, Daly KM, O'Connor PM, Cotter PD, Hill C & Ross RP (2012) Bioengineered nisin derivatives with enhanced activity in complex matrices. *Microb Biotechnol* **5**: 501-508.
- Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B & Sahl HG (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J Biol Chem* **276**: 1772-1779.

Wiedemann I, Bottiger T, Bonelli RR, *et al.* (2006) The mode of action of the lantibiotic lactacin 3147--a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. *Mol Microbiol* **61**: 285-296.

Wirawan RE, Klesse NA, Jack RW & Tagg JR (2006) Molecular and genetic characterization of a novel nisin variant produced by *Streptococcus uberis*. *Appl Environ Microbiol* **72**: 1148-1156.

Yuan J, Zhang ZZ, Chen XZ, Yang W & Huan LD (2004) Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. *Appl Microbiol Biotechnol* **64**: 806-815.

Zendo T, Fukao M, Ueda K, Higuchi T, Nakayama J & Sonomoto K (2003) Identification of the lantibiotic nisin Q, a new natural nisin variant produced by *Lactococcus lactis* 61-14 isolated from a river in Japan. *Biosci Biotechnol Biochem* **67**: 1616-1619.

Zhang Q, Yu Y, Velasquez JE & van der Donk WA (2012) Evolution of lanthipeptide synthetases. *Proc Natl Acad Sci U S A* **109**: 18361-18366.

### 3.8 Tables and Figures

**Table 3.1** Plasmids & strains used in used in this study

| Plasmid/Strains                         | Characteristic  | Reference/Source                  |
|---|---|-----------------------------------|
| pDF05                                   | pCI372 with <i>nisA</i>                                   | Field <i>et al.</i> (2008)        |
| pDF05 AAK                               | pDF05 with N20A/M21A substitution in <i>nisA</i>          | This study                        |
| pDF05 AAA                               | pDF05 AAK with K22A substitution in <i>nisA</i> AAK       | This study                        |
| <i>L. lactis</i> NZ9800                 | <i>L. lactis</i> NZ9700 $\Delta$ <i>nisA</i>              | Rea <i>et al.</i> (2011)          |
| <i>L. lactis</i> NZ9800 pDF05           | Wild-type nisin A producer                                | Field <i>et al.</i> (2008)        |
| <i>E. coli</i> Top10                    | Intermediate cloning host                                 | Invitrogen                        |
| <i>M. smegmatis</i> MC2155              | Model microorganism for slow-growing mycobacteria species | ATCC                              |
| <i>S. agalactiae</i> ATCC 13813         | Indicator strain  | ATCC                              |
| <i>L. lactis</i> ssp <i>cremoris</i> HP | Indicator strain  | UCC Culture Collection            |
| <i>S. aureus</i> RF122                  | Bovine mastitis-causing isolate                           | Herron-Olson <i>et al.</i> (2007) |

ATCC: American Type Culture Collection, UCC: University College Cork

**Table 3.2** Oligonucleotides used in this study.

| Oligonucleotide       | Sequence  |
|-----------------------|---|
| NisAXXXHingeFor       | 5'- PHO TGATGGGTTGT <b>NKNNKNNK</b> ACAGCAACTTGTCATTGTAGT -3' |
| NisAXXXHingeRev       | 5'- CAAGTTGCTGTM <b>NNMNNMNN</b> ACAACCCATCAGAGCTCCTGT -3'    |
| pCI372Rev             | 5'- ACCTCTCGGTTATGAGTTAG -3'                                  |
| For Primer (AAA)      | 5'- GTTGTGCTGCG <b>GGCA</b> ACAGCAACTTGTCATTGTAGTATTAC -3'    |
| Rev Primer (AAA)      | 5'- CAAGTTGCTGT <b>TGCC</b> CGCAGCACAACCCATCAGAGCTCCTGT -3'   |
| AAA Check Primer For  | 5'- CTGATGGCTTGTGCTGCG <b>GGCA</b> -3'                        |
| SAA HC For            | 5'- TGATGGGTTGT <b>TCAG</b> C GCGCTACAGCAACTTGTCATTGTAGT -3'  |
| SAA HC Rev            | 5'- GCTGTAGCCGCT <b>TGA</b> ACAACCCATCAGAGCTCCTGTTTTACA -3'   |
| SAA Forward SLT Codon | 5'- TGATGGGTTGT <b>TCG</b> GCGGCTACAGCAACTTGTCATTGTAGT -3'    |
| SAA Reverse SLT Codon | 5'- GCTGTAGCCGCC <b>CGA</b> ACAACCCATCAGAGCTCCTGTTTTACA -3'   |
| GGG Forward Primer    | 5' GATGGGTTGT <b>GGAGGTGGA</b> ACAGCAACTTGTCATTGTAGTA '3      |
| GGG Reverse Primer    | 5' AGTTGCTGT <b>TCCACCTCC</b> ACAACCCATCAGAGCTCCTGTTT '3      |
| GGG Check Primer      | 5' TCTGATGGGTTGT <b>GGAGGTGGA</b> '3                          |

PHO – 5'- Phosphate modification. Emboldened – Degenerate codons, emboldened & underlined – locations for site-directed mutagenesis

**Table 3.3** Nisin A ‘hinge’ variants with enhanced bioactivity identified through the initial screen.

| <b>Variant</b> | <b>Molecular Mass</b> | <b>Variant</b> | <b>Molecular Mass</b> |
|----------------|-----------------------|----------------|-----------------------|
| HVS            | 3304                  | AIT            | 3266                  |
| MAQ            | 3311                  | QVQ            | 3336                  |
| ASS            | 3226                  | SMT            | 3300                  |
| PVN            | 3291                  | HSQ            | 3332                  |
| ASV            | 3238                  | HAA            | 3260                  |
| HLA            | 3301                  | SIN            | 3294                  |
| NAI            | 3279                  | PQK            | 3334                  |
| ANP            | 3263                  | AQV            | 3278                  |
| SLS            | 3268                  | HSQ            | 3332                  |
| AAI            | 3236                  | PNA            | 3262                  |
| AAK            | 3250                  | NQV            | 3321                  |
|                |                       | HLS            | 3308                  |

The three letter code corresponds to the amino acids located at each of the three ‘hinge’ sites.



**Table 3.4** Frequency with which amino acids are located at each hinge site among the derivatives presented in Table 3.3.

| <b>Position 20</b><br><b>(% frequency)</b> | <b>Position 21</b><br><b>(% frequency)</b> | <b>Position 22</b><br><b>(% frequency)</b> |
|--|--|--|
| Alanine 7 (30.4)                           | Alanine 5 (21.7)                           | Serine 4 (17.4)                            |
| Histidine 6 (26.1)                         | Serine 4 (17.4)                            | Glutamine 4 (17.4)                         |
| Proline 3 (13.0)                           | Valine 3 (13.0)                            | Alanine 3 (13.0)                           |
| Serine 3 (13.0)                            | Leucine 3 (13.0)                           | Valine 3 (13.0)                            |
| Asparagine 2 (8.7)                         | Glutamine 3 (13.0)                         | Isoleucine 2 (8.7)                         |
| Glutamine 1 (4.3)                          | Asparagine 2 (8.7)                         | Asparagine 2 (8.7)                         |
| Methionine 1 (4.3)                         | Isoleucine 2 (8.7)                         | Lysine 2 (8.7)                             |
|  | Methionine 1 (4.3)                         | Threonine 2 (8.7)                          |
|  |  | Proline 1 (4.3)                            |

**Table 3.5** Actual and expected frequencies of hinge amino acids from randomly selected representatives of the hinge mutant bank

| <b>Amino Acid Residue</b> | <b>Actual Frequency (%)</b> | <b>Expected Frequency (%)</b> |
|---------------------------|-----------------------------|-------------------------------|
| Serine                    | 8.33                        | 9.38                          |
| Alanine                   | 6.67                        | 6.25                          |
| Asparagine                | 6.67                        | 3.13                          |
| Lysine                    | 6.67                        | 3.13                          |
| Tyrosine                  | 6.67                        | 3.13                          |
| Arginine                  | 5.00                        | 9.38                          |
| Glutamine                 | 5.00                        | 3.13                          |
| Glycine                   | 5.00                        | 6.25                          |
| Histidine                 | 5.00                        | 3.13                          |
| Isoleucine                | 5.00                        | 3.13                          |
| Methionine                | 5.00                        | 3.13                          |
| Stop                      | 5.00                        | 3.13                          |
| Valine                    | 5.00                        | 6.25                          |
| Aspartic Acid             | 3.33                        | 3.13                          |
| Cytosine                  | 3.33                        | 3.13                          |
| Glutamic Acid             | 3.33                        | 3.13                          |
| Leucine                   | 3.33                        | 9.38                          |
| Proline                   | 3.33                        | 6.25                          |
| Threonine                 | 3.33                        | 6.25                          |
| Tryptophan                | 3.33                        | 3.13                          |
| Phenylalanine             | 1.67                        | 3.13                          |

**Table 3.6** Deferred Antagonism Results

|                                 |     | Deferred Antagonism             |             |                       |
|---------------------------------|-----|---------------------------------|-------------|-----------------------|
|                                 |     | Zone Area<br>(mm <sup>2</sup> ) | p-<br>value | Relative to<br>WT (%) |
| <i>L. lactis</i> HP             | WT  | 299.58 ± 7.04                   |             |                       |
|                                 | AAA | 492.83 ± 40.27                  | 0.012       | 164.51                |
|                                 | AAK | 408.89 ± 18.72                  | 0.005       | 136.49                |
|                                 | SAA | 483.14 ± 33.89                  | 0.009       | 161.28                |
|                                 | SLS | 370.75 ± 28.28                  | 0.042       | 123.76                |
|                                 | NAI | 439.52 ± 47.88                  | 0.034       | 146.71                |
| <i>S. aureus</i> RF122          | WT  | 138.31 ± 3.36                   |             |                       |
|                                 | AAA | 292.24 ± 11.46                  | 0.001       | 211.29                |
|                                 | AAK | 292.44 ± 10.36                  | 0.001       | 211.43                |
|                                 | SAA | 236.28 ± 13.53                  | 0.004       | 170.83                |
|                                 | SLS | 153.93 ± 7.15                   | 0.045       | 111.29                |
|                                 | NAI | 163.23 ± 10.95                  | 0.049       | 118.02                |
| <i>S. agalactiae</i> ATCC 13813 | WT  | 226.55 ± 2.96                   |             |                       |
|                                 | AAA | 401.32 ± 15.62                  | 0.002       | 177.14                |
|                                 | AAK | 232.00 ± 21.58                  | 0.706       | 102.41                |
|                                 | SAA | 407.98 ± 18.452                 | 0.003       | 180.08                |
|                                 | SLS | 209.45 ± 17.11                  | 0.223       | 92.45                 |
|                                 | NAI | 318.81 ± 7.915                  | 0.034       | 140.72                |
| <i>M. smegmatis</i> MC2155      | WT  | 51.31 ± 10.08                   |             |                       |
|                                 | AAA | 277.65 ± 60.42                  | 0.02        | 541.09                |
|                                 | AAK | 199.47 ± 32.36                  | 0.009       | 388.73                |
|                                 | SAA | 303.85 ± 59.93                  | 0.016       | 592.15                |
|                                 | SLS | 230.31 ± 20.31                  | 0.001       | 448.84                |
|                                 | NAI | 270.04 ± 58.30                  | 0.02        | 526.26                |


The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 'spot' in mm<sup>2</sup>.

**Table 3.7** Specific Activity Results

|                                    |     | 100 mg L <sup>-1</sup> Agar Diffusion |         |                       | MIC                                |
|------------------------------------|-----|---------------------------------------|---------|-----------------------|------------------------------------|
|                                    |     | Zone Area<br>(mm <sup>2</sup> )       | p-value | Relative to<br>WT (%) | Specific<br>Activity as<br>% of WT |
| <i>L. lactis</i> HP                | WT  | 267.69 ± 9.21                         |         |                       |                                    |
|                                    | AAA | 416.00 ± 17.99                        | 0.001   | 155.41                | 100                                |
|                                    | AAK | 320.08 ± 14.20                        | 0.009   | 119.57                | 50                                 |
|                                    | SAA | 344.76 ± 18.50                        | 0.008   | 138.71                | 50                                 |
|                                    | SLS | 321.93 ± 22.43                        | 0.038   | 120.26                | 25                                 |
|                                    | NAI | 371.32 ± 19.60                        | 0.004   | 128.79                | 100                                |
| <i>S. aureus</i> RF122             | WT  | 99.34 ± 12.33                         |         |                       |                                    |
|                                    | AAA | 155.77 ± 3.30                         | 0.011   | 156.81                | 25                                 |
|                                    | AAK | 178.23 ± 13.39                        | 0.002   | 179.42                | 50                                 |
|                                    | SAA | 130.60 ± 4.46                         | 0.036   | 131.47                | 25                                 |
|                                    | SLS | 98.82 ± 10.14                         | 0.957   | 99.47                 | <6                                 |
|                                    | NAI | 129.75 ± 11.36                        | 0.035   | 130.61                | 25                                 |
| <i>S. agalactiae</i><br>ATCC 13813 | WT  | 246.31 ± 2.74                         |         |                       |                                    |
|                                    | AAA | 305.58 ± 2.39                         | 0.000   | 124.06                | 200                                |
|                                    | AAK | 234.55 ± 4.23                         | 0.021   | 95.23                 | 50                                 |
|                                    | SAA | 301.62 ± 8.18                         | 0.004   | 122.46                | 100                                |
|                                    | SLS | 226.05 ± 4.10                         | 0.003   | 91.78                 | 25                                 |
|                                    | NAI | 291.52 ± 8.46                         | 0.007   | 118.36                | 200                                |
| <i>M. smegmatis</i><br>MC2155      | WT  | 67.79 ± 4.308                         |         |                       |                                    |
|                                    | AAA | 149.24 ± 4.776                        | 0.000   | 220.15                | ND                                 |
|                                    | AAK | 105.73 ± 6.930                        | 0.003   | 155.96                | ND                                 |
|                                    | SAA | 101.19 ± 11.510                       | 0.026   | 149.27                | ND                                 |
|                                    | SLS | 119.56 ± 8.59                         | 0.003   | 176.36                | ND                                 |
|                                    | NAI | 78.50 ± 8.16                          | 0.137   | 115.8                 | ND                                 |

MIC: Minimum Inhibitory Concentration ND: Not Determined

**Figure 3.1** A - Nisin A mature peptide, B - AAA Producer (Deferred Antagonism Assay).



Panel A. Dha – Dehydroalanine; Dhb – Dehydrobutyrine. Hinge region highlighted. Five (β-methyl)lanthionine rings labelled A-E. Arrows denote amino acid changes to produce AAA derivative in the nisin hinge region. Panel B. Zones of inhibition produced by *L. lactis* NZ9800 pDF05(left) and AAA ‘hinge’ variant (right) against *L. lactis* HP.

## **Chapter IV**

### **Bioengineering to create a trypsin resistant Nisin A derivative**

Brian Healy, Des Field, Paula M O'Connor Colin Hill, Paul D. Cotter and R. Paul Ross

Manuscript in Preparation

## 4.1 Abstract

Nisin A is a 34 amino acid Class 1 lantibiotic. It has a long and successful history of use in the food industry having been approved as a food preservative by the EU, the WHO and the USFDA. Lantibiotics also have potential as alternatives to clinical antibiotics due to their effectiveness against many human, including multi-drug resistant pathogens. However, their somewhat proteolytically labile nature results in their breakdown during transit in the gastro-intestinal tract, a major hurdle in nisin's potential use in a clinical setting.

Numerous studies have demonstrated the amenability of the prototypic lantibiotic nisin to genetic engineering in order to improve on its already impressive functionality and antimicrobial activity. In this study we employed both site-specific and site-saturation PCR based mutagenesis techniques to confer onto the peptide a greater ability to resist trypsin digestion, through the substitution of trypsin sensitive lysine and arginine residues. By targeting the lysine 12 amino acid of a nisin A derivative in which the innate hinge residues have been replaced by a triplet of alanines (AAA), a derivative containing a lysine to methionine substitution at this position, K12M-AAA, exhibited both enhanced bioactivity and a loss of trypsin sensitivity.

## 4.2 Introduction

The lantibiotic (**lantionine-containing antibiotic**) class of bacteriocins (Rea *et al.*, 2011) are a distinctive class of cationic antimicrobial peptides due to the presence of unusual amino acids found within their structures arising from a number of post-translational modifications. The most thoroughly studied lantibiotic, the *Lactococcus lactis* produced nisin A, contains five thio-ether bridged amino acids; one lantionine bridge (Lan) and four  $\beta$ -methylanthionine bridges (meLan) (Sahl *et al.*, 1995). These bridges result from the coupling of dehydrated serines (dehydroalanines) and threonines (dehydrobutyrines) with proximal cysteines through the combined action of a dehydratase (NisB) and a cyclase (NisC) and provide the mature/ modified peptides with increased protection from thermal and proteolytic stress (Suda *et al.*, 2010).

The importance of lantionine bridges in protecting lantibiotics from proteases has been demonstrated through the study of peptides from which lantionine bridges have been removed (Bierbaum *et al.*, 1996) (Suda *et al.*, 2010). This removal lead to destabilization of the peptides, exposing the otherwise sheltered cleavage sites to proteases. Notably, while lantibiotics exhibit an enhanced resistance to proteolytic degradation relative to unmodified bacteriocins, they are nonetheless ribosomally synthesised peptides and thus remain more sensitive to proteases than non-ribosomal antibiotics (Caboche *et al.*, 2008). In the context of the use of lantibiotics in the food industry as a preservative and shelf-life extender (Deegan *et al.*, 2006), this proteolytic sensitivity, and in particular sensitivity to trypsin and chymotrypsin in the small intestine, has been viewed as advantageous as it ensures that the peptides are broken down before they negatively influence the gut microbiota (O'Shea *et al.*, 2010). However, this perceived advantage can be viewed



as a disadvantage in the context of the use of nisin, and other lantibiotics, as alternatives to antibiotics to control clinical or veterinary gastrointestinal tract (GIT) pathogens (Piper *et al.*, 2009, Jabés *et al.*, 2011, Piper *et al.*, 2012, Cotter *et al.*, 2013) such as colonic *Clostridium difficile* or colonization by vancomycin-resistant enterococci (VRE). In order to circumvent the proteolytic sensitivity of bacteriocins, encapsulation has been investigated as a means of facilitating transit through the GIT. Indeed *in vitro* studies have found that a pectin/ HPMC (Hydroxypropyl methyl cellulose) envelope is suitable for delivery of nisin to the colon (Ugurlu *et al.*, 2007). It should also be noted that not all bacteriocins are trypsin sensitive. One such exception is salivaricin D, produced by *Streptococcus salivarius* 5M6c, which is intrinsically resistant to trypsin due to the absence of lysine and arginine residues within its sequence (Birri *et al.*, 2012).

Another consequence of the ribosomal, i.e. gene encoded, nature of lantibiotics is that they can be relatively easily altered through gene manipulation. Indeed, an ever growing number of studies have shown how this has been exploited specifically for nisin to improve various physicochemical traits and specific activity against a number of very relevant Gram-positive and negative pathogenic bacteria including MRSA and *Clostridium difficile* (Field *et al.*, 2008, Field *et al.*, 2010, Field *et al.*, 2012, Rouse *et al.*, 2012, Healy *et al.*, 2013, Molloy *et al.*, 2013). Here we apply this tolerance of nisin to change in order to bioengineer a derivative that is resistant to trypsin.

More specifically, a dual approach of site-specific and site-saturation mutagenesis technique to introduce amino acid substitutions is employed with the specific aim to create/ unearth active nisin derivatives resistant to trypsin while, importantly, also maintaining antimicrobial activity. With respect to trypsin, nisin

contains three cut sites; lysine at amino acid position 12, asparagine 20 and lysine 22 while asparagine 20, methionine 22 and histidine 31 are chymotrypsin sensitive cut sites (Figure 4.1)(Slootweg *et al.*, 2013). This approach led to the creation of four putatively trypsin or chymotrypsin resistant derivatives of which one, K12M-AAA, (lysine at position 12 replaced by alanine and the three ‘hinge’ associated residues, i.e. N20, M21 and K22, replaced by alanines) was characterised in greater depth and confirmed to be trypsin resistant and to retain antimicrobial activity. To our knowledge this represents the first occasion whereby a rationally designed, bioengineering strategy resulted in the creation of a bioactive trypsin resistant nisin variant.

## 4.3 Materials and Methods

### 4.3.1 Bacterial strains and growth conditions

The strains and plasmids used in this study are listed in Table 4.1. *Lactococcus lactis* cultures were grown in M17 agar and broth (both Oxoid) supplemented with 0.5% glucose at 30°C overnight. *Escherichia coli* strains were grown in 1% NaCl (Sigma-Aldrich), 1% Yeast Extract (Merck) and 0.5% Tryptone (Merck) at 37°C overnight with constant shaking. *Streptococcus agalactiae* ATCC 13813 was grown in Tryptic Soy Broth (TSB) (Merck) supplemented with 0.6% (w/v) Yeast Extract (Merck) at 37°C overnight. Where applicable, chloramphenicol (Sigma-Aldrich) was added at 10 µg/ml.

### 4.3.2 Site-saturation mutagenesis of the K12A

The targeted change of the lysine at position 12 was achieved through a PCR based method using the oligonucleotides NisK12A-AAFor and NisK12ARev (Table 4.2). The plasmid pDF05-AAA (Healy *et al.*, 2013) (Table 4.1), which had been extracted from *dam*<sup>+</sup> *E. coli* Top10 (Invitrogen) to ensure its methylation, was used as the template for this reaction. Amplification was achieved through a 50 µl PCR reaction consisting of 0.02 U/µl KOD Hot-Start Polymerase (Novagen), 1.5 mM MgSO<sub>4</sub>, 0.2 mM of each dNTP, 0.3 µM of both oligonucleotides and approximately 10 ng of template. Cycling conditions were as follows: 98°C for 30 sec, 60.0°C for 15 sec and 72°C for 3.5 min for 40 cycles followed by final extension for 10 min. The resulting product was *DpnI* treated (Stratagene) at 37°C for 3 hours with subsequent cleaning using GeneJet PCR Purification Kit (ThermoScientific). 2.5 µl of mutated pDF05-AAA added to a vial of Top 10 Chemically Competent *E.coli* (Invitrogen). Transformants were selected for on LB Cm<sup>10</sup> agar. pDF05-K12A-AAA was

extracted using a High Pure Plasmid Isolation Kit (Roche), transformed into electro-competent *L. lactis* ssp. *lactis* NZ9800 $\Delta$ *nisA* and selected for on GM17 Cm<sup>10</sup> agar. The changes to the *nisA* genes within the corresponding pDF05 derivative were confirmed through DNA sequencing (MWG, Biotech, Germany).

### **4.3.3 Site-saturation mutagenesis of K12,H31 and combination of both**

Site-saturation mutagenesis was achieved through a PCR based method using the oligonucleotide sets NisH31DegFor and NisH31DegRev, and NisK12DegAAFor and NisK12DegREV (Molloy *et al.*, 2013) (Table 4.2) with pDF05 pDF05-AAA extracted from dam<sup>+</sup> *E. coli* Top10 used as the template on both occasions. Intermediate *E. coli* cloning with subsequent expression in *L. lactis* NZ9800 $\Delta$ *nisA* was carried out as outlined in the previous section. Approximately 150 randomly chosen transformants from the respective PCR reactions were assayed through deferred antagonism in order to select for derivatives displaying activity comparable or greater than that of the wild-type nisin A producer.

In order to produce a bank in which both the K12 and H31 positions are randomised on a single derivative, pDF05-K12X-AAA was used as a template for a subsequent H31X saturation. A bank of 2400 *L. lactis* derivatives were picked using Genetix QPIX II-XT colony-picking robot and added to GM17 Cm<sup>10</sup> within 96-well plates, incubated overnight at 30°C and stored at -80°C.

### **4.3.4 Derivative Identification**

Colony mass spectrometric analysis was carried using an Axima TOF<sup>2</sup> MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) and analyzed in positive-ion linear mode as previously described (Field *et al.*, 2008) to confirm production

and the size of the resulting derivative. DNA sequencing of the *nisA* gene within the pDF05 AAA derivative was carried out (Source Biosciences, Dublin, Ireland) to confirm the desired change had occurred.

#### **4.3.5 Peptide Purification**

Two 10 ml overnights of the culture of interest were added to 2 l of Tryptone Yeast (TY) and incubated at 30°C for at least 20 hours. The sample was next centrifuged for 20 min at 8630 g. The cell free supernatant (CFS) was passed through 60g of pre-equilibrated Amberlite XAD16 beads (Sigma-Aldrich) with subsequent washing of the column with 500ml of 30% ethanol and elution in 500ml of 70% isopropanol (IPA) (Fisher) with 0.1% trifluoroacetic acid (TFA) (Sigma-Aldrich). Concurrently, the cell pellets was resuspended in 500 ml 70% IPA 0.1% TFA and stirred at room temperature for a minimum of 3 hours followed by centrifugation. This supernatant was combined with the CFS eluate (800 ml) and reduced to a final volume of 250 ml through rotary evaporation (Buchi, Switzerland) and the pH adjusted to 4.5. The sample was further purified and concentrated to 60 ml through a Phenomenex SPE C-18 column. Purification of the peptide was achieved using a Phenomenex C12 Reverse-Phase (RP) HPLC column (Jupiter 4  $\mu$  proteo 90 Å, 250 X 10.0 mm, 4  $\mu$ m). Peaks were evident within a gradient of 30–50% acetonitrile (Fisher) containing 0.1% TFA. These fractions were pooled and the acetonitrile removed through rotary evaporation and freeze-dried (LABCONCO). To ensure the integrity before subsequent analysis, the peptide purity was determined by MALDI TOF mass spectrometric analysis.

#### **4.3.6 Bioactivity and specific activity assays**

Initial screening of the various derivative banks was carried out using the deferred antagonism assay whereby approximately 3µl volumes of the putative producers were ‘spotted’ onto GM17 agar with 10 ng/ml nisin (so as to allow for the possibility that induction may have being affected by bioengineering) and allowed to grow overnight followed by UV treatment. The indicator was seeded at 0.5% (v/v) into the specific growth media with an agar concentration of 0.75% (w/v), poured over the test plate and incubated overnight. Those displaying zones of inhibition comparable to the wild-type producer were identified and purified if the amino acid changes that occurred led to substitution of an enzyme susceptible residue.

Agar well diffusion assays (WDA) were carried out through the addition of 50 µl volumes of 30 µM purified peptide solutions into wells bored into the specific growth media for the indicator in question with a final volume of 50ml and an agar concentration of 0.75%. The plates for kept at 4°C for 3 hours followed by incubation overnight.

The minimum inhibitory concentration assays (MIC) were carried out as stated previously (Healy *et al.*, 2013). In brief, the assay was performed in triplicate in 96-well plates (Sarstedt) pre-treated with bovine serum albumin. 500 nm concentrations of both the wild-type and derivative purified powders were added to the first well and serially diluted in 2-fold increments down to a concentration of <1 nmol. An overnight culture of the indicator was subcultured and incubated until reaching an OD 600 nm of 0.5 and diluted to 10<sup>5</sup> cfu/ml in 200 µl, which was added to each test well. The plates were incubated for 16 hours and the MIC read as the lowest peptide concentration where growth was not visible.

#### **4.3.7 Trypsin Digestions**

20 µg of New England Biolabs Trypsin Ultra, Mass Spectrometry Grade (P81015) was resuspended into 20 µl of 25 mM ammonium bicarbonate pH 8.0 to give a stock solution of 1 mg/ml. RP-HPLC purified nisin A and Nisin K12M-AAA peptides were resuspended at 1 mg/ml in Milli Q water. The peptide purity was checked using MALDI TOF mass spectrometry (MS).

Trypsin digests were set up as follows. 50 µl of 1 mg/ml peptide and 50 µl of 200 µg/ml trypsin were added to 100 µl of ammonium bicarbonate buffer. Control digests were set-up by substituting the peptides for ammonium bicarbonate buffer. Digests were incubated on a heating block at 37°C for 48 hrs. MALDI-TOF MS was carried out at T0, T24 and T48 hrs with the addition of fresh 1 mg/ml trypsin (10 µl final volume) added at T29. 4 µl aliquots, diluted to 50 µl, were taken for well diffusion assays (WDA) using *L. lactis* ssp. *cremoris* HP as an indicator.

135 µl of both digestions was taken at T0 and T48 and RP-HPLC analysis of the each was run on a Dionex micro analytical C18 RE-HPLC column (2.1 x 150 mm, 100Å, 3 µm) running on a 10-45% acetonitrile 0.1% TFA gradient over 40 minutes.

## 4.4 Results

A nisin derivative peptide that contained the alanine(A)-alanine(A)-alanine(A) hinge (Positions 20, 21 and 22) with a lysine to alanine change at position 12 was designed with a view to making a trypsin resistant form of the peptide. A derivative containing a AAA ‘hinge’ is advantageous on two levels; a peptide containing these substitutions has previously been shown to exhibit increased bioactivity and specific activity relative to nisin A (Healy *et al.*, 2013) while also, it lacks two of the three trypsin cleavage sites. The remaining cleavage site is the lysine at position 12, which has also been shown to be amenable to change as evidenced by the enhanced (bio)activity of a K12A-containing derivative (Molloy *et al.*, 2013). To generate a putatively trypsin-resistant derivative, these changes were combined in a peptide designated K12A-AAA using the oligonucleotides NisK12A-AAFor and NisK12AREv (Table 4.2). To determine if other changes at the K12 site could yield additional peptides of interest, a site saturation reaction was completed using the primers NisK12DegAAFor and NisK12DegREV (Table 4.2). From this, K12M-AAA emerged as an attractive candidate for more in depth characterisation due to the zone of inhibition it produced in a deferred antagonism assay (Table 4.3). Nisin derivatives containing an ‘AAA’ hinge and a K12 mutation retain a single chymotrypsin cut-site, the histidine residue at position 31. To expand on the number of protease resistant derivatives at our disposal, a double site saturation mutagenesis was undertaken by using the previously mutated pDF05K12X from the *E. coli* Top 10 plasmid pool as a template for a reaction using the NisH31Deg For and NisH31Deg Rev primer set in order to produce a bank of derivatives in which both K12 and H31 sites are randomised. Both sites were randomised simultaneously in order to increase the chances of generating a trypsin/ chymotrypsin derivative that



retains activity. As the total number of unique codon combinations of a two amino acid, NNK degenerative primer set produced bank is 1024 (32 x 32) it was decided to screen a bank of 2400 putative producers in order to obtain 2X coverage. Two derivatives that retained bioactivity (Table 4.3) and which were predicted to be chymotrypsin resistant emerged from this screen, i.e. K12A-AAA-H31R and AAA-H31R. However, the H31R substitution present in both peptides results in the re-introduction of a trypsin cleavage site. As none of the four lead derivatives generated to this point, K12A-AAA, K12M-AAA, K12A-AAA-H31R or AAA-H31R, were predicted to be resistant to both proteases, it was decided to create another derivative in which a proline was inserted directly after the R31 residue, so as to negate the trypsin sensitivity (Keil's Rule) (Keil, 1992), yielding K12A-AAA-H31R-V32P.

The bioactivity of each derivative was determined in triplicate using both *L. lactis* HP and *S. agalactiae* ATCC 13813 as the indicators. The zone size was expressed as a percentage relative to that produced by the wild-type (Table 4.3). K12A-AAA gave a zone size of 107% (p-value 0.119) and 104% (p-value 0.681) against *L. lactis* HP and *S. agalactiae* ATCC 13813, respectively, while K12A-AAA-H31R generated zones 77% (0.059) and 86% (0.165) that of wild-type against the same indicators. Both K12M-AAA and AAA-H31R displayed bioactivity at levels statistically greater than wild-type. The former giving zone sizes of 125% (p-value 0.019) and 116% (0.041) against *L. lactis* HP and *S. agalactiae* ATCC 13813, respectively, while the latter displayed bioactivity that was 126% (0.027) and 135% (0.003), respectively, of that of the wild-type against the same targets. K12A-AAA-H31R-V32P did not give a zone of inhibition. Based on these results both K12M-AAA and AAA-H31R were brought forward for purification and further assessment of their activity.

The activity of the purified peptides was first assessed using equimolar concentrations of the peptides (30  $\mu$ M) and agar well diffusion assays. AAA-H31R and K12M-AAA produced zones against *L. lactis* HP that were not significantly different from that produced by the wild-type peptide (98%, p-value 0.298 and 99%, p-value 0.568, respectively) Table 4.4. When using *S. agalactiae* ATCC 13813 as the indicator, AAA-H31R produced a zone that was 120% (p-value 0.001) that of the wild-type while K12M-AAA produced a zone with an 80% (p-value 0.001) relative size. As these assays reflect both the activity of the peptides and their ability to diffuse through a complex media such as agar, further assessments focused on specific activity only. These broth-based minimum inhibitory concentration (MIC) assays were again carried out using the HP and ATCC 13813 strains (Table 4.4). K12M-AAA had an MIC of 31.3 nM, compared to 15.6 nM for wild-type nisin A, against HP. The MIC of AAA-H31R against the same strain was 62.5 nM. When *S. agalactiae* ATCC 13813 was used as an indicator, the reduction in the activity of AAA-H31R (125 nM) relative to wild-type (62.5 nM) was less. K12M-AAA had an MIC of 95.5 nM against the same strain.

As a consequence of its greater specific activity and our particular interest in the creation of trypsin resistant nisinA derivatives, purified K12M-AAA was selected to be brought forward for trypsin digestion assays. This was achieved through assays whereby both the derivative peptide and the wild-type were digested for 48 hours at 37°C at a ratio of 5:1 peptide to trypsin with samples taken for WDAs using *L. lactis* HP as an indicator at T0, T24 and T48 hrs. Concurrently, digests were set-up whereby trypsin was replaced by ammonium bicarbonate buffer as a control (in order to view possible non-trypsin associated breakdown of the peptide during the run-time of the assay). From Figure 4.2 A, the detrimental impact of trypsin on

the nisin A peptide is evident as peptide that was pre-digested for 48 hrs did not produce a zone of inhibition. This contrasts with the ammonium bicarbonate control where only a slight decrease in the zone size was observed. When K12M-AAA was tested under identical conditions a substantial level of inhibitory activity was retained, even after 48 hours in the presence of trypsin (Figure 4.2 B). The presence of a zone at T48 for K12M-AAA confirms its trypsin resistance.

In order to more fully investigate this phenomenon, RP-HPLC was carried out to purify nisin A and K12M-AAA peptides before and after exposure to trypsin. Figure 4.3 displays the chromatographs corresponding to nisin A before (T0; top) and after (T48; bottom) treatment with trypsin. Most noticeable from both chromatographs is the dramatic decrease in the size of the peak corresponding to intact nisin A between T0 (A) and T48 (B) which corresponds to the decrease in the zone of inhibition in Figure 4.2 A. Also visible in Figure 4.3 are the various fragments resulting from the trypsin digestion, the most prominent of which are nisin 1-12 (1150 Da) and nisin 21-34 (1492 Da). Figure 4.4 displays the corresponding K12M-AAA chromatographs i.e. before (T0; A) and after (T48; B) exposure to trypsin. From these chromatographs the trypsin resistance of K12M-AAA is clearly apparent.

## 4.5 Discussion

There have been some previous attempts to decrease the trypsin-sensitivity of bacteriocins through amino acid substitution. This can be achieved by either substituting arginine, lysine or adjacent residues with non-sensitive residues or by decreasing the conformational flexibility of the peptide therefore limiting exposure to the proteases catalytic cleft both of which can negatively influence the bioactivity of bacteriocins. For example, proteolytic resistance has been increased in derivatives of the lantibiotic gallidermin using the former approach but this was accompanied with a dramatic decrease in antimicrobial activity (Ottenwalder *et al.*, 1995). One such gallidermin derivative was Dhb14P(threonine at position 14 substituted by proline) which follows a lysine residue at position 13. This amino acid orientation negates the action of trypsin (Keil, 1992). The former approach has also been successfully implemented in the synthesis of trypsin-resistant derivatives of one of the peptides of the two component bacteriocin Class IIb bacteriocin salivarcin P (O'Shea *et al.*, 2010), leading to a histidine-substituted derivative that exhibited only a modest decrease in activity. While the lantibiotic group of bacteriocins are an attractive candidate to fill the void in novel antibiotic discovery against the rise of multi-drug resistant pathogens, their sensitivity to a number of proteases can be viewed as a shortfall. Although a partial intrinsic protease protection is afforded by the eponymous lanthionine bridges, nisin A remains trypsin sensitive, as is clearly apparent (Figure 4.2 A). When digested with trypsin it is observed that the peak corresponding to the intact lantibiotic (Figure 4.3) is reduced drastically after 48 hours with the emergence of a number fragments corresponding to those predicted to arise as a consequence of trypsin digestion. Notably the identification of a peak corresponding to nisin A 21-34 (Peak E 1491 Da, Figure 4.3) confirms that the

asparagine residue at position 20 is trypsin sensitive, as previously reported by Slootweg *et al* (2013).

In this study, by exploiting the gene encoded nature of bacteriocins and through applying the knowledge base gained through previous nisin A mutagenesis studies (Healy *et al.*, 2013, Molloy *et al.*, 2013), a number of nisin derivatives were engineered which were enhanced in comparison with nisin A in terms of bioactivity while conferring onto it trypsin or chymotrypsin resistance and therefore improved functionality. This resistance would facilitate transit through the small intestine in which (chymo)trypsin is found and allow such derivatives to arrive intact in the large intestine tract to control undesirable gut microorganisms, such as *C. difficile* (which is very sensitive to nisin (Field *et al.*, 2010)). The fact that the derivatives continue to be ribosomal peptides, and are likely to be eventually degraded by other proteases present in the large intestine (Gibson *et al.*, 1989), including those produced by the gut microbiota, is significant in light of the importance of the gut microbiota to human health and the complexity of the bacterial community relationships within has gained huge attention (Walsh *et al.*, 2014).

Interestingly, both regions of the nisin A peptide that are sensitive to trypsin cleavage, i.e. K12 and the asparagine and lysine of the 'hinge' region, and which are the targeted for modification in this study are thought to be involved in the conformational flexibility of the peptide and subsequent antimicrobial activity (Breukink *et al.*, 1997, Wiedemann *et al.*, 2001, Molloy *et al.*, 2013). This flexibility is important as the bactericidal mode of action of nisin is twofold with the N-terminal region involved in binding to a precursor of peptidoglycan synthesis leading to a conformational change facilitated by the 'hinge' region which results in pore formation by the C-terminal end. Thus, manipulations to increase trypsin resistance

had the potential to reduce flexibility and, in turn, antimicrobial activity and so it was important to specifically screen peptides in which target sites for proteases were removed but which retained significant levels of activity. Bioactivity at levels comparable to that of nisin A was achieved through the bioengineering of a derivative whereby a hinge consisting of three alanines was combined with a lysine to alanine substitution at position 12 leading to the formation of K12A-AAA. Through a site saturation technique it was found that the incorporation of the hydrophobic residue methionine at this position, K12M-AAA, lead to statistically significant increase in bioactivity compared to nisin A. Also from this study, two possible candidates have emerged from the site saturation mutagenesis approach on histidine 31, K12A-AAA-H31R and AAA-H31R which theoretically should show a lack of sensitivity to chymotrypsin. Although outside the scope of this study, the enhanced bioactivity which has been attributed to AAA-H31R clearly merits further study in the future.

In all cases, it is notable that there is a decrease in the overall charge of nisin by two without having a detrimental effect on the bioactivity. This is despite studies suggesting that the overall positive charge of nisin aids in the binding of the peptide to the negatively charged phospholipid layer of sensitive cells (van Kraaij *et al.*, 1999). More specifically, it was claimed that the +4 charge of the C-terminus region plays an important role in this respect. However, as can be seen with the bioactive derivatives generated in this study, a decrease in charge to +3 in this region also does not lead to deleterious consequences.

The well assays and RP-HPLC chromatographs from the trypsin digestion, or lack of digestion, of K12M-AAA (Figure 4.2 B and Figure 4.4) demonstrates how the functionality of nisin can be improved upon by bioengineering. From the well

diffusion assays and chromatographs it is clearly evident that the derivative peptide has retained activity/ integrity, while the wild-type has not and it is clear that the goal of the study has been achieved.

In conclusion, in this study we improved upon two already enhanced nisin derivatives, AAA and K12M, through their combination and have shown that the resulting derivative, K12M-AAA, maintains considerable antimicrobial activity while gaining a resistance to trypsin. This could be seen as a major step forward for the use of lantibiotics as systemic anti-bacterials. From a more fundamental lantibiotic viewpoint these derivatives may provide the blueprint for the design of narrow spectrum nisin derivatives, which transit the small intestine but are even less likely to impact on the gut microbiota, through further bioengineering studies.

## **4.6 Acknowledgements**

This work was financed by a grant from the Irish Department of Agriculture, Food and the Marine through the Food Institutional Research Measure (08/RD/C/691) and with Science Foundation Ireland Investigator award (10/IN.1/B3027).



## 4.7 Bibliography

Bierbaum G, Szekat C, Josten M, Heidrich C, Kempter C, Jung G & Sahl HG (1996) Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. *Appl Environ Microbiol* **62**: 385-392.

Birri DJ, Brede DA & Nes IF (2012) Salivaricin D, a novel intrinsically trypsin-resistant lantibiotic from *Streptococcus salivarius* 5M6c isolated from a healthy infant. *Applied and Environmental Microbiology* **78**: 402-410.

Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP & de Kruijff B (1997) The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. *Biochemistry* **36**: 6968-6976.

Caboche S, Pupin M, Leclere V, Fontaine A, Jacques P & Kucherov G (2008) NORINE: a database of nonribosomal peptides. *Nucleic Acids Research* **36**: D326-D331.

Cotter PD, Ross RP & Hill C (2013) Bacteriocins - a viable alternative to antibiotics? *Nat Rev Microbiol* **11**: 95-105.

Deegan LH, Cotter PD, Hill C & Ross P (2006) Bacteriocins: biological tools for bio-preservation and shelf-life extension. *International Dairy Journal* **16**: 1058-1071.

Field D, Connor PM, Cotter PD, Hill C & Ross RP (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. *Mol Microbiol* **69**: 218-230.

Field D, Quigley L, O'Connor PM, *et al.* (2010) Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. *Microbial Biotechnology* **3**: 473-486.

Field D, Begley M, O'Connor PM, *et al.* (2012) Bioengineered Nisin A Derivatives with enhanced activity against both Gram-positive and Gram-negative pathogens. *Plos One* **7**: e46884

Gibson SA, McFarlan C, Hay S & MacFarlane GT (1989) Significance of microflora in proteolysis in the colon. *Appl Environ Microbiol* **55**: 679-683.

Healy B, Field D, O'Connor PM, Hill C, Cotter PD & Ross RP (2013) Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives. *PLoS One* **8**: e79563.

Jabés D, Brunati C, Candiani G, Riva S, Romanó G & Donadio S (2011) Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens. *Antimicrobial Agents and Chemotherapy* **55**: 1671-1676.

Keil B (1992) *Specificity of proteolysis* pp.66-69 Springer-Verlag, New York

Kuipers OP, Rollema HS, de Vos WM & Siezen RJ (1993) Biosynthesis and secretion of a precursor of nisin Z by *Lactococcus lactis*, directed by the leader peptide of the homologous lantibiotic subtilin from *Bacillus subtilis*. *FEBS Lett* **330**: 23-27.

Molloy EM, Field D, PM OC, Cotter PD, Hill C & Ross RP (2013) Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity. *PLoS One* **8**: e58530.

O'Shea EF, O'Connor PM, Cotter PD, Ross RP & Hill C (2010) Synthesis of trypsin-resistant variants of the Listeria-active bacteriocin salivaricin P. *Applied and Environmental Microbiology* **76**: 5356-5362.

Ottenwalder B, Kupke T, Brecht S, Gnau V, Metzger J, Jung G & Gotz F (1995) Isolation and characterization of genetically engineered gallidermin and epidermin analogs. *Applied and Environmental Microbiology* **61**: 3894-3903.

Piper C, Cotter PD, Ross RP & Hill C (2009) Discovery of medically significant lantibiotics. *Current Drug Discovery Technologies* **6**: 1-18.

Piper C, Casey PG, Hill C, Cotter PD & Ross RP (2012) The lantibiotic lacticin 3147 prevents systemic spread of *Staphylococcus aureus* in a murine infection model. *International Journal of Microbiology* **2012**.

Rea MC, Ross RP, Cotter PD & Hill C (2011) Classification of bacteriocins from Gram-positive bacteria. *Prokaryotic antimicrobial peptides*, Drider, D and Rebuffat, S., 29-53. Springer.

Rouse S, Field D, Daly KM, O'Connor PM, Cotter PD, Hill C & Ross RP (2012) Bioengineered nisin derivatives with enhanced activity in complex matrices. *Microb Biotechnol* **5**: 501-508.

Sahl HG, Jack RW & Bierbaum G (1995) Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. *European Journal of Biochemistry* **230**: 827-853.

Slootweg JC, Liskamp RM & Rijkers DT (2013) Scalable purification of the lantibiotic nisin and isolation of chemical/enzymatic cleavage fragments suitable for semi-synthesis. *Journal of Peptide Science* **19**: 692-699.

Suda S, Westerbeek A, O'Connor PM, Ross RP, Hill C & Cotter PD (2010) *Chemistry & Biology* **17**: 1151-1160.

Ugurlu T, Turkoglu M, Gurer US & Akarsu BG (2007) Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. *European Journal of Pharmaceutics and Biopharmaceutics* **67**: 202-210.

van Kraaij C, de Vos WM, Siezen RJ & Kuipers OP (1999) Lantibiotics: biosynthesis, mode of action and applications. *Natural Product Reports* **16**: 575-587.

Walsh CJ, Guinane CM, O'Toole PW & Cotter PD (2014) Beneficial modulation of the gut microbiota. *FEBS Letters*. **588**, 4120-4130.

Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B & Sahl HG (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J Biol Chem* **276**: 1772-1779.

## 4.8 Tables and Figures

**Table 4.1** Plasmids & strains used in this study

| Plasmid/Strains                          | Characteristic                                    | Reference/Source             |
|--|---|------------------------------|
| pDF05                                    | pCI372 with <i>nisA</i>                           | Field <i>et al.</i> (2008)   |
| pDF05-AAA                                | pDF05 with hinge NMK to AAA substitution          | Healy <i>et al.</i> (2013)   |
| pDF05-K12A-AAA                           | pDF05-AAA with K to A substitution at position 12 | This study                   |
| pDF05-K12X-AAA                           | pDF05-AAA randomly saturated at position 12       | This study                   |
| pDF05-AAA-H31X                           | pDF05-AAA randomly saturated at position 31       | This study                   |
| <i>L. lactis</i> NZ9800                  | <i>L. lactis</i> NZ9700 $\Delta nisA$             | Kuipers <i>et al.</i> (1993) |
| <i>L. lactis</i> NZ9800 pDF05            | Wild-type nisin A producer                        | Field <i>et al.</i> (2008)   |
| <i>E. coli</i> Top10                     | Intermediate cloning host                         | Invitrogen                   |
| <i>S. agalactiae</i> ATCC 13813          | Indicator strain                                  | ATCC                         |
| <i>L. lactis</i> ssp. <i>cremoris</i> HP | Indicator strain                                  | UCC Culture Collection       |

ATCC: American Type Culture Collection, UCC: University College Cork

**Table 4.2** Oligonucleotides used in this study.

| Oligonucleotide | Sequence  |
|-----------------|---|
| NisK12A-AA For  | 5'-CCCGGTTGTGCTACAGGAGCTCTGATGGGTTGTGCTGC -3'   |
| NisK12ARev      | 5'-AGCTCCTGTAGCACAAACCGGGTGTACATAGCGAAATACT-3'  |
| NisH31DegFor    | 5'-PHO-TGTAGTATTNKGTAAGCAAATAATCTAGAGTCGACCT-3' |
| NisH31DegRev    | 5'-TTTGCTTACMNNAATACTACAATGACAAGTTGCTGT-3'      |
| NisK12DegAAFor  | 5'-CCCGGTTGTNNKACAGGAGCTCTGATGGGTTGTGCTGCG-3'   |
| NisK12DegREV    | 5'-AGCTCCTGTMNNAACAACCGGGTGTACATAGCGAAATACT -3' |
| NisH31RV32PFor  | 5'-TGTAGTATTCGGCCCAGCAAATAATCTAGAGTCGACCTG-3'   |
| NisH21RV32PRev  | 5'-TTTGCTGGGCCGAATACTACAATGACAAGTTGCTGT-3'      |

PHO – 5' - Phosphate modification.

**Table 4.3** Deferred Antagonism Results

| Indicator                          | Producer           | Deferred Antagonism             |                                    |             |
|------------------------------------|--------------------|---------------------------------|------------------------------------|-------------|
|                                    |                    | Zone Area<br>(mm <sup>2</sup> ) | Zone size<br>relative to WT<br>(%) | p-<br>value |
| <i>L. lactis</i> HP                | WT                 | 311.96                          |                                    |             |
|                                    | K12M-AAA           | 390.22                          | 125.08                             | 0.019       |
|                                    | AAA-H31R           | 393.87                          | 126.26                             | 0.027       |
|                                    | K12A-AAA           | 332.41                          | 106.56                             | 0.119       |
|                                    | K12A-AAA-H31R      | 239.64                          | 76.82                              | 0.059       |
|                                    | K12A-AAA-H31R-V32P | No Zone                         |                                    |             |
| <i>S. agalactiae</i><br>ATCC 13813 | WT                 | 234.04                          |                                    |             |
|                                    | K12M-AAA           | 270.97                          | 115.78                             | 0.041       |
|                                    | AAA-H31R           | 315.63                          | 134.86                             | 0.003       |
|                                    | K12A-AAA           | 244.20                          | 104.34                             | 0.681       |
|                                    | K12A-AAA-H31R      | 201.09                          | 85.92                              | 0.165       |


The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 'spot' in mm<sup>2</sup>

**Table 4.4** Specific Activity Results

| Indicator                          | Producer | 30 $\mu$ M Agar Diffusion    |         |                       | MIC $\mu$ g/ml<br>(nM) |
|------------------------------------|----------|------------------------------|---------|-----------------------|------------------------|
|                                    |          | Zone Area (mm <sup>2</sup> ) | p-value | Relative to<br>WT (%) |                        |
| <i>L.lactis</i> HP                 | WT       | 272 $\pm$ 4.86               |         |                       | 3.14 (15.6)            |
|                                    | AAA-H31R | 265.99 $\pm$ 7.77            | 0.298   | 97.61                 | 12.04 (62.5)           |
|                                    | K12M-AAA | 270.52 $\pm$ 2.20            | 0.568   | 99.27                 | 5.98 (31.3)            |
| <i>S. agalactiae</i><br>ATCC 13813 | WT       | 223.37 $\pm$ 3.99            |         |                       | 12.58 (62.5)           |
|                                    | AAA-H31R | 268.47 $\pm$ 5.44            | 0.001   | 120.19                | 24.08 (125)            |
|                                    | K12M-AAA | 178.32 $\pm$ 6.51            | 0.001   | 79.83                 | 95.53 (500)            |

The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 'spot' in mm<sup>2</sup>. MIC: Minimum Inhibitory Concentration


**Figure 4.1** A. Nisin A (chymo)trypsin cleavage sites. B. Amino acid changes made across the various nisin A derivatives described in this study



**Panel A.** Dha – Dehydroalanine; Dhb – Dehydrobutyrine. Arrows denote the (chymo)trypsin cleavage sites within the nisin A peptide. **Panel B** Amino acid changes (in grey) made to produce the bioactive (chymo)trypsin resistant derivatives in the nisin peptide.




**Figure 4.2** Enzyme Digest Well Diffusion Assays




Nisin A wild-type (Panel A.) and K12M-AAA (Panel B.) digests with or without trypsin at T0, T24 hrs and T48hrs.

**Figure 4.3** RP-HPLC chromatograms displaying the fragments produced after a 48 hour digestion of nisin A with trypsin



The top chromatogram shows T0, the lower chromatogram shows T48. A: Nisin A WT, B: Nisin A WT, C: Nisin 1-12, D: Trypsin autolysis fragment, E: 21-34, F: 23-34, G: 21-34 (Ser33) and H: 13-20.

**Figure 4.4** RP-HPLC chromatograms displaying the fragments produced after a 48 hour digestion of K12M-AAA with trypsin.



The top chromatogram shows T0, the lower chromatogram shows T48. A: K12M-AAA, B: K12M-AAA

## **Chapter V**

### **Comparison of the efficacy of a variety of nisin derivatives against *Streptococcus agalactiae***

Brian Healy, Colin Hill, Paul D. Cotter and R. Paul Ross

## 5.1 Abstract

*Streptococcus agalactiae* is one of a number of pathogens that can cause sub-clinical or clinical bovine mastitis, an inflammation of the mammary glands of infected animals. From an economic viewpoint, bovine mastitis is one of the most important diseases of the dairy industry. *S. agalactiae* is also known to cause neonatal septicaemia in humans. Nisin A, the prototypic member of the lantibiotic (antimicrobial peptides containing lanthionine linkages) class of bacteriocins, exhibits specific activity at the nanomolar level against *S. agalactiae*. We have used molecular bioengineering to create derivatives of nisin that are enhanced with respect to a number of significant traits, such as increased diffusion and/ or specific activity. For this study, a collection of 15 'lead' nisin derivatives were compared with nisin A in order to identify those that most effectively inhibit *S. agalactiae*. Of these, a derivative in which the 3-amino acid hinge region 'NMK' was converted to the residues 'AAA' proved to be twice as effective as the wild-type in controlling the pathogen in milk over a 24 hour period. Apart from the AAA derivative, both K22T and a variant with an SAA hinge were also more effective than wild-type against *S. agalactiae*. A system was also created allowing the growth of nisin producers in the presence of lactose, which can ultimately facilitate large-scale peptide production in dairy substrates.

## 5.2 Introduction

Mastitis can be defined as any inflammatory process occurring in the mammary gland (Keane *et al.*, 2013) and is the most common and costly contagious disease affecting dairy farms in the western world (Barkema *et al.*, 2009). A number of Gram-positive and negative pathogens can be the causative agents for the disease, with *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Staphylococcus aureus* and *Escherichia coli* being the most prevalent (Barkema *et al.*, 1998). Two major forms of the disease exist, clinical and subclinical mastitis, with the latter being considerably more difficult to detect and treat. Regardless, the outcome of each form is a decrease in the quality and volume of milk produced by the infected animal (Wu *et al.*, 2007).

An important indication of the presence of sub-clinical mastitis is the Bulk Milk Somatic Cell Count (BMSCC), with the legal accepted limit set at 400 000 cells/ ml (EU Council Directive 92/46/ECC) (More, 2009). Although the average BMSCC count in Ireland is far below this limit (252 000 cfu/ml) (Geary *et al.*, 2014), the number is continually increasing, leading to a negative impact on quality, volume and profit (Teagasc, 2012). This is of great concern due to the importance of the Irish dairy industry to the national economy. Ireland exports 85% of its annual dairy production and there is a 3% annual increase in global demand for dairy products (More, 2009). Secondly, there is a need to increase the volume of milk being produced in the near future. The Department of Agriculture, Food and the Marine (DAFM) has set a target of a 50% increase in the volume of milk produced in Ireland to coincide with the removal of the milk quota in 2015. It is estimated that every reduction in BMSCC by 100 000 cells results in a 142.1 million litre gain (5% of the target) (Geary *et al.*, 2013).

One strategy routinely employed for the treatment of mastitis is the administration of a long-acting antibiotics during the drying off period of the cow (Crispie *et al.*, 2004). It is during this drying off period that non-lactating cows become more susceptible to acquiring new infections (Twomey *et al.*, 2000). However, the emergence of mastitis-associated antibiotic resistant bacteria resulting from this treatment has become an issue. In fact, mastitis treatment is the most common reason for antibiotic use in dairy herds (Rajala-Schultz *et al.*, 2004). As the quantity administered increases, the contamination of milk with antibiotics also becomes an issue due to concerns for human health from antibiotic residues and the inhibition of lactic acid bacteria essential for dairy processes, such as cheese and yoghurt making (Cao *et al.*, 2007).

Bacteriocins, bacterially produced antimicrobial peptides with narrow or broad spectrum host ranges (Cotter *et al.*, 2005), have recently gained greater attention as realistic alternatives to traditional antibiotics. In particular, the Class 1 post-translationally modified lanthionine containing antibiotics, the lantibiotics, have come to prominence due to their ability to inhibit food-associated and antibiotic resistant pathogens (Deegan *et al.*, 2006, Piper *et al.*, 2009). Their attractiveness stems from a number of key characteristics. Many lantibiotics are produced from generally regarded as safe (GRAS) lactic acid bacteria, they are often effective at nanomolar concentrations against clinically relevant pathogens, they are amenable to relatively economic large-scale production and, because they are synthesised through ribosomal pathways, are open to genetic manipulation (Healy *et al.*, 2010). This genetic tolerance to change has been exploited with great success in order to understand the structure/ function of many lantibiotics and, although less common, the appliance of various bioengineering strategies to increase the bioactivity or

functionality of the prototypic lantibiotic nisin has yielded very promising results (Molloy *et al.*, 2012).

*S. agalactiae*, a leading cause of bovine mastitis, is one of the pathogens against which bioengineered nisin derivatives have been found to be particularly effective. Indeed, *S. agalactiae* was the first Gram-positive pathogen against which a nisin derivative (Nisin K22T- a nisin A derivative containing a threonine rather than a lysine at position 22) with enhanced activity was identified (Field *et al.*, 2008). This breakthrough led to a focus on the central three amino acid hinge region of the nisin peptide (N20, M21 and K22) and the subsequent use of both site specific and site saturation mutagenesis techniques to generate other enhanced nisin derivatives that are altered in this region; i.e. N20P, M21V and K22S (Field *et al.*, 2008). This research provided the impetus for even further studies which lead to the creation of additional enhanced nisin derivatives (Field *et al.*, 2008, Field *et al.*, 2012, Rouse *et al.*, 2012, Healy *et al.*, 2013, Molloy *et al.*, 2013).

For this study, a collection of these lead nisin derivatives, and their producers, were tested in order to identify those that most effectively control the growth of *S. agalactiae*. Nisin A and derivatives were expressed in the *Lactococcus lactis* Lac<sup>-</sup>/ Prt<sup>-</sup> NZ9800 (Kuipers *et al.*, 1993) background, a derivative of the nisin A producer *L. lactis* NZ9700 with a 4 bp deletion in the *nisA* structural gene. Nisin production by this strain is restored through complementation of NZ9800 with a functioning *nisA* gene, or derivative, on the plasmid pCI372 (pDF05) (Field *et al.*, 2008). In total, 15 derivatives were tested and ranked according to the levels of bioactivity displayed against *S. agalactiae* ATCC13813. Six derivatives were brought forward for further study in the form of miniature milk trials. Finally, to facilitate the growth of the various producers in a dairy-based substrate to facilitate



peptide generation, a variety of strains were created that possessed both the ability to produce nisin derivatives and to utilise lactose and degrade casein, as a consequence of containing the plasmid pLP712 (Lac<sup>+</sup> Pro<sup>+</sup>) (Gasson, 1983).

## **5.3 Materials and Methods**

### **5.3.1 Bacterial strains and growth conditions**

The strains used in this study are listed in Table 5.1. *L. lactis* NZ9800 was grown in M17 agar and broth (Oxoid) supplemented with 0.5% glucose. *L. lactis* MG1614 pLP712 was grown in M17 agar and broth supplemented with 0.5% lactose. Both cultures were grown at 30°C for 18 hrs. *S. agalactiae* ATCC13813 was grown on Tryptic Soy Broth (TSB) (Merck) supplemented with 0.6% (w/v) Yeast Extract (Merck) and incubated at 37°C for 18hrs. Where required, chloramphenicol (Sigma-Aldrich) was added at 10 µg/ml and rifampicin (Sigma-Aldrich) was added at 50 µg/ml.

### **5.3.2 Rifampicin tagging of *S. agalactiae* ATCC13813**

*S. agalactiae* ATCC 13813 was grown overnight at 37°C in a 10 ml volume with constant shaking. The culture was centrifuged at 7000 rpm for 10 min. The supernatant was decanted with the remaining pellet resuspended in 1 ml of Phosphate Buffered Saline (PBS). A 100 µl volume was spread plate onto TSB-YE agar containing rifampicin (Sigma) concentrations ranging from 10 µg/ml to 200 µg/ml and incubated overnight at 37°C. Colonies were present at a highest concentration of 100 µg/ml and subsequently restreaked onto TSB-YE agar Rif 100 µg/ml. An isolated colony was passaged 10 times in TSB-YE broth without rifampicin and plated on TSB-YE Rif 100 µg/ml to determine that the tagging was stable. Subsequent selection was made on TSB-YE Rif 50 µg/ml.

### 5.3.3 Bioactivity Assays

Cultures of nisin A wild-type and the derivatives were grown overnight, with a 1% subculture for 8 hours followed by a second 1% subculture for 16 hr. At each step 10 ng/ml of nisin A was added to the 10 ml GM17 broth. 3 µl of each culture was 'spotted' onto GM17 agar, allowed to dry and incubated for 16 hr at 30°C. The remaining sample was centrifuged at 5000 rpm for 10 min, the supernatant carefully removed and heated to 80°C for 10 min and stored at -20°C until required. The spotted plates were UV treated for 20 min in order to kill the producer and overlaid with *S. agalactiae* ATCC 13813 Rif<sup>R</sup> (0.5% v/v) in TSB-YE 0.75% agar and incubated at 37°C for 16 hr. Well diffusion assays were carried out in TSB-YE 1% agar. 70 ml volumes of this agar were inoculated with 0.5% (v/v) of an overnight culture of *S. agalactiae* ATCC 13813 Rif<sup>R</sup>. Wells were bored using an inverted glass Pasteur pipette and 70 µl of the cell-free supernatant (CFS) from above added. Before incubation (37°C for 16 hr) the plates were refrigerated for three hours so as to allow diffusion of the peptides before commencement of indicator growth.

### 5.3.4 Determination of Antimicrobial Activity in Milk

In order to measure the level of antagonism of the CFS from nisin A wild-type and the derivatives in an applied setting, a miniature milk trail was completed in triplicate. 1.4 mls of commercially available milk (Avonmore) was inoculated with *S. agalactiae* ATCC 13813 Rif<sup>R</sup> at 10<sup>6</sup> cfu/ml in 24-well tissue culture flasks (Sarstedt). 0.6 mls of CFS was added from each of the nisin derivatives brought forward and the plates incubated at 37°C for 24 hrs. Counts were taken at T0 and T24.

### 5.3.5 Creation of *L. lactis* NZ9800 pLP712

*L. lactis* MG1614 pLP712 (donor) was grown to a final volume of 30 mls in LM17 broth and *L. lactis* NZ9800 pDF05 (recipient) was grown to a final volume of 10 mls in GM17 broth with 10 µg/ml chloramphenicol. Both strains were washed in fresh media without antibiotic. 10 mls of the recipient was passed through a 0.45 µM filter followed by 500 µl of 800 µg/ml chymotrypsin and left for 5 minutes in order to hydrolyse any residual nisin. 30 mls of the donor was next passed through the same filter until dry. The filter was next removed and placed top-side down onto GM17 agar without chloramphenicol and incubated for 24 hrs at 30°C. The filter and the agar underneath was removed, sliced and placed in 10 mls of ¼ strength ringer solution and vortexed for 5 mins or until the turbidity of the ringer solution increased. 10 µl of this solution was streaked onto lactose indicator agar (LIA) Cm<sup>10</sup>. Desired transconjugates (*L. lactis* NZ9800 pDF05 pLP712) were selected due to their ability to ferment lactose, and therefore appear as yellow, and grow in the presence of chloramphenicol. pDF05 was cured from the strain through continual passaging of the strain in LM17 broth without chloramphenicol until sensitivity to the antibiotic was apparent.

## 5.4 Results

15 previously generated nisin derivatives were selected to compare their activity against *S. agalactiae*. The rationale used to select these nisin derivatives was as follows. Firstly, derivatives were chosen which had been reported to have particularly enhanced features during the course of previous studies. These were N20P, M21V, K22T and K22S (Field *et al.*, 2008), SVA (Rouse *et al.*, 2012), S29A (Field *et al.*, 2012), K12A (Molloy *et al.*, 2013), hinge ‘SAA’ and hinge ‘AAA’ (hereafter SAA and AAA) (Healy *et al.*, 2013). Secondly, a number of additional derivatives that have not been investigated to the same degree, but which possess potential anti-*S. agalactiae* bioactivity were also included. These were peptides in which the hinge regions had been altered to SLS, AAK, SMT, NAI or QVQ (Healy *et al.*, 2013). Finally, a derivative containing a NAT hinge was included it has emerged as a peptide of interest during various screening studies (unpublished). For this study, enhanced bioactivity is used to describe a change that results in greater inhibition regardless of whether this is due to increased specific activity, enhanced production levels and/ or other physico-chemical properties (such as enhanced diffusion). In order to determine the most promising candidates from this pool as potential bioprotectants, the deferred antagonism assay and well diffusion assays were employed as a measure of bioactivity against *S. agalactiae* ATCC 13813 Rif<sup>R</sup>. As the focus of this study was the identification of strains that most effectively control the pathogen, and not the characterisation of their conferred benefit, general bioactivity was used as a measure of potential. All peptides were produced by derivatives of *L. lactis* NZ9800.

The results from well diffusions assays (Table 5.2) showed that cell free supernatant (CFS) containing nisin A, AAA, K22T, K22S, SAA and K12A most

effectively inhibited the pathogen. However, of these, CFS containing AAA, K22T, K22S, and SAA produced zones that did not differ significantly from that of the control while K12A produced a significantly smaller zone. The results from the deferred antagonism assay (Table 5.3) clearly demonstrate the enhanced bioactivity of the majority of derivatives relative to the control, nisin A-producing strain. The five strains with greatest bioactivity (all p-values <0.05) were those producing the AAA, NAT, SAA, K22S and K22T derivatives. When the area of inhibition is expressed as a percentage of that generated by the control, AAA shows the greatest enhancement (70.54% increase) followed by NAT (51.94% increase), SAA (51.63% increase), K22S (49.68% increase) and K22T (46.60% increase). Another five strains showed relative increases ranging from 42.05% (QVQ) down to 27.09% (SMT). Only N20P displayed a zone significantly lower than that generated by the control. Ultimately, 6 derivatives were brought forward to the miniature milk assay (Table 5.4); AAA, SAA, NAT, K22T, K22S and K12A.

Miniature milk trials were performed to ensure that the derivatives retain activity in a dairy setting and used commercially available, pasteurized and homogenised full fat milk. *S. agalactiae* ATCC 13813 Rif<sup>R</sup> was inoculated at 5.1 X 10<sup>6</sup> cfu/ml of milk. 600 µl of nisin-containing CFS was added to 1400 µl of milk and incubated at 37°C for 24 hrs. The procedure was carried out in triplicate with plate counts carried out at T0 and T24. Milk to which neither the pathogen nor CFS was added was used as a negative control and milk inoculated with *S. agalactiae* ATCC 13813 Rif<sup>R</sup> was used as a positive control. CFS from the non-nisin producer NZ9800 was also used as a control and was found to have no significant impact on the growth of *S. agalactiae*. The results of this trial were expressed in terms of log reduction of growth relative to that observed in the presence of CFS from NZ9800 after T24

(Table 5.4) The CFS from the AAA derivative producer brought about a log reduction of 2.30 (p-value 0.032), the largest reduction of any of the samples tested, being twice as effective as wild-type CFS (1.15 log reduction). K22T also brought about a greater than 2 log reduction (2.10,  $p = 0.036$ ). SAA, WT and K12A all displayed a greater than 1 log reduction while K22S and NAT proved to be the least effective of those tested, failing to give a greater than 1 log reduction. Following on from these results, it was clear that AAA and K22T showed the greatest potential as biologically produced inhibitors of *S. agalactiae* in a milk environment.

The creation of forms of these nisin derivative-producing starter cultures that could grow in dairy substrates was the final aim of this study. This was achieved through the conjugation of the plasmid pLP712 from *L. lactis* MG1614 to *L. lactis* NZ9800 through a filter-mating procedure in order to provide the latter strain with the genes necessary for lactose catabolism and casein proteolysis. The transconjugant generated, *L. lactis* NZ9800 pLP712, was grown in 10% total solids Reconstituted Skimmed Milk (RSM) to demonstrate its ability to ferment lactose at 30°C for 16 hrs with subsequent clotting of the milk. Lantibiotic production was reintroduced by transformation of the *nisA* structural gene or a bioengineered equivalent on pCI372 into the transconjugant. The production of the nisin derivatives AAA, K22T and SAA by such strains was demonstrated by the deferred antagonism assay with the producer ‘spotted’ onto both GM17 and LM17 agar with *S. agalactiae* as the indicator. MALDI TOF mass spectrometric analysis was used to confirm the production of the relevant peptides (data not shown). These strains can be grown on cheap lactose-containing substrates to facilitate large scale peptide generation.

## 5.5 Discussion

LAB-associated bacteriocins, and in particular lantibiotics, are an attractive option for the control of pathogenic and spoilage organisms in the food industry. This is due in part to the long and safe history of nisin use by the food industry (Cotter *et al.*, 2005) and the variety of ways in which bacteriocins can be incorporated into foods. Indeed, bacteriocins can be introduced through direct addition as a preservative, as an ingredient in the form of a dried fermentate or through *in situ* production. In the case of nisin, all three methods of delivery have been exploited in commercial products (Healy *et al.*, 2010, Elsser-Gravesen and Elsser-Gravesen, 2013). For this study, the anti-*S. agalactiae* bioactivity of a number of nisin derivatives was assessed and a system developed that could potentially be employed to facilitate their production on cheap lactose-based substrates.

Lantibiotics, including nisin and lacticin 3147, have been shown to be very effective against a number of mastitis associated pathogens (Ryan *et al.*, 1998, Field *et al.*, 2008) *in vitro*. This activity has also translated well to a number of potential therapeutic applications to treat mastitis infections as either purified forms or through the introduction of the live culture. For example, lacticin 3147 has proved effective in treating *S. dysgalactiae* and *Staph. aureus* when introduced by means of an intramammary teat seal formulation (Ryan *et al.*, 1999, Twomey *et al.*, 2000, Crispie *et al.*, 2008) and against the pathogens and *Streptococcus uberis* when employed in the form of a teat dip (Klostermann *et al.*, 2010). Intramammary infusions (IMI's) of nisin have also displayed a therapeutic effect in the treatment of both subclinical and clinical mastitis (Cao *et al.*, 2007, Wu *et al.*, 2007). The use of lantibiotics as an alternative to antibiotics in the treatment of mastitis also could also



address issues and concerns regarding the emergence of multidrug resistant human pathogens due to exposure to antibiotic residues in milk (Cao *et al.*, 2007). It is therefore not surprising that nisin has been commercialised as a teat wipe, Wipe Out®, and as the active ingredient in an IMI product, Mast Out® (both produced by ImmuCell).

The results of this study demonstrate that the nisin ‘hinge’ derivative, AAA, is a leading candidate that merits further investigations as either a bio-preservative or as an alternative to antibiotics in prophylactic anti-*S. agalactiae* mastitis treatments. In all three assays employed here, this derivative, in which the all three of the naturally occurring amino acid residues within the ‘hinge’ were replaced with alanines, displayed activity at levels greater or similar to that of the parental producer. Of the other derivatives, the activities of both K22T and SAA with respect to pathogen inhibition in milk were also impressive. As discussed previously (Field *et al.*, 2008, Healy *et al.*, 2013), the hinge region of nisin has proved to be extremely important in respect to the creation of enhanced derivatives with its flexibility in terms of both the residues tolerated within and in terms of overall mode of action of the peptide. This was again apparent in this study.

It was noticeable that the relative ability of the derivatives to control the pathogen varied depending on the approach used. Of the fifteen strains tested, thirteen displayed a zone of inhibition larger than the wild-type when ‘spotted’ while only CFS containing nisin AAA produced a zone larger (albeit non-significantly) than wild-type *via* the well diffusion approach. This suggests that production of the candidate derivatives by Lac<sup>+</sup> Prt<sup>+</sup> lactococci *in situ* in the teat canal in order to control *S. agalactiae* merits consideration. Having Lac<sup>+</sup> Prt<sup>+</sup> producers of these derivatives also provides the opportunity to use cheap protein-rich substrates for

large scale peptide production. One means of generating such a strain would be through a homologous recombination event in an already available nisin wild-type producing culture in order to ‘swap’ the *nisA* structural gene with that of the derivative of interest. This technique can be time consuming and relatively difficult to achieve and so, before initiating such a strategy, we first used an alternate strategy by creating a transconjugant of the *L. lactis* strain NZ9800 containing a plasmid which confers onto the host the genes necessary for lactose catabolism and proteolysis (pLP712). Although lacking the rapid acidification rates of the more established starter cultures, this strain does provide a simpler and quicker means to assess the bioactivity and peptide producing capacity of nisin derivative producers on milk-based substrates. This system provides a means whereby not only the derivatives assessed here but any potential designer lantibiotics could be assessed in a more time efficient manner through the production of fermentates/ dairy products using relatively inexpensive whey-based substrates to produce large quantities of powders. The producers of greatest value could then be created in a non-GM manner through a homologous recombination-based approach and, potentially, also introduced into the lactose rich environment of the mammary gland as an IMI.

The treatment of mastitis through the use of nisin derivatives is potentially very worthwhile due to the activity of many of these antimicrobial peptides against many of the Gram-positive causative agents (Field *et al.*, 2010). In this study, three derivatives of nisin were identified (AAA, K22T and SAA) which showed enhanced activity when compared to nisin in a CFS form against *S. agalactiae* in a miniature milk trail. As all three have also demonstrated enhanced activity against *Staph. aureus* previously (Field *et al.*, 2010, Healy *et al.*, 2013), their inclusion for any potential trials to assess the therapeutic effectiveness of nisin derivatives as an

alternative to antibiotics would be merited. Further investigations into the addition of these derivatives as bio-preservatives in dairy preparations either as an additive or by production as a starter may also prove beneficial.

## **5.6 Acknowledgements**

This work was financed by a grant from the Irish Department of Agriculture, Food and the Marine through the Food Institutional Research Measure (08/RD/C/691) and with Science Foundation Ireland Investigator award (10/IN.1/B3027).

## 5.7 Bibliography

- Barkema H, Schukken Y, Lam T, Beiboer M, Wilmink H, Benedictus G & Brand A (1998) Incidence of clinical mastitis in dairy herds grouped in three categories by bulk milk somatic cell counts. *J Dairy Sci* **81**: 411-419.
- Barkema HW, Green MJ, Bradley AJ & Zadoks RN (2009) Invited review: The role of contagious disease in udder health. *J Dairy Sci* **92**: 4717-4729.
- Cao L, Wu J, Xie F, Hu S & Mo Y (2007) Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. *J Dairy Sci* **90**: 3980-3985.
- Cotter PD, Hill C & Ross RP (2005) Bacteriocins: developing innate immunity for food. *Nature Reviews Microbiology* **3**: 777-788.
- Crispie F, Flynn J, Ross RP, Hill C & Meaney WJ (2004) Update on the development of a novel dry cow therapy using a bismuth-based intramammary teat seal in combination with the bacteriocin lactacin 3147. *Irish Vet J* **57**: 652.
- Crispie F, Alonso-Gomez M, O'Loughlin C, Klostermann K, Flynn J, Arkins S, Meaney W, Paul Ross R & Hill C (2008) Intramammary infusion of a live culture for treatment of bovine mastitis: effect of live lactococci on the mammary immune response. *J Dairy Res* **75**: 374-384.
- Deegan LH, Cotter PD, Hill C & Ross P (2006) Bacteriocins: biological tools for bio-preservation and shelf-life extension. *International Dairy Journal* **16**: 1058-1071.
- Elsser-Gravesen D & Elsser-Gravesen A (2013) Biopreservatives. 1-20.
- Field D, Connor PM, Cotter PD, Hill C & Ross RP (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. *Molecular Microbiology* **69**: 218-230.
- Field D, Quigley L, O'Connor PM, Rea MC, Daly K, Cotter PD, Hill C & Ross RP (2010) Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. *Microbial Biotechnology* **3**: 473-486.
- Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C & Ross RP (2012) Bioengineered nisin A derivatives with enhanced activity against both Gram-positive and Gram-negative pathogens. *PloS One* **7**: e46884.
- Gasson MJ (1983) Plasmid Complements of *Streptococcus-Lactis* Ncdo-712 and Other Lactic Streptococci after Protoplast-Induced Curing. *J Bacteriol* **154**: 1-9.
- Geary U, Lopez-Villalobos N, O'Brien B, Garrick DJ & Shalloo L (2013) Examining the impact of mastitis on the profitability of the Irish dairy industry. *Irish J Agr Food Res* **52**: 135-149.

Geary U, Lopez-Villalobos N, O'Brien B, Garrick DJ & Shalloo L (2014) Estimating the impact of somatic cell count on the value of milk utilising parameters obtained from the published literature. *J Dairy Res* **81**: 223-232.

Healy B, O'Mahony J, Hill C, Cotter P & Ross R (2010) Lantibiotic-related research and the application thereof. *Antimicrobial peptides: discovery, design and novel therapeutic strategies* **18**: 22-39.

Healy B, Field D, O'Connor PM, Hill C, Cotter PD & Ross RP (2013) Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives. *PloS One* **8**: e79563.

Keane OM, Budd KE, Flynn J & McCoy F (2013) Pathogen profile of clinical mastitis in Irish milk-recording herds reveals a complex aetiology. *Vet Rec* **173**: 17-17.

Klostermann K, Crispie F, Flynn J, Meaney WJ, Paul Ross R & Hill C (2010) Efficacy of a teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-positive pathogens associated with bovine mastitis. *J Dairy Res* **77**: 231-238.

Kuipers OP, Beerthuyzen MM, Siezen RJ & De Vos WM (1993) Characterization of the nisin gene cluster nisABTCIPR of *Lactococcus lactis*. Requirement of expression of the nisA and nisI genes for development of immunity. *European Journal of Biochemistry / FEBS* **216**: 281-291.

Molloy E, Ross RP & Hill C (2012) 'Bac'to the future: bioengineering lantibiotics for designer purposes. *Biochemical Society Transactions* **40**: 1492-1497.

Molloy EM, Field D, Cotter PD, Hill C & Ross RP (2013) Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity. *PloS One* **8**: e58530.

More SJ (2009) Global trends in milk quality: implications for the Irish dairy industry. *Irish Vet J* **62**: 5-14.

O'Sullivan D, Coffey A, Fitzgerald GF, Hill C & Ross RP (1998) Design of a phage-insensitive lactococcal dairy starter *via* sequential transfer of naturally occurring conjugative plasmids. *Applied and Environmental Microbiology* **64**: 4618-4622.

Piper C, Cotter PD, Ross RP & Hill C (2009) Discovery of medically significant lantibiotics. *Current Drug Discovery Technologies* **6**: 1-18.

Rajala-Schultz P, Smith K, Hogan J & Love B (2004) Antimicrobial susceptibility of mastitis pathogens from first lactation and older cows. *Veterinary Microbiology* **102**: 33-42.

Rouse S, Field D, Daly KM, O'Connor PM, Cotter PD, Hill C & Ross RP (2012) Bioengineered nisin derivatives with enhanced activity in complex matrices. *Microbial Biotechnology* **5**: 501-508.

Ryan M, Flynn J, Hill C, Ross R & Meaney W (1999) The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental

challenge with *Streptococcus dysgalactiae* in nonlactating dairy cows. *J Dairy Sci* **82**: 2625.

Ryan MP, Meaney WJ, Ross RP & Hill C (1998) Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. *Applied and Environmental Microbiology* **64**: 2287-2290.

Teagasc (2012) National Farm Survey Results. 2011 Dairy Enterprise. Available online:<http://www.teagasc.ie/publications/2012/1398/DairyFactsheet2011-TeagascNFS.pdf>.

Twomey DP, Wheelock AI, Flynn J, Meaney WJ, Hill C & Ross RP (2000) Protection against *Staphylococcus aureus* mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147. *J Dairy Sci* **83**: 1981-1988.

Wu JQ, Hu SH & Cao LT (2007) Therapeutic effect of nisin Z on subclinical mastitis in lactating cows. *Antimicrob Agents Ch* **51**: 3131-3135.

## 5.8 Tables and Figures

**Table 5.1** Strains used in this study

| Strains  | Characteristic  | Reference/Source                |
|--|---|---------------------------------|
| <i>L. lactis</i> NZ9800                          | <i>L. lactis</i> NZ9700 $\Delta$ <i>nisa</i>                  | Kuipers <i>et al.</i> (1993)    |
| <i>L. lactis</i> NZ9800 pDF05                    | Wild-type nisin A producer                                    | Field <i>et al.</i> (2008)      |
| <i>S. agalactiae</i> ATCC 13813 Rif <sup>R</sup> | Rifampicin tagged indicator strain                            | This study                      |
| <i>L. lactis</i> MG1614 pLP712                   | Lactococcal donor of Lac <sup>+</sup> Pro <sup>+</sup> pLP712 | O'Sullivan <i>et al.</i> (1998) |
| <i>L. lactis</i> NZ9800 pLP712                   | Lac <sup>+</sup> Pro <sup>+</sup> <i>L. lactis</i> NZ9800     | This study                      |



**Table 5.2** Well Diffusion Assay using Cell Free Supernatant

| Indicator  | Producer | Well Diffusion                  |               |         |           |
|--|----------|---------------------------------|---------------|---------|-----------|
|  |          | Average Area<br>mm <sup>2</sup> | As % of<br>WT | p-value | Std. Dev. |
| <i>S. agalactiae</i><br>ATCC 13813<br>Rif <sup>R</sup> | WT       | 209.49                          |               |         | 9.02      |
|  | AAA      | 225.17                          | 107.49        | 0.13    | 10.71     |
|  | K22T     | 206.89                          | 98.76         | 0.69    | 5.29      |
|  | K22S     | 204.35                          | 97.55         | 0.46    | 5.87      |
|  | SAA      | 204.35                          | 97.55         | 0.46    | 5.87      |
|  | K12A     | 190.27                          | 90.83         | 0.05    | 7.49      |
|  | M21V     | 184.74                          | 88.19         | 0.07    | 14.05     |
|  | NAT      | 178.24                          | 85.09         | 0.01    | 6.87      |
|  | S29A     | 168.25                          | 80.32         | 0.01    | 12.52     |
|  | NAI      | 165.94                          | 79.21         | 0.01    | 11.45     |
|  | AAK      | 156.08                          | 74.51         | 0.00    | 3.85      |
|  | SVA      | 148.09                          | 70.69         | 0.00    | 5.44      |
|  | SMT      | 147.38                          | 70.36         | 0.00    | 6.45      |
|  | QVQ      | 145.34                          | 69.38         | 0.00    | 11.19     |
|  | SLS      | 128.61                          | 61.40         | 0.00    | 0.00      |
|  | N20P     | 109.37                          | 52.21         | 0.00    | 6.64      |
| NZ9800   | 20.69    | 9.88                            | 0.00          | 0.47    |           |

The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 'well' in mm<sup>2</sup>

**Table 5.3** Deferred Antagonism Results

| Indicator  | Producer | Deferred Antagonism             |               |         | Std. Dev. |
|--|----------|---------------------------------|---------------|---------|-----------|
|  |          | Average Area<br>mm <sup>2</sup> | As % of<br>WT | p-value |           |
| <i>S. agalactiae</i><br>ATCC 13813<br>Rif <sup>R</sup> | WT       | 279.95                          |               |         | 10.48     |
|  | AAA      | 477.44                          | 170.54        | 0.00    | 14.23     |
|  | NAT      | 425.37                          | 151.94        | 0.00    | 7.06      |
|  | SAA      | 424.50                          | 151.63        | 0.00    | 11.88     |
|  | K22S     | 418.81                          | 149.60        | 0.00    | 21.27     |
|  | K22T     | 410.40                          | 146.60        | 0.00    | 16.47     |
|  | QVQ      | 397.67                          | 142.05        | 0.01    | 24.86     |
|  | K12A     | 390.92                          | 139.64        | 0.02    | 31.69     |
|  | SVA      | 381.53                          | 136.29        | 0.01    | 22.41     |
|  | NAI      | 356.6                           | 127.38        | 0.07    | 39.91     |
|  | SMT      | 355.78                          | 127.09        | 0.00    | 13.12     |
|  | M21V     | 342.11                          | 122.20        | 0.07    | 32.01     |
|  | S29A     | 325.58                          | 116.30        | 0.03    | 18.18     |
|  | SLS      | 288.61                          | 103.09        | 0.61    | 24.21     |
|  | AAK      | 272.00                          | 97.16         | 0.48    | 14.04     |
|  | N20P     | 202.57                          | 72.36         | 0.02    | 23.00     |
| NZ9800   | 0.00     | 0.00                            | 0.00          | 0.00    |           |


The zone of inhibition is expressed as the area of the zone of inhibition minus the area of the 'colony' in mm<sup>2</sup>

**Table 5.4** Miniature Milk Trial using Cell Free Supernatant

| Indicator            | Producer         | Mean Log cfu/ml ± SEM at T24 | p-Value relative to NZ9800 | Log reduction relative to NZ9800 |
|----------------------|------------------|------------------------------|----------------------------|----------------------------------|
|                      | NZ9800 (Control) | 9.44 ± 0.05                  |                            |                                  |
|                      | <b>AAA</b>       | <b>7.14 ± 0.43</b>           | <b>0.032</b>               | <b>-2.30</b>                     |
|                      | <b>K22T</b>      | <b>7.33 ± 0.42</b>           | <b>0.036</b>               | <b>-2.10</b>                     |
| <i>S. agalactiae</i> | <b>SAA</b>       | <b>7.77 ± 0.43</b>           | <b>0.061</b>               | <b>-1.66</b>                     |
| ATCC 13813           | WT               | 8.18 ± 0.36                  | 0.069                      | -1.25                            |
| Rif <sup>R</sup>     | K12A             | 8.29 ± 0.33                  | 0.072                      | -1.15                            |
|                      | K22S             | 8.48 ± 0.21                  | 0.041                      | -0.96                            |
|                      | NAT              | 8.58 ± 0.25                  | 0.069                      | -0.85                            |
|                      | Positive         | 9.26 ± 0.03                  | 0.073                      |                                  |
|                      | Negative         | ≤ 0.15 ± 0.00                |                            |                                  |

T0 count 6.70 ± 0.02. SEM: Standard error of the mean. Those giving a log reduction greater than wild-type are emboldened.

**Figure 5. 1** Nisin A amino acid structure



Dha – Dehydroalanine; Dhb – Dehydrobutyrine. Areas in red denote locations of derivatives described in this study.

## Summary

Lantibiotics are ribosomally produced antimicrobial peptides (Sahl *et al.*, 1995). The mature lantibiotic peptide structure is the result of a number of post-translational modifications. The unmodified and inactive prepeptide is first exposed to the actions of a dehydratase enzyme (generally referred to as LanB) which leads to the formation of 2,3-dehydroalanine and 2,3-dehydrobutyrine from specific serine and threonine amino acid residues, respectively. A number of these residues are subsequently coupled with the thiol groups of neighbouring cysteine residues resulting in the formation of the eponymous (methyl)lanthionine bridges. The peptide is transported to the cell surface through the action of an ABC transport system where it becomes active following cleavage of its leader sequence.

This thesis focuses on two of the most widely studied members of this class of bacteriocins, the single component peptide nisin A and the two peptide lactacin 3147. The mode of action of both is similar in that it involves binding to the essential cell wall precursor, lipid II, followed by pore formation. Nisin A acts through the combined action of its N and C-termini through an intra-molecular conformational change facilitated by the flexible three amino acid 'hinge' region (Breukink *et al.*, 1997, Wiedemann *et al.*, 2001). For lactacin 3147, a synergistic interaction between both peptide components is facilitated through the formation of a complex between the  $\alpha$  peptide and lipid II, which then recruits the  $\beta$  peptide and leads to rapid cell death (McAuliffe *et al.*, 1998, Wiedemann *et al.*, 2006).

In Chapter 1, the lantibiotic-associated post-translational modifications are reviewed in greater detail, while an overview of the various lantibiotic classification systems is provided. This review also summarises that which is known about the

structure and mode of action of the lantibiotic subgroups, the ways in which these peptides are used in the food industry, the current and potential lantibiotic uses in medical applications or as veterinary therapeutics and the bioinformatics-based screening techniques that are emerging as alternative approaches to discovering novel lantibiotics.

In Chapter 2, we investigated the *in situ* production of lacticin 3147 by the starter culture *Lactococcus lactis* DPC3147 during the manufacture of a smear-ripening raw milk cheese with a view to controlling the growth of *Mycobacterium avium* subsp. *paratuberculosis* (*MAP*). *MAP*, an extremely fastidious bacterium, is the causative agent of Johne's disease (Cocito *et al.*, 1994), a chronic enteritis of the small intestine primarily affecting ruminants and a disease of economic importance to dairy industries. Similarities in disease pathologies have led to suggestions of a link between *MAP* and Crohn's disease, although the existence of such a relationship is not clear. Due to the robust nature of the microorganism in terms of its innate resistance to various physical treatments, such as pasteurization and disinfectant agents such as chlorine, contaminated milk from Johne's diseased dairy cattle could possibly offer a route of entry into the human food chain (Rowe & Grant, 2006). In a previous study (Carroll *et al.*, 2010), lacticin 3147 was shown to display *in vitro* activity against *MAP* (MIC<sub>90</sub>, 15 mg/l) while nisin was at least four times less effective (MIC<sub>90</sub>, >60 mg/l). While our study demonstrated a limited reduction in *MAP* numbers, as determined by culture based analysis, at the end of the ripening period, this was attributed to the cheese making process rather than the presence of lacticin 3147. A real-time PCR strategy was implemented which provided results that were consistent with those provided by plate counts. This rapid alternative to detecting/ quantifying *MAP* is noteworthy as the incubation time required for the

visualization of *MAP* on synthetic media is normally six weeks and was further complicated by the levels of background flora associated with this type of cheese.

In Chapter 3, the gene encoded nature of lantibiotics was exploited with a view to the creation of derivatives with enhanced (bio)activity. The focus here switched to nisin A and in particular the three amino acid ‘hinge’ region consisting of asparagine, methionine and lysine residues at positions 20, 21 and 22. This region allows for the conformational realignment of the peptide once a complex is formed with lipid II, facilitating the permeabilization of the cell membrane by the C-terminus. Studies by Field *et al.* (2008) had demonstrated that the substitution of the lysine at position 22 for a threonine (K22T) residue displayed enhanced activity against *Streptococcus agalactiae*. Further investigations revealed the relative tolerance of this region to change and lead to the creation of three further enhanced nisin derivatives; N20P, M21V and K22S. We undertook a complete randomisation of the hinge region whereby a derivative bank was produced using indiscriminate site saturation through the use of degenerate primers. A bank of 12,000 putative producers was screened against a fast growing mycobacteria species, *Mycobacterium smegmatis*, as well as clinical pathogens (*Staphylococcus aureus* and *S. agalactiae*) and a nisin sensitive indicator (*L. lactis* HP). From this bank, a total 23 enhanced derivatives were identified. The frequency at which alanine was present at each position prompted the creation of a nisin derivative whereby the ‘hinge’ consisted of three alanines. Characterisation of this derivative revealed that this change enhanced the bioactivity of the producing strain while the specific activity of the purified form was twice as potent as nisin A against *S. agalactiae*. An additional derivative was created based on the observation that a number of the aforementioned derivatives possessed a serine at position 20. This derivative, SAA, also displayed enhanced

bioactivity against all indicators. This study once again established the ‘hinge’ as a productive target for bioengineering and specifically illustrated the benefits of incorporating small chiral amino acids into this site. This approach led to the creation of two enhanced nisin A derivatives through a rational approach for the first time.

Improvements in terms of the functionality of the nisin A peptide were demonstrated in Chapter 4. A major hurdle in the utility of nisin in a clinical setting is due to its sensitivity to proteolytic degradation during transit through the gastrointestinal tract. One such protease is trypsin, which normally cleaves after lysine and arginine residues. However, it was recently found that the asparagine amino acid residue at position 20 is also subject to the endopeptidase activity of this enzyme (Slootweg *et al.*, 2013). While the lanthionine bridges confer the mature peptide with a natural partial trypsin resistance, unmodified lysines at positions 12 and 22 and the asparagine at position 20 are still vulnerable. As the ‘hinge’ region of the AAA derivative from Chapter 3 no longer contains these residues, position 12 (previously shown to be receptive to change (Molloy *et al.*, 2013)), is the only remaining trypsin sensitive region in nisin AAA. Through the implementation of site saturation mutagenesis, a mutant was identified which displayed enhanced bioactivity compared with the wild-type nisin producer, while also gaining resistance to trypsin digestion (as confirmed through RP-HPLC and mass spectrometric analysis). During the screening aspect of this study a number of putative chymotrypsin derivatives were also uncovered which will merit more in-depth characterisation in the future.

Chapter 5 of this thesis highlights the potential of a number of nisin A derivatives against the mastitis associated pathogen *S. agalactiae*. Lantibiotics may provide an alternative means of controlling this bacterium as it is extremely sensitive to nisin. Notably, as a result of the evolution of nisin bioengineering strategies, a



large bank of anti-*S. agalactiae* derivatives has been generated. In this study, 15 of these derivatives were assessed in order to identify those which most effectively inhibit the pathogen in a milk matrix. Again, nisin AAA, along with K22T and SAA, emerged from this study as lead candidates. A system was also developed to facilitate large-scale peptide production of these peptides in dairy substrates with a view to the manufacture of mastitis therapeutics as either fermentates or powdered ingredients.

In conclusion, lantibiotics are attractive alternatives to antibiotics for a number of reasons. This includes their potency against clinically relevant pathogens and their amenability to bioengineering. In this thesis a number of lantibiotic derivatives of interest were discovered. These add to our understanding of fundamental lantibiotic biology and strengthen the case for a greater role for these antimicrobial peptides in a clinical and food setting.

## Bibliography

- Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP & de Kruijff B (1997) The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. *Biochemistry* **36**: 6968-6976.
- Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD & O'Mahony J (2010) Comparison of the activities of the lantibiotics nisin and lactacin 3147 against clinically significant mycobacteria. *International Journal of Antimicrobial Agents* **36**: 132-136.
- Cocito C, Gilot P, Coene M, de Kesel M, Poupart P & Vannuffel P (1994) Paratuberculosis. *Clinical Microbiology Reviews* **7**: 328-345.
- Field D, Connor PM, Cotter PD, Hill C & Ross RP (2008) The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. *Molecular Microbiology* **69**: 218-230.
- McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P & Abee T (1998) Lactacin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. *Applied and Environmental Microbiology* **64**: 439-445.
- Molloy EM, Field D, Cotter PD, Hill C & Ross RP (2013) Saturation mutagenesis of lysine 12 leads to the identification of derivatives of nisin A with enhanced antimicrobial activity. *PloS One* **8**: e58530.
- Rowe M & Grant I (2006) *Mycobacterium avium* ssp. *paratuberculosis* and its potential survival tactics. *Letters in Applied Microbiology* **42**: 305-311.
- Sahl HG, Jack RW & Bierbaum G (1995) Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. *European Journal of Biochemistry* **230**: 827-853.
- Slootweg JC, Liskamp RM & Rijkers DT (2013) Scalable purification of the lantibiotic nisin and isolation of chemical/enzymatic cleavage fragments suitable for semi-synthesis. *Journal of Peptide Science* **19**: 692-699.
- Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B & Sahl H-G (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *Journal of Biological Chemistry* **276**: 1772-1779.
- Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutschmann T, Seydel U, Deegan L, Hill C & Ross P (2006) The mode of action of the lantibiotic lactacin 3147—a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. *Molecular Microbiology* **61**: 285-296.

## Acknowledgments

When you spend just less than six years completing your Ph.D studies you meet a lot of people. In this section, I will try to remember everyone who has encouraged, guided, motivated, and helped me throughout but I know there will be people I forget. For this reason I will start with saying thank you to everyone who I met along the way.

However there are people who I would like to thank specifically. To my three supervisors, Professor Colin Hill, Dr. Paul Cotter and Professor Paul Ross, thank you all for permitting me to undertake my studies under your guidance. It is genuinely an honour to have gained my Ph.D from your research groups. Thanks for your patience and advice.

Thank you to my family who must have wondered what I was thinking leaving the job I had at twenty nine years old to go back to college. I'm still not too sure how I ever made the decision to go back. You were always very supportive of every decision I have ever made. This thesis is also for you. You can now get a new dress for the graduation Mam. Also thank you Selena, it was about time I got the Ph.D finished☺.

I must also thank my lab-group 335-337. The five years I spent with you all was an "emotional roller-coaster". I still laugh at our rendition of Sonny and smile when I hear Belinda Carlisle on the radio. There is truly no other lab like you. In particular I need to thank Lorraine, Karen, Alicia, Des and Harsh. I really enjoyed my time there and will always consider myself from 335-337. You have all helped me more than you could know.

I also need to thank Jennifer Mahony for all her advice and her proactive approach in both scientific matters and well beyond. To Eamonn, we are finally both doctors, ‘gasp’, who would have thought. Back then it looked like we’d be lucky if they let us keep our degrees never mind actually giving us Ph.Ds.

To everyone in the School of Microbiology – thank you so much!!

I also need to acknowledge everyone I have worked with in Teagasc, Moorepark. I especially need to thank Mary Rea for her continued advice and guidance. I would also like to say thank you to all the members of APC1 and APC2, Caitriona in Vision 1, Rob K, and Carmel in Vision 2. Also I’d like to thank Beatriz for taking the time to read my thesis just before my viva.

Finally I would like to thank the Department of Agriculture, Food and Marine for their funding of this project.

“Research is what I'm doing when I don't know what I'm doing”.

Wernher von Braun